Novel Compounds Useful as Neuro-Protective Agents

专利摘要:
The present invention relates to novel phenyl oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuroprotective agents.
公开号:KR20010024402A
申请号:KR1020007003636
申请日:1998-09-23
公开日:2001-03-26
发明作者:벤자민 앨란 앤더슨；로런스 요셉 하인즈；질 앤 파네따；마이클 르로이 필립스；존 앨란3세 리크；존 로버트 리조；존 케빈 샤들；데이비드 리 바리
申请人:피터 지. 스트링거；일라이 릴리 앤드 캄파니；
IPC主号:

专利说明:

Novel Compounds Useful as Neuro-Protective Agents
[1] The present invention relates to novel phenyl oxazoles, triazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuroprotective agents.
[2] Neurodegeneration progression may occur in various regions of the central nervous system (CNS). Neurodegeneration is clinically manifested in the disruption of functionally connected neural circuits with corresponding alterations of neurotransmitter systems and morphological tissues of affected cell systems.
[3] The normal function of the CNS is premised on a well balanced interaction between different biochemical and structurally connected nervous systems. When a component of a neural circuit changes its structural or biochemical identity, an imbalance in the functional system occurs and a compensatory mechanism must be activated to maintain physiological equilibrium.
[4] The most serious form of neurodegeneration is probably seen after stroke. This form of cerebral ischemia causes the death of neuronal units as well as glial cells and vascular components of the brain. Stroke very often leads to paralysis, memory loss, speech disorders and even death. Reactive oxygen intermediates are thought to play a role in causing brain death in stroke patients.
[5] Another form of cerebral ischemia that can significantly destroy important groups of nerve units that are selectively susceptible to attack is systemic ischemia. Global cerebral ischemia is commonly seen in patients with cardiac arrest while the heart is undergoing fibrillation. Neuronal death by general ischemia generally occurs in heart attack patients who have suffered heart arrest, and cardiac arrest typically occurs in heart attack patients.
[6] Reactive oxygen species are also thought to be one of the factors responsible for neuronal death during reperfusion states after general ischemia. Ischemia-reperfusion injury caused by gross or local ischemia or during transplantation can also affect other major organs of the body such as the kidneys, liver and heart. It is believed that reactive oxygen intermediates produced during the reperfusion state in these organs cause serious damage.
[7] Other degenerative diseases of the central nervous system are thought to worsen or develop through the process of generating reactive oxygen intermediates. Parkinson's disease (PD) is characterized by a reduced magnitude and speed of behavior. In Alzheimer's disease (AD), cognitive impairment is a major clinical symptom. In motor neuron disease (eg, amyotrophic lateral sclerosis, ALS), degeneration of the central vertebral bodies, peripheral motor system, or both is the reason for the clinical situation.
[8] Idiopathic PD is a motor disorder in which the overall symptom is characterized by three major symptoms: tremor, stiffness and dysfunction during resting (Fahn, 1989). The progression of the disease is gradual. For a long time, anticholinergic drugs have been effective only in the treatment of Parkinson's symptoms. The beneficial effects of L-3,4-dihydrophenylalanine (L-DOPA) therapy have increased the patient's life expectancy significantly. However, in the advanced stages of the disease, L-DOPA therapy is complicated and L-DOPA response is reduced. The limiting factor in PD therapy is the psychotic potential of many antiparkinsonian drugs.
[9] ALS is a chronic progressive degenerative disorder that occurs sporadically in its typical form. Most major pathological changes in ALS patients are the loss of many motor neurons in the motor muscle envelope, brain stem and spinal cord.
[10] Cognitive decline is a fundamental clinical feature of AD that is manifested by memory loss, disorientation, and thus loss of play in life. Only after death or by the presence of numerous genetic powders and nerve spots in the brain can a pathological diagnosis be assured.
[11] At present, the pathological therapy of neurodegenerative disorders is limited to the treatment of symptoms that do not alter the course of a latent disease.
[12] On the other hand, there is a general dissatisfaction with the currently available therapeutics for the above-described signs that prevail among people with disease, slowing the process of neurodegeneration associated with local or global ischemia, ALS, Alzheimer's disease, and Parkinson's disease. Or there is still a need for safer and better calibrated drugs that can even prevent all of these neurodegenerations.
[13] The present invention provides novel phenyl oxazole and phenyl thiazole compounds useful for treating damage by neurodegeneration and reperfusion of peripheral organs. Compounds of the present invention are thought to inhibit the formation of reactive oxygen species in mammals and thereby to be caused by increased free radical production. It is useful for treating symptoms and diseases such as ischemia / reperfusion injury.
[14] US Pat. No. 5,428,0478 to Malamas et al. Discloses phenyl oxazoles useful for treating diseases of inflammation, allergic reactions and atherosclerosis, and European Patent Application No. 677,517 to Panetta et al. Teaches benzylidene rodanine for treating Alzheimer's disease.
[15] The present invention provides a compound of formula III or a pharmaceutically acceptable salt, hydrate or optical isomer thereof.
[16]
[17] In the above formula,
[18] Ar is - (C ₁ -C ₆₎ - as a phenyl, pyridyl, tetrahydro-naphthyl, benzofuranyl or chromanyl substituted with zero to two substituents selected from the group consisting of alkyl, hydroxy and halo,
[19] (i) -O (CH ₂ ) _t R ⁶ , And-(C ₁ -C ₆ alkyl) R ⁶ one or two substituents selected from the group consisting of: wherein R ⁶ is -NR ⁷ R ⁸ , wherein R ⁷ and R ⁸ are independently of each other hydrogen,-(C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
[20] (ii) substituted with two substituents together with the carbon atom to which they are attached to form a pyridyl or tetrahydropyridyl ring, provided that the substituent pattern (i) is present, the phenyl or pyridyl group of Ar with the carbon atom to which they are attached May be further substituted with two substituents that together form a phenyl ring,
[21] Represents a double or single bond,
[22] X is -O- or -S-,
[23] Y is -CR ^{5 '} R ^5- , wherein R ^5' is H and R ⁵ is -H or -OH or R ⁵ and R ^{5 '} together are = O, -O- is -S-,
[24] Z is -CH ₂ -or -N-,
[25] R is H or-(C ₁ -C ₆ ) alkyl,
[26] R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
[27] R ³ is H or — (C ₁ -C ₆ ) alkyl, or R ³ and R ⁴ together form a phenyl group with the ring to which they are attached,
[28] R ⁴ is hydrogen or —OH, or when Y is —CHR ⁵ , R ⁴ and R ⁵ are independently of each other H or form a bond together,
[29] m is an integer from 0 to 2,
[30] q is 0 or 1,
[31] n is an integer from 0 to 4,
[32] p is an integer from 1 to 6,
[33] t is an integer of 1-4.
[34] Another aspect of the invention is characterized in that it comprises as an active ingredient a compound of formula III or a pharmaceutically acceptable salt, hydrate or optical isomer thereof, together with one or more pharmaceutically acceptable diluents, carriers and excipients thereof. Provide a pharmaceutical composition.
[35] The invention also provides a method of inhibiting the formation of reactive oxygen species in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula III.
[36] The present invention also provides a method of inhibiting lipid peroxidation in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound of Formula III to a mammal in need thereof. do.
[37] In addition, it has finally been found that the compounds of formula I are also useful for preventing ischemic induced cell damage that may occur by stroke, myocardial infarction, cardiac arrest or during transplantation. Ischemia is a phenomenon in which part or entire blood flow of tissue is deprived of hypoxia. Reperfusion of such tissues causes additional tissue damage associated with the consequences of ischemia in living organs such as lungs, liver, kidneys, heart and small intestine. Accordingly, the present invention also provides a method of preventing ischemia-induced cell damage in mammals by administering a therapeutically effective amount of a compound of formula III to a mammal in need thereof.
[38] The present invention also provides a method of treating Parkinson's disease in a mammal in need thereof, comprising administering a therapeutically effective amount of the compound of formula I to a mammal in need thereof.
[39] Another aspect of the invention provides a method of treating Alzheimer's disease in a mammal in need thereof, comprising administering a therapeutically effective amount of a compound of Formula III to a mammal in need thereof. do.
[40] Another aspect of the invention provides a method for treating atrophic lateral sclerosis (ALS) of a mammal, characterized by administering a therapeutically effective amount of the compound of formula III.
[41] The present invention
[42] Reacting a compound of formula X with an activator and treating with a base to form a formula of formula IX,
[43] Cyclizing the compound of formula IX to form a compound of formula VIII,
[44] Reducing formula VIII to form a compound of formula VII,
[45] Mesylating or tosylation a compound of formula VII to form a compound of formula VI wherein PG is mesylate or tosylate, and
[46] Alkylating a compound of formula (VI) with a compound of formula (V) to form a compound of formula (IV): or a pharmaceutically acceptable salt, hydrate or optical isomer thereof To provide.
[47]
[48] In the above formula,
[49] R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
[50] R ³ is H or-(C ₁ -C ₆ ) alkyl,
[51] R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
[52] q is 0 or 1,
[53] t is 1-6.
[54]
[55]
[56]
[57]
[58]
[59]
[60] In another embodiment, the present invention
[61] Reacting a compound of formula XXVII with an activator (Wherein, R ³ is H or - (C ₁ -C ₆₎ alkyl) to the coupling with a serine methyl ester to form a compound of formula XXVI,
[62] Cyclizing a compound of formula XXVI to form a compound of formula XXV,
[63] Oxidizing the compound of formula XXV to form a compound of formula XXIV,
[64] Reducing the compound of formula XXIV to form a compound of formula XXIII,
[65] Halogenating the compound of formula XXIII to form a compound of formula XXII,
[66] Compound of formula (XXII) Wherein R ³⁰ is — (CO) R ⁶ or NR ⁴⁰ R ⁴¹ wherein one of R ⁴⁰ and R ⁴¹ is hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, ,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, And the other is — (CO) C ₁ -C ₆ alkyl) to form a compound of formula XXI, and
[67] A method for preparing a compound of formula XX, or a pharmaceutically acceptable salt, hydrate or optical isomer thereof, comprising reducing a compound of formula XXI to form a compound of formula XX.
[68]
[69]
[70]
[71]
[72]
[73]
[74]
[75] In the above formula, X is halo.
[76]
[77] The present invention also provides novel compounds of formula XXI or a pharmaceutically acceptable salt, hydrate or optical isomer thereof. Compounds of formula (XXI) are useful as intermediates in the preparation of compounds of formula (I).
[78] <Formula XXI>
[79]
[80] In the above formula,
[81] R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
[82] R ³ is H or-(C ₁ -C ₆ ) alkyl,
[83] R ³⁰ is — (CO) R ⁶ where R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Is piperazin-1-yl) or -NR ⁴⁰ R ⁴¹ wherein one of R ⁴⁰ and R ⁴¹ is hydrogen,-(C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, The other is-(CO) C ₁ -C ₆ alkyl),
[84] q is 0 or 1,
[85] t is 1-6.
[86] Other objects, features and advantages of the invention will be apparent from the following description and the appended claims.
[87] As used herein, the term “C ₁ -C ₆ alkyl” refers to a linear or branched alkyl chain having 1 to 6 carbon atoms. Typical C ₁ -C ₆ alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, t-butyl, n-pentyl, isopentyl, neopentyl, hexyl and the like.
[88] The term "halo" means chloro, fluoro, bromo or iodo.
[89] The term “(C ₁ -C ₆ ) alkoxy” refers to methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, n- attached to the remainder of the molecule via an oxygen atom. Group such as groups such as pentoxy, isopentoxy, neopentoxy, and hexoxy.
[90] The term "pharmaceutically acceptable salts" refers to salts of compounds of the above formula that are substantially nontoxic to living organisms. Conventional pharmaceutically acceptable salts include those prepared by reacting a compound of the formula with a pharmaceutically acceptable inorganic or organic acid or a pharmaceutically acceptable alkali metal or organic base, depending on the type of substituents present on the compound of formula. have.
[91] Examples of pharmaceutically acceptable inorganic acids that can be used to prepare pharmaceutically acceptable salts include hydrochloric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, phosphorous acid, and the like. Examples of pharmaceutically acceptable organic acids that can be used to prepare pharmaceutically acceptable salts include aliphatic mono and dicarboxylic acids such as oxalic acid, carbonic acid, citric acid, succinic acid, phenyl substituted alkanoic acid, aliphatic and aromatic sulfuric acid, and the like. have. Accordingly, such pharmaceutically acceptable salts prepared from inorganic or organic acids include hydrochloride, hydrobromide, nitrate, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate, monohydrogen phosphate, dihydrogen phosphate, metaphosphate, Pyrophosphate, hydroiodide, hydrofluoric acid, acetate, propionate, formate, oxalate, citrate, lactate, p-toluenesulfonate, methanesulfonate, maleate and the like.
[92] It is to be understood that the particular anion or cation that forms part of any salt of the present invention is not critical and usually is in salt form and is pharmaceutically acceptable and only requires that the anion or cationic moiety does not contribute to undesirable qualities.
[93] As used herein, the term "amino protecting group" refers to a group which, as is often used in synthetic organic chemistry, prevents the involvement of amino groups in reactions carried out on some other functional groups of the molecule and can be removed from the amine if desired. . In a similar manner, the term "hydroxy protecting group" means a removable group that prevents the hydroxy group from participating in the reaction carried out on the molecule. These creeper tees. W. T. W. Greene (Chapters 2 and 7, John Wiley and Sons, New York, 1981 in Protective Group in Organic Synthesis) and Jay. W. JW Barton, Chapter 2, JFW McOmie, ed., Plenum Press, New York, 1973 in Protective Groups in Organic Chemistry, which is hereby incorporated by reference in its entirety. . Examples of amino protecting groups include benzyl and substituted benzyl, for example 3,4-dimethoxybenzyl, ο-nitrobenzyl and triphenylmethyl, and the formula -COOR, wherein R is methyl, ethyl, propyl, isopropyl, 2 , 2,2-trichloroethyl, 1-methyl-1-phenylethyl, isobutyl, t-utyl, t-amyl, vinyl, allyl, phenyl, benzyl, p-nitrobenzyl, ο-nitrobenzyl and 2,4 -Acyl groups and substituted acyls, such as formyl, acetyl, chloroacetyl, dichloroacetyl, trichloroacetyl, trifluoroacetyl, benzoyl and p-methoxybenzoyl And other groups such as methanesulfonyl, p-toluenesulfonyl, p-bromobenzenesulfonyl, p-nitrophenylethyl and p-toluenesulfonylaminocarbonyl. Preferred amino-blockade groups are t-butoxycarbonyl.
[94] Examples of hydroxy protecting groups include ethers and substituted ether forming groups such as methyl, methoxymethyl, t-butoxymethyl, 1-ethoxyethyl and benzyl, silyl ether forming groups such as trimethylsilyl, triethylsilyl and Methyl-diisopropylsilyl, ester forming groups such as formate, acetate and trichloroacetate, and carbonate groups such as methyl, 2,2,2-trichloroethyl, carbonate and p-nitro Phenyl carbonate.
[95] Compounds of the invention are, for example, phenyl or pyridyl substituted with one or two-(C ₁ -C ₆ alkyl) R ⁶ groups, or R ⁴ and R ⁵ together form a bond or Y is- It may exist in various isomeric forms which are C (OH) H-. The present invention is not limited to any particular isomer but includes all possible individual isomers and racemates.
[96] Experts say that Z is nitrogen It will be understood that when N is a double bond between Z and the carbon to which it is attached, N has no R ³ substituent.
[97] Many compounds of formula (I) may combine with water to form hydrates. The present invention includes hydrates of formula (I).
[98] <Preferred Compounds of the Present Invention>
[99] Preferred groups include the following.
[100] (a) Ar And - and (C ₁ -C ₆ alkyl) R ⁶ 1 or 2 substituents, or they are phenyl substituted with a carbon atom attached to two substituents which form a pyridyl or tetrahydropyridyl ring selected from pyridyl,
[101] (b) Ar is phenyl substituted with-(C ₁ -C ₆ ) alkyl, hydroxy, halo or with two substituents which together with the carbon to which they are attached form a phenyl ring,
[102] (c) Ar is pyridyl substituted with — (C ₁ -C ₆ alkyl), hydroxy, halo or with two substituents which together with the carbon atom to which they are attached form a phenyl ring,
[103] (d) Ar is phenyl substituted with-(C ₁ -C ₆ alkyl) R ⁶ ,
[104] (e) Ar is Phenyl substituted by
[105] (f) R ⁶ is —NR ⁷ R ⁸ ,
[106] (g) R ⁶ is morpholin-1-yl or thiomorpholin-1-yl,
[107] (h) R ⁶ is imidazol-1-yl or 4,5-dihydro-1-1H-imidazol-2-yl,
[108] (i) R ⁶ is piperazin-1-yl, or-(C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
[109] (j) R ⁷ and R ⁸ are independently of each other hydrogen or — (C ₁ -C ₆ ) alkyl,
[110] (k) R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,
[111] (l) R ³ is-(C ₁ -C ₆ ) alkyl,
[112] (m) Y is -O- or -S-,
[113] (n) Y is -CHR ^5- ,
[114] (o) m is 1,
[115] (p) p is an integer of 1-3.
[116] Preferred groups of compounds include the compounds of formula II or their pharmaceutically acceptable salts, hydrates or optical isomers.
[117]
[118] In the above formula,
[119] Ar is phenyl, pyridyl or tetrahydronaphthyl substituted with 0 to 2 substituents selected from the group consisting of-(C ₁ -C ₆ ) alkyl, hydroxy and halo,
[120] (i) -O (CH ₂ ) _t R ⁶ , And-(C ₁ -C ₆ alkyl) R ⁶ 1 to 2 substituents selected from the group consisting of, or
[121] (ii) the carbon atoms to which they are attached are substituted with two substituents that together form a pyridyl or tetrahydropyridyl ring, provided that when the substituent pattern (i) is present, the phenyl or pyridyl groups of Ar and May be further substituted with two substituents that together form a phenyl ring,
[122] R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, — (CH ₂ ) _p -piperidyl ,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl or Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
[123] Represents a double or single bond,
[124] X is -O- or -S-,
[125] Y is -CHR ^5- , -O- or -S-,
[126] Z is -CH ₂ -or -N-,
[127] R is H or-(C ₁ -C ₆ ) alkyl,
[128] R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl or-(C ₁ -C ₆ ) alkoxy,
[129] R ³ is H or — (C ₁ -C ₆ ) alkyl, or R ³ and R ⁴ together form a phenyl group with the ring to which they are attached,
[130] When R ⁴ is hydrogen or —OH or Y is —CHR ⁵ , R ⁴ and R ⁵ are independently of each other H or form a bond together,
[131] m is an integer from 0 to 2,
[132] q is 0 or 1,
[133] n is an integer from 0 to 4,
[134] p is an integer from 1 to 6,
[135] t is an integer of 1-4.
[136] Another preferred group of compounds is the compound of formula (I) or a pharmaceutically acceptable salt, hydrate or optical isomer thereof.
[137]
[138] In the above formula,
[139] Ar is phenyl or pyridyl substituted with 0 to 2 substituents selected from the group consisting of —C ₁ -C ₆ alkyl, hydroxy and halo,
[140] (i) And-(C ₁ -C ₆ alkyl) R ⁶ 1 to 2 substituents selected from the group consisting of, or
[141] (ii) the carbon atoms to which they are attached are substituted with two substituents that together form a pyridyl or tetrahydropyridyl ring, provided that when the substituent pattern (i) is present, the phenyl or pyridyl groups of Ar and May be further substituted with two substituents that together form a phenyl ring,
[142] R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, — (CH ₂ ) _p -piperidyl ), Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or-( C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
[143] X is -O- or -S-,
[144] Y is -CHR ^5- , -O- or -S-,
[145] R is H or (C ₁ -C ₆ ) alkyl,
[146] R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,
[147] R ³ is H or-(C ₁ -C ₆ ) alkyl,
[148] R ⁴ is hydrogen or when Y is —CHR ⁵ , R ⁴ and R ⁵ are independently of each other H or form a bond together,
[149] m is 0 or 1,
[150] n is an integer from 0 to 4,
[151] p is an integer of 1-6.
[152] It is to be understood that the above classes may be combined to form another preferred class.
[153] Preferred types of compounds
[154] Ar is And-(C ₁ -C ₆ alkyl) R ⁶ , wherein R ⁶ is -NR ⁷ R ⁸ , wherein R ⁷ and R ⁸ are H or-(C ₁ -C ₆ ) alkyl Phenyl substituted with 2 to 2 substituents and 1 to 2 substituents selected from hydrogen,-(C ₁ -C ₆ ) alkyl and hydroxy, or 2 substituents which together with the carbon to which they are attached form a phenyl group,
[155] R ¹ and R ² are — (C ₁ -C ₆ ) alkyl,
[156] R, R ³ and R ⁴ are hydrogen,
[157] X is -O-,
[158] There are compounds in which Y is -O- or -S-, and compounds in which R ¹ and R ² are 1,1-dimethylethyl are more preferred.
[159] Among the more preferred kinds of the above, Ar is substituted with ₁ or 2-(C ₁ -C ₆ alkyl) R ⁶ groups and 1 or 2 substituents selected from hydrogen and-(C ₁ -C ₆ ) alkyl Particular preference is given to compounds which are phenyl.
[160] Among the above particularly preferred kinds, compounds in which Ar is phenyl substituted with-(C ₁ -C ₆ alkyl) R ⁶ are particularly preferred.
[161] Another common example of a compound of formula (I) useful in the present invention is
[162] 2- (3-methyl-4-hydroxy-5-ethyl) phenyl-4- (2- (4-methyl-3-aminoprop-1-ylphenoxy) ethyl) oxazole,
[163] 2- (3-isopropyl-4-ethoxy-5-n-propyl) phenyl-4- (2- (4-N-propyl-6-aminohex-1-ylphenoxy) ethyl) thiazole oxalate ,
[164] 2- (3-hexyl-4-pentoxy-5-t-butyl) phenyl-4- (2- (4-N-ethylaminomethylphenoxy) ethyl) oxazole,
[165] 2- (3-n-propyl-4-hydroxy-5-neopentyl) phenyl-4- (2- (4-N-ethylaminomethylphenoxy) ethyl) -5-methyloxazole melate,
[166] 2- (3-isopropyl-4-propoxy-5-ethyl) phenyl-4- (2- (4-N-ethylaminomethylphenoxy) ethyl) -5-ethylthiazole,
[167] 2- (3-methyl-4-n-pentoxy-5-sec-butyl) phenyl-4- (2- (4-N-ethylaminomethylphenoxy) ethyl) -5-isopropyloxazole tosylate,
[168] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-ethylaminomethylphenoxy) ethyl) thiazole,
[169] 2- (3-methyl-4-methoxy-5-n-butyl) phenyl-4- (2- (2-fluoro-4-N-ethylaminomethylphenoxy) ethyl) oxazole hydrobromide,
[170] 2- (3-t-butyl-4-hydroxy-5-ethyl) phenyl-4- (2- (2-propyl-4-N-ethylaminomethylphenoxy) ethyl) oxazole,
[171] 2- (3-isobutyl-4-hydroxy-5-n-pentyl) phenyl-4- (2- (4-N-ethylaminomethyl-5-hydroxyphenoxy) ethyl) thiazole,
[172] 2- (3,5-dimethyl-4-ethoxyphenyl) -4- (2- (2-hexyl-4-N-ethylaminomethylphenoxy) ethyl) oxazole mesylate,
[173] 2- (3-n-butyl-4-pentoxy-5-isopropylphenyl) -4- (2- (5-N-ethyl-N-methylaminomethylpyrid-2-yloxy) ethyl) thiazole ,
[174] 2- (3-Neopentyl-4-hydroxy-5-ethylphenyl) -4- (2- (5-N-ethyl-N-methylaminomethylpyrid-2-yloxy) ethyl) -5-methyl Oxazole nitrate,
[175] 2- (3,5-di-sec-butyl-4-hydroxyphenyl) -4- (2- (5-N-ethyl-N-methylaminomethylpyrid-2-yloxy) ethyl) -5- Isobutyl Oxazole,
[176] 2- (3,5-di-n-propyl-4-methoxyphenyl) -4- (2- (5-N-ethyl-N-methylaminomethylpyrid-2-yloxy) ethyl) oxazole fatigue Sulfate,
[177] 2- (3-sec-butyl-4-methoxy-5-ethyl) phenyl-4- (2- (2-bromo-5-N-ethyl-N-methylaminomethylpyrid-2-yloxy) Ethyl) -5-isopropyloxazole,
[178] 2- (3,5-di-isopropyl-4-hydroxyphenyl) -4- (2- (3-hydroxy-5-thiomorpholinomethylpyrid-2-yloxy) ethyl) thiazole meta Phosphate,
[179] 2- (3-methyl-4-propoxy-5-ethyl) phenyl-4- (2- (5-N-methyl-N-ethyl-4-aminobut-1-ylpyrid-2-yloxy) ethyl Oxazole,
[180] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (5- (N-methyl-N- (3- (piperidin-3-yl) propyl) amino Methyl) pyrid-2-yloxy) ethyl) oxazole methanesulfonate,
[181] 2- (3,5-di-t-butyl-4-methoxyphenyl) -4- (2- (5-N-ethyl-N-methyl-3-aminopropyl-1-yl-pyrid-2- Yloxy) ethyl) oxazole sulfate,
[182] 2- (3,5-di-t-butyl-4-ethoxyphenyl) -4- (2- (5-N-ethyl-N-n-propylaminomethylpyrid-2-yloxy) ethyl) thiazole,
[183] 2- (3-hexyl-4-ethoxy-5-ethylphenyl-4- (2- (4-N-methyl-N-n-butylaminomethylphenylthio) ethyl) oxazole phosphate,
[184] 2- (3-n-propyl-4-methoxy-5-hexylphenyl) -4- (2- (4-N-methyl-N-ethylaminomethylphenylthio) ethyl) thiazole,
[185] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-chloro-4-N, N-dimethylaminomethylphenylthio) ethyl) -5-isopropyloxazole Citrate,
[186] 2- (3-t-butyl-4-hydroxy-5-neopentyl) phenyl-4- (2- (3,5-dimethyl-4-N, N-diethyl-3-aminopropyl-1-yl Phenylthio) ethyl) oxazole,
[187] 2- (3,5-dimethyl-4-hydroxyphenyl) -4- (2- (4- (N-methyl-N-3- (pipelin-3-yl) prop-1-yl-2- Aminoethyl-1-ylphenylthio) ethyl) oxazole bisulfate,
[188] 2- (3-methyl-4-hydroxy-5-ethyl) phenyl-4- (2- (4-N-n-propyl-N-ethylaminomethylphenylthio) ethyl) thiazole,
[189] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) ethyl) -5-methyltazol lactate,
[190] Z-2- (3,5-di-t-butyl-4-propoxyphenyl) -4- (3- (4-N-N-di-n-butylaminomethylphenyl) -2-propenyl) oxazole,
[191] E-2- (3-methyl-5-n-butyl-4-ethoxyphenyl) -4- (4- (4-methylethylaminomethylpyridyl) ethyl) oxazole,
[192] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) oxazole,
[193] Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) -2-propenyl) oxazole,
[194] E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) -2-propenyl) oxazole .
[195] <Synthesis method>
[196] Ar is phenyl substituted with one or two — (C ₁ -C ₆ alkyl) R ⁶ groups, wherein the alkyl group is —CH ₂ —, X and Y are oxygen, R ⁴ is hydrogen and m is A compound of formula I of 1 is prepared according to Scheme I (a) (1) below.
[197]
[198] In step (a) of the above scheme, an appropriately substituted benzoic acid is 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT), 1,1'-carbonyldiimidazole (CDI). ) Or reflux with an activator such as dicyclohexylcarbodiimide (DCC), preferably CDMT, and then cooled to ambient temperature and treated with ammonia equivalents such as concentrated aqueous ammonia or hexamethyldisilazine Switch to 1). The reaction can be carried out in an aprotic polar solvent, preferably tetrahydrofuran, for 1 to 24 hours.
[199] The oxazoleacetic acid compound (2) preferably reacts the benjamid (1) in step (b) with an inert gas such as nitrogen at about 50 ° C to 130 ° C, preferably at 130 ° C for about 1 to 2 hours, preferably pure ethyl. Prepared by cyclization with a reagent such as -4-chloroacetoacetate, followed by hydrolysis to form an acid that can be isolated to recrystallization if desired. Optionally, a solvent such as xylene or toluene can be used and the reaction can be carried out at reflux temperature.
[200] Phenyloxazole (3) is prepared by reducing the acid (2) in step (c) with a reducing agent, preferably excess borane tetrahydrofuran, and treating with an alcoholic or protic solvent, preferably methanol. Other suitable reducing agents are borane 4,6-dimethyloxybenzene-1,3-disulfonyl chloride, lithium aluminum hydride, sodium borohydride or lithium borohydride. The reaction can be carried out in an aprotic polar solvent, for example tetrahydrofuran or dioxane, preferably tetrahydrofuran, at about −10 ° C. to ambient temperature, preferably at ambient temperature for about 1 to 24 hours.
[201] In step (d), phenyloxazole (3) is coupled with hydroxy substituted benzaldehyde by first mesylating with a mesylating agent such as methanesulfonyl chloride and then coupling the benzaldehyde and the mesylated compound. Ring to form aldehyde (4). The coupling reaction can be carried out in an aprotic polar solvent such as dimethylsulfoxide in the presence of potassium t-butoxide while heating to a temperature of about 70 ° C. for up to 24 hours.
[202] When R ¹ and R ² are small lower alkyl substituents such as methyl or ethyl, the hydroxy of the phenyl ring is preferably protected with a hydroxy protecting group to prevent mesylation of the phenol. The protecting group can then be removed after the coupling step.
[203] When R ¹ and R ² are bulky alkyl substituents such as t-butyl, mesylation occurs preferentially on the alcohol attached to the oxazole or thiazole ring, and therefore no hydroxy protection is required.
[204] The preparation of (4) can also be accomplished by Mitsunobu coupling, which can be carried out in an aprotic polar solvent such as tetrahydrofuran at ambient temperature.
[205] Reductive amination of the aldehyde to form the desired product (5) is carried out in step (e) by the use of a reducing agent such as sodium borohydride with an appropriately substituted amine and titanium IV isopropoxide (Ti ( OiPr) ₄ ). The reaction is preferably carried out at ambient temperature in a low molecular weight alcohol such as ethanol. The reaction is actually completed within 16 hours to 3 days.
[206] Reduction step (e) also dissolves aldehyde (4) in a low molecular weight alcohol such as methanol and acidifies this solution with an excess of an organic acid such as acetic acid, and then aldehyde (4) to sodium cyanoborohydride (sodium cyan). By reacting with an appropriately substituted amine using a reducing agent such as novolohydride). The reaction is carried out at ambient temperature under an inert gas such as nitrogen, and the reaction is actually completed in about 6 hours. Abdel-Maged, et al., J. Org. Chem., 1996, 61, 3849.
[207] Similarly, reductive amination reactions can be achieved in dichloroethane using sodium (triacetoxy) borohydride.
[208] R is - (C ₁ -C ₆₎ alkyl, then the compound of formula (I) is the coupling step (d), tetrahydrofuran and dimethyl in an aprotic polar solvent or solvent mixture such as formamide, methyl iodide and the appropriate same- It can be prepared by alkylating the phenol of compound (4) of Scheme I (a) using (C ₁ -C ₆ ) alkyl halide and sodium hydride. The reaction can be carried out at ambient temperature and is actually completed in 31 hours. Reductive amination can then be achieved as described in Scheme I (a), step (e).
[209] In another procedure as shown in Scheme I (a) (2) below, phenyl oxazole (3) is treated with a mesylating agent, preferably methanesulfonyl chloride, in the presence of a base, preferably triethylamine. do. Other suitable bases are pyridine or 2,6-lutidene or diisopropyl ethylamine. The reaction is preferably carried out using an aprotic solvent, preferably methylene chloride, under an inert environment such as nitrogen. Tetrahydrofuran or acetonitrile are other suitable solvents. At temperatures between −10 ° C. and ambient temperature, preferably about 0 ° C., the reaction is effectively completed in 1 to 24 hours.
[210] In one preferred procedure, phenol oxazole (3) is treated with tosyl chloride, or preferably tosylating agent, such as tosic anhydride, in the presence of a base, preferably pyridine, and a catalyst such as dimethylaminopyridine. Other tertiary amines such as triethylamine or 2,6-lutidine can also be used. The reaction is preferably carried out under an inert gas such as nitrogen at a temperature of about −10 ° C. to 35 ° C., preferably at ambient temperature. Preferred are aprotic solvents such as tetrahydrofuran or methylene chloride.
[211] The desired product 5 can then be readily obtained by refluxing the mesylate or tosylate 110 together with the amine 111 in the presence of a strong base, preferably sodium hydride or sodium t-butoxide. Potassium bases may also be acceptable but are not as preferred as sodium. Suitable solvents include, but are not limited to, aprotic solvents such as tetrahydrofuran, dimethylsulfoxide, dimethylformamide or dioxane.
[212] In one preferred one-pot alkylation, tosylate 110 and amine 111 are refluxed under an inert gas such as nitrogen in the presence of solid sodium hydroxide anhydride as base using tetrahydrofuran as solvent.
[213]
[214] In the above scheme,
[215] PG is tosylate or mesylate and t is 1-6.
[216] When t is 1, the amine 111 is prepared according to the procedure of the literature described above by Abdel-Maged et al.
[217] In addition, when t is 1-6, preparation of (111) is achieved as shown by following Reaction Scheme I (a) (3).
[218] The solution of carboxylic acid 115 in an aprotic solvent such as tetrahydrofuran is treated with an activator, preferably isobutylchloroformate, in the presence of a base such as 4-methyl-morpholine. Other suitable activators are arylalkyl chloroformates, for example phenyl chloroformate. The reaction is carried out at a temperature of about -78 ° C to ambient temperature, preferably about -50 ° C.
[219] The amine of the formula HNR ⁷ R ⁸ can be added and the reaction can proceed at a temperature of preferably about -50 ° C. The amide 116 is then readily reduced to the amine 111 using a reducing agent such as borane dimethylsulfide.
[220]
[221] In the above scheme, t is 1 or 6.
[222] R ⁷ or R ⁸ is — (CH ₂ ) _p piperidyl, — (CH ₂ ) _p S (C ₁ -C ₆ ) alkyl or Compounds of formula I are reacted with aldehyde (4) with an amine or an amine hydrochlorite salt of formula H ₂ NR ¹⁰ , wherein R ¹⁰ is H or-(C ₁ -C ₆ ) alkyl. 6), followed by use of sodium hydride in an aprotic polar solvent such as dimethylformamide with an amino protective piperidine such as N-tert-butoxycarbonyl-3- (3-bromopropyl ) Can be prepared as shown in Scheme I (b) by alkylation with piperidine and an alkylating agent or by alkylation with 2-chloroethylmethyl sulfide to form (7). A temperature of about 20 ° C. to 80 ° C. is preferred and the reaction is completed in practically 4 hours. Deprotection of the piperidyl group can be achieved by techniques known to those skilled in the art, such as by treating (7) with an acid such as hydrochloric acid. Conversion to sulfoxides can be accomplished by treatment with an oxidizing agent such as m-chloroperbenzoic acid.
[223]
[224] In the above scheme,
[225] R ^a is oxo substituted C ₁ -C ₆ alkyl,
[226] R ^b is C ₁ -C ₆ alkyl,
[227] R ^g is piperidyl, S (C ₁ -C ₆ ) alkyl or to be.
[228] Ar is phenyl substituted with one or two straight chain-(C ₂ -C ₆ alkyl) R ⁶ groups and X, Y and R ⁴ are compounds of formula (I) as defined above in Scheme I (a) It may be prepared as described in (ce).
[229]
[230] In the above scheme,
[231] R ^c is (CH ₂ ) _q , where q is an integer from 2 to 6, and
[232] R ^d is H or-(C ₁ -C ₅ ) alkyl.
[233] In Scheme I (c), the amino substituted phenol starting material (8) is reacted with an acylating agent such as acetic anhydride and sodium methoxide in a low molecular weight alcohol such as methanol to form compound (9). Compound (10) can be prepared by reducing carbonyl with a reducing agent such as lithium aluminum hydride in an aprotic solvent such as tetrahydrofuran. The acylation of (10) reacts 1,1-carbonyldiimidazole with carboxylic acid in an aprotic polar solvent such as tetrahydrofuran at a temperature of about 0 ° C to about 20 ° C, followed by N-ethyl-p- It can be achieved by treatment with hydroxyphenethyl amine (10). The reaction is actually completed in 2 to 24 hours.
[234] Compound (11) may then be coupled with phenyloxazole appropriately substituted by a michunobu reaction to prepare (12). The reaction can be carried out in a polar aprotic solvent such as tetrahydrofuran at ambient temperature. After approximately 24 hours, the reaction is virtually complete. Compound (12) can then be reduced using a reducing agent such as aluminum hydride in an aprotic solvent such as tetrahydrofuran to prepare (13). The reaction is carried out appropriately at ambient temperature and is completed in about 3 hours.
[235] In another procedure, a suitably substituted phenylalkanol starting material (14) dissolved in an organic solvent such as methylene chloride is reacted with a halogenating agent such as dibromotriphenylphosphorane, as shown in Scheme I (d) below. To prepare compound (15). The reaction can be carried out at ambient temperature and proceeds for about 4 hours.
[236] The halogenated compound (15) was then coupled with phenyl oxazole appropriately substituted by the michunobu reaction to prepare (16) and in formula -NR ⁷ R in a polar aprotic solvent such as dimethylformamide at about 80 ° C. for about 5 hours. Substitution of halogen with ⁸ amines gives the desired final product.
[237]
[238] In the above scheme,
[239] R ^e is (C ₂ -C ₆ alkyl) and A is halo.
[240] Scheme I (e) below describes a third procedure for preparing compounds of formula (I) wherein Ar is phenyl substituted with one or two straight chain — (C ₂ -C ₆ alkyl) R ⁶ groups.
[241] In the michunobu reaction, compound (17) is first coupled with an appropriately substituted phenyl oxazole to form intermediate oxazole (18). Compound (19) is prepared by reducing and hydrolyzing the cyano group. Amination of compound (19) is achieved by one of the methods described in Schemes I (a), step (e).
[242]
[243] In the above scheme,
[244] R ^h is (C ₁ -C ₅ ) alkyl.
[245] 1 or 2 Ar Is phenyl substituted with a group, and X and Y are compounds of formula (I) as defined in Scheme I (ae) above, can be prepared as outlined in Scheme II below.
[246]
[247] In the above scheme, A is halo.
[248] In Scheme II, suitably substituted phenyl oxazole (20) dissolved in an aprotic polar solvent, such as tetrahydrofuran, is coupled with suitably substituted phenol (21) to form (22) in a michunobu reaction. At ambient temperature, the reaction is actually completed within 5 hours. Compound (22) is then treated with sodium iodide to form iodoketone, which is then replaced using an appropriately substituted amine while heating to about 50 ° C to 80 ° C. Amination can be carried out in a nonpolar organic solvent such as toluene and is virtually complete in about 3 hours.
[249] Ar is phenyl substituted with one or two branched-(C ₁ -C ₆ alkyl) R ⁶ groups, and X and Y are compounds of formula (I) as described above in Scheme I (ae) Can be prepared accordingly.
[250]
[251] In the above scheme,
[252] R ^a is oxo substituted — (C ₁ -C ₆ ) alkyl.
[253] Properly substituted phenyloxazole (24) dissolved in an aprotic polar solvent, such as tetrahydrofuran, is coupled with the appropriately substituted ketone (25) in a michunobu reaction to form compound (26). Reductive amination of (26) can be achieved by one of the methods described in Schemes I (a), step (e).
[254] Ar is - (C ₁ -C ₆₎ phenyl, a compound of Reaction Scheme I, II or III further substituted with one or two substituents selected from alkyl, halo and hydroxy can be prepared as shown in Scheme IV have.
[255]
[256] In the above scheme,
[257] R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl,
[258] R ^f is hydrogen, — (C ₁ -C ₆ ) alkyl, halo or protected hydroxy.
[259] Properly substituted phenyl oxazole and suitably substituted phenol (27) are coupled in a michunobu reaction to form intermediate compound (28) as described in Scheme I (a), step (d), followed by Scheme I ( a), it can be aminated using one of the two methods described in step (e). The hydroxy can then be deprotected if appropriate.
[260] Compounds of Schemes I, II or III, which are substituted with two substituents to form a phenyl ring when Ar is taken together, can be prepared as shown in Scheme V below.
[261]
[262] In the above scheme,
[263] R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl,
[264] R ^f is hydrogen, — (C ₁ -C ₆ ) alkyl, halo or protected hydroxy.
[265] In the case of using the michunobu coupling, the phenyloxazole starting material is reacted with an appropriately substituted hydroxynaphthaldehyde (29). The resulting product is then subjected to reductive amination using one of the methods of Scheme I, step (e) and deprotecting the hydroxy if appropriate.
[266] Ar is And / or-(C ₁ -C ₆ alkyl) R ⁶ wherein R ⁶ is morpholin-1-yl, piperazin-1-yl, thiomorpholin-1-yl or substituted piperazin-1- Is substituted phenyl), wherein the compound of Scheme I, II or III is prepared according to Scheme VI.
[267]
[268] In the above scheme,
[269] B is -O-, -NH-, , -N (C ₁ -C ₄ alkyl) or -S-,
[270] R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl,
[271] R ^b is — (C ₁ -C ₆ ) alkyl.
[272] Properly substituted starting material 30 may be prepared according to the reaction of Schemes I (a), step (e), ie using a reducing agent such as sodium cyanoborohydride in an aprotic polar solvent such as tetrahydrofuran, or In a low molecular weight alcohol such as titanium IV isoprooxide (Ti (OiPr) ₄ ) using an appropriately substituted phenyloxazole with reductive amination to form (31).
[273] Compounds of formula I wherein R ⁶ is piperazin-1-yl Compound (31) of Phosphorus Scheme VI may be prepared by treatment with an excess of an inorganic acid such as hydrochloric acid.
[274] Compounds of formula (I) wherein R ⁶ is imidazol-1-yl are prepared according to Scheme VII below.
[275]
[276] In the above scheme,
[277] R ^b is-(C ₁ -C ₆ ) alkyl and A is halo.
[278] A methoxyphenylalkylhalide, such as p-methoxybenzyl chloride, is refluxed with imidazole to form (32). The reaction carried out in a polar organic solvent such as acetonitrile is virtually complete in about 16 hours. Treatment with an agent such as boron tribromide demethylates (32) to form compound (33). In michinobu coupling, compound (33) can be coupled with phenyloxazole (34) to form the desired product (35).
[279] Compounds of formula (I) wherein R ⁶ is 4,5-dihydro-1-H-imidazol-2-yl are prepared according to Scheme VIII.
[280]
[281] In the above scheme, R ^a is — (C ₁ -C ₆ ) alkyl.
[282] The phenyloxazole starting material is coupled with the hydroxyphenylalkyl cyanide compound in the michunobu reaction. Cyclization of the cyano group to form dihydroimidazole 37 is achieved by first treating 36 with hydrogen chloride gas in ethanol at low temperature for about 4 hours and then refluxing with ethylenediamine for up to 32 hours Can be.
[283] Compounds of formula (I) wherein Ar is phenyl substituted with two substituents to form pyridyl or tetrahydropyridyl together with the carbon to which they are attached can be prepared according to Schemes IX (a) and IX (b).
[284]
[285] In the above scheme,
[286] PG is a protector,
[287] R ^f is hydrogen, — (C ₁ -C ₆ ) alkyl, halo or protected hydroxy.
[288]
[289] In the above scheme,
[290] R ^f is hydrogen, — (C ₁ -C ₆ ) alkyl, halo or protected hydroxy.
[291] In Schemes IX (a) and IX (b) above, the starting material 38 is cyclized with the appropriate aldehyde in acidic solution to form an intermediate 39 to the oxalate salt.
[292] In Scheme IX (a), intermediate 39 is prepared by first refluxing oxalate salt 38 with hydrogen bromide and then protecting nitrogen with an amino protecting agent such as di-tert-butyl dicarbonate. By demethylation.
[293] In Scheme IX (b), the free amine 39 can be aromaticized in the presence of a dehydrogenating agent by heating with palladium black and then demethylating to form (42) as discussed above.
[294] Compound (40) or (42) may then be coupled with phenyloxazoles appropriately substituted by the michunobu reaction to form the desired product (41) or (43). Nitrogen protecting groups can be removed by standard methods such as treatment with a suitable t-butyl cation collecting agent such as trifluoroacetic acid and thiophenol. When hydroxy protecting groups are used, the hydroxy groups can be deprotected, for example by treatment with hydrolysis or acid, depending on the protecting group chosen.
[295] Ar is a substituted pyridyl compound can be obtained by the following Scheme X.
[296]
[297] In the above scheme,
[298] R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl,
[299] R ^f is hydrogen, — (C ₁ -C ₆ alkyl), halo or protected hydroxy.
[300] Compound (44) is prepared using suitably substituted pyridone carboxaldehyde and appropriately substituted phenyloxazoles in the michunobu coupling reaction. If R ^f is a protected hydroxy group, it can be deprotected after the coupling step. Compound (44) may then be subjected to reductive amination using one of the methods described in Schemes I (a), step (e) above.
[301] Compounds of formula I, wherein Y is sulfur, can be prepared as illustrated in Scheme XI below.
[302]
[303] In the above scheme,
[304] R ^a is oxo substituted — (C ₁ -C ₆ ) alkyl.
[305] Properly substituted phenyloxazole is coupled with mercaptobenzaldehyde 45 which is suitably substituted by the michunobu reaction. The resulting intermediate 46 can then be reduced to the desired amine using one of the reductive amination reactions described in Scheme I (e), step (e).
[306] R ³ is-(C ₁ -C ₆ ) alkyl and R, R ¹ , R ² , R ⁴ , X and Y are the compounds of formula I as described above, which may be prepared as follows.
[307]
[308] In the above scheme,
[309] A is halo and R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl.
[310] Potassium ethyl malonate is stirred with a base such as triethylamine and a metal halide such as magnesium chloride in an aprotic polar solvent such as acetonitrile at an inert gas such as nitrogen at ambient temperature and then such as μ-chloro-propionyl chloride React with acid halides to form starting halides 47.
[311] Intermediate 48 is prepared and formed as described in Scheme I (a) above by reacting appropriately substituted benzamide (1) with halide (47). The reaction proceeds at a temperature of about 100 ° C. to 150 ° C. under an inert gas such as nitrogen for about 1 to 8 hours.
[312] Reduction of the intermediate 48 with a reducing agent such as lithium aluminum hydride provides compound 49. The reduction is carried out under an inert gas such as nitrogen in an aprotic polar solvent or ether, for example tetrahydrofuran, for 1 to 24 hours.
[313] The appropriately substituted benzaldehyde is combined with the intermediate (49) to form compound (50) using a michunobu coupling, followed by reduction with reductive amination as described in Scheme I (a), step e, to give the desired product. Can be formed.
[314] Compounds of formula I, wherein X is S, can be prepared as follows.
[315]
[316]
[317] In the above formula,
[318] A is halo and R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl.
[319] Benzamide 52 is refluxed with an appropriately substituted benzoic acid with an activator such as carbonyldiimidazole under an inert gas such as nitrogen and then reacted with methylamine as described in Scheme I, step (a) above. Are manufactured. Using an aprotic polar solvent, such as tetrahydrofuran, the reaction is actually complete in about 2 to 24 hours.
[320] The conversion to thiobenzamide (53) was carried out with Lawessens reagent (52) at a temperature of 80 ° C to 120 ° C in an organic solvent such as hexamethylphosphoramide under an inert gas such as nitrogen for about 1 to 2 hours. It is achieved by reacting.
[321] Synthesis of intermediate 55 is accomplished by refluxing thioamide 53 under an inert gas such as nitrogen with μ-haloketone such as ethyl 4-chloroacetoacetate in the presence of potassium iodide. Aprotic polar solvents or ethers such as tetrahydrofuran are preferred and the reaction is completed in 1 to 6 hours.
[322] Cyclization for preparing thiazole 56 is accomplished by reacting an excess of ammonium acetate with thioester 55 in an acid such as acetic acid under an inert gas such as nitrogen for 1 to 5 hours.
[323] Reduction of thiazole ester 56 is accomplished with a reducing agent such as lithium aluminum hydride. The reduction is preferably carried out under an inert gas such as nitrogen in an aprotic polar solvent such as tetrahydrofuran. The reaction is actually completed in 1 to 2 hours.
[324] Using the michunobu reaction, the thiazole intermediate 57 can be coupled with an appropriately substituted benzaldehyde to form 58, which is isolated and purified and described in Scheme I (a), step (e) above. It may be reduced to the desired amine by reductive amination as such.
[325] Compounds of formula (I) wherein Y is CHR ⁵ and R ⁴ and R ⁵ are independently hydrogen or R ⁴ and R ⁵ together form a bond can be prepared according to Scheme XIV as follows.
[326]
[327] In the above scheme,
[328] A is halo, R ^a is oxo substituted-(C ₁ -C ₆ ) alkyl and APG is a protected aldehyde.
[329] At ambient temperature, in polar solvents such as methylene chloride, suitably substituted starting alcohols (59) are halogenated by treatment with a halogenating agent, for example triphenylphosphine and bromine, in the presence of a base or acid scavenger such as imidazole. . The reaction is actually completed in 1 to 24 hours.
[330] In the substitution reaction, the halogenated compound (60) is refluxed with triphenylphosphine in a nonpolar solvent such as xylene for about 24 hours to form an activated intermediate (61).
[331] Intermediate 62 is prepared in a Wittig reaction using a strong base such as sodium hexamethyldisilazane and a suitably protected aldehyde such as terephthalaldehyde mono- (diethylacetal). The reaction is preferably carried out in an aprotic polar solvent such as tetrahydrofuran at a temperature of about −20 ° C. to about 0 ° C. and is actually completed in about 3 to 10 hours.
[332] Those skilled in the art will readily understand that intermediate 62 forms the E and Z isomers that can be easily separated by conventional chromatographic techniques.
[333] The desired aldehyde 63 can then be deprotected by treatment with an aqueous acid such as hydrochloric acid for about 24 hours. Deprotection is preferably carried out in a polar solvent or ether such as diethyl ether at ambient temperature.
[334] Reductive amination can be achieved by using one of the procedures described in Schemes I (a), step (e).
[335] Compounds of formula (I) wherein Y is —CHR ⁵ where R ⁵ is hydrogen may be prepared by hydrogenating compound (64) with 5% palladium on hydrogen and carbon. The reduction is preferably carried out in a nonpolar solvent such as toluene at ambient temperature and is actually completed in about 4 hours.
[336] A compound of formula I wherein Ar, X and Y and R ⁴ are as defined in Scheme I (a) above and m is 0 can be prepared as demonstrated in Scheme XV.
[337]
[338] In the above scheme, A is halo.
[339] Starting material 66 is achieved by treating benzoic acid appropriately substituted with a peptide coupling reagent such as CDI, DCC, or preferably CDMT to form an activated acylating agent. The reaction is preferably carried out in an aprotic solvent, such as methylene chloride, at a temperature of about −5 ° C. to ambient temperature, preferably ambient temperature. The activated intermediate is then reacted with an appropriately substituted serine compound, preferably d, 1-serine methyl ester. The reaction is carried out at a temperature of -30 ° C to ambient temperature, preferably about -10 ° C.
[340] Methyl ester 66 may be cyclized to oxazoline by reacting with a brominating agent such as triphenylphosphine and carbon tetrabromide in the presence of a base. The reaction is carried out in an aprotic polar solvent such as acetonitrile at ambient temperature for about 1 to 24 hours.
[341] Preferably, the cyclization of the methyl ester 66 is achieved by treatment with an equal amount of thionyl chloride for the ester, preferably using an aprotic solvent such as methylene chloride or tetrahydrofuran.
[342] Oxazoline 67 is oxidized to compound 68 by reflux with an oxidizing agent, preferably 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDO). Other oxidants such as activated magnesium oxide or NiO ₂ are also useful. The reaction is preferably carried out in an aprotic solvent such as toluene, benzene or preferably dioxane and is actually completed in 1 to 24 hours.
[343] The oxazole 68 can then be reduced with a reducing agent such as lithium aluminum hydride in a lithium borohydride-methanol reduction system or preferably in an aprotic polar solvent such as tetrahydrofuran. The reaction is initiated at −10 ° C. to ambient temperature, preferably about 0 ° C. and then stirred at ambient temperature for 30 minutes to 12 hours.
[344] Halogenation of (69) is characterized in that triphenylphosphine and carbon tetrabromide, phosphorus tribromide, phosphorus tribromide, carbon tetrabromide or boron triphenylphosphine, preferably tribromide, in aprotic polar solvents such as methylene chloride or acetonitrile Achieved by treatment with a halogenating agent such as phosphorus. The reaction is preferably carried out at ambient temperature for 1 to 24 hours but may also be carried out at temperatures of −10 ° C. to ambient temperature.
[345] In the substitution reaction under Finkelstein condition, the halogen is replaced with an appropriately substituted benzaldehyde.
[346] Reductive amination of (70) as described in Schemes I (a), step (e) above yields the desired product (71).
[347] Compounds of formula (I) wherein Ar, X and Y and R ⁴ are as described in Scheme 1 (ce) above and m is 0, can be prepared as shown in Scheme XVI.
[348]
[349] In the above scheme,
[350] R ^c is (CH ₂ ) _q , where q is an integer from 2 to 6, and
[351] R ^d is H or C ₁ -C ₅ alkyl and A is halo.
[352] The starting material 11 is coupled with the oxazole starting material 70 in the presence of a base such as sodium hydride in an aprotic solvent, preferably tetrahydrofuran. The reaction is preferably carried out at ambient temperature for 1 to 24 hours to produce intermediate amide 72.
[353] Reduction of the intermediate 72 can be made by treating 73 with a reducing agent such as boranedimethylsulfide.
[354] In addition, the coupling reaction can be accomplished by reacting 116 and (70) (prepared as described in Scheme I (a) (3)) and reducing the carbonyl with a reducing agent such as borane. The reaction is carried out in an aprotic solvent, preferably tetrahydrofuran at ambient temperature.
[355] Compounds in which m is 2 can be prepared as described in Scheme XVII below.
[356]
[357] In the above scheme, A is halo.
[358] The starting material 59 is reacted with a halogenating agent such as triphenylphosphine and iodine in the presence of a weak base. The reaction can be carried out in an aprotic polar solvent at ambient temperature for 1 to 24 hours.
[359] In the substitution reaction, the halogenated compound (60) is heated with sodium cyanide in an aprotic polar solvent such as dimethylsulfoxide for about 1 to 2 hours to form intermediate cyano compound (74).
[360] The cyano compound (74) can then be reduced with a reducing agent such as diisobutylaluminum hydride in a nonpolar solvent such as toluene. Preferably, the reaction is initiated at -78 ° C and then warmed to ambient temperature for 1-2 hours.
[361] Formyl compound (75) can then be reduced in a solvent such as diethyl ether with a reducing agent such as sodium borohydride to produce the intermediate (76).
[362] (77) can be prepared, isolated, purified and converted to the desired amine 78 by reductive amination by intermediate chain 76 with the appropriately substituted hydroxy benzaldehyde.
[363] Compounds wherein R ¹ and R ² are independently of each other — (C ₁ -C ₆ ) alkoxy are prepared as described in Scheme XVIII below.
[364]
[365] In the above scheme,
[366] PG is a protecting group and R ^b is — (C ₁ -C ₆ ) alkyl.
[367] After the procedure described in Scheme I (a), step (a) above, the appropriately substituted benzoic acid (79) is converted to intermediate benzamide (80).
[368] The intermediate benzamide 80 may then be cyclized to ester 81 by heating to a temperature of 50 ° C. to 130 ° C. with 4-chloroacetoacetate under an inert gas.
[369] For example, reduction of the ester with lithium aluminum hydride provides the primary alcohol 82.
[370] After the schematic procedure of Schemes I (a), steps (d) and (e), an amine 84 is prepared. For example, the desired product 85 is obtained by removal of the protecting group by hydrolysis.
[371] Compounds in which R ³ and R ⁴ together with the ring to which they are attached form a benzoxazole group are prepared as described in Scheme XIX below.
[372]
[373] Properly substituted benzoic acid (81) is coupled with 2-hydroxy-5-methoxyaniline in the presence of an acid such as boric acid to form intermediate benzoxazole (87).
[374] For example, alcohol 88 is obtained by demethylation of (87) with boron tribromide. Preferably, the reaction is carried out in an organic solvent such as methylene chloride at a temperature of about -10 ° C to -70 ° C.
[375] Preparation of (89) was carried out in the Ullman reaction by heating (88) to a temperature of preferably about 140 ° C with an appropriately substituted arylhalide such as 4-bromobenzaldehyde in the presence of potassium carbonate and copper iodide. Is achieved.
[376] Reductive amination as described in Scheme I (a), step (e) provides (90).
[377] Compounds wherein X is -O- and Y is -N- are obtained as shown in Scheme XX.
[378]
[379] Oxadiazole (91) is prepared by first treating an appropriately substituted benzoic acid (86) with thionyl chloride to produce an acid chloride intermediate capable of reacting with an appropriately substituted alkylamide oxime such as methylethylamide oxime.
[380] After steps (b)-(d) as described in Scheme XIX above, the desired product 94 is obtained.
[381] Compounds in which X is -O- and this single bond can be prepared as described in Scheme XXI below.
[382]
[383] Reduction of 95 is accomplished by treatment with a reducing agent such as lithium aluminum hydride. Preferably, the reaction is carried out in an aprotic polar solvent such as tetrahydrofuran at a temperature of about −10 ° C. to prepare intermediate alcohol 96.
[384] Aldehyde 97 is prepared in a michunobu coupling, as described in Scheme I (a), step (d). Reductive amination, as described in Scheme I (a), step (e), provides (98).
[385] A compound wherein Ar is tetrahydronaphthyl is prepared as shown in Scheme XXII.
[386]
[387] As described in Scheme I, step (d), in the michunobu coupling, ester 99 is prepared. The ester is hydrolyzed by treatment with a base such as lithium hydroxide to produce acid (100).
[388] Cyclization to tetrahydronaphthyl 101 is accomplished by first converting the acid to hydrochloric acid, for example by treating with thionyl chloride and then reacting the hydrochloric acid intermediate with ethylene gas. The desired product 102 is obtained by reductive amination as described in Scheme I, step (e).
[389] Intermediates and final products can be isolated and purified by conventional techniques, for example by concentrating the solvent, washing the residue with water and then purifying by conventional techniques such as chromatography or recrystallization.
[390] When Ar is phenyl substituted with one or two — (C ₁ -C ₆ alkyl) R ⁶ groups, the present invention may have one or two stereogenic centers. The methods, formulations and compounds of the present invention include diastereomers and racemates and their individual stereoisomers. A pair of diastereoisomers can be obtained according to procedures well known in the art. For example, the formation of diastereomeric salts from racemic amines can be accomplished by treatment with chiral acid, such as tartaric acid or diisopropylidene-keto-gulonic acid.
[391] Those skilled in the art will readily understand that substituted benzoic acids, amides, amines, alcohols, aldehydes, heterocycle compounds, imidazoles and thiaphenol starting materials are either commercially available or can be readily prepared by known techniques from commercially available starting materials. All other reactants used to prepare the compounds of the present invention are commercially available.
[392] The following examples further illustrate the preparation of the compounds of the present invention. The examples are illustrative only and are not intended to limit the scope of the invention in any way.
[393] <Example 1>
[394] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-ethylaminomethylphenoxy) ethyl) oxazole hydrochloride dihydrate
[395] A. Preparation of 3,5-bis (1,1-dimethylethyl) -4-hydroxybenzamide
[396] In a 22 L morton flask, 749 g (3.0 moles) of 3,5-bis (1,1-dimethylethyl) -4-hydroxybenzoic acid, 533 g (3.3 moles) of carbonyldiimidazole and tetrahydrofuran (THF) were combined And slowly heated to reflux for 2.5 hours. The reaction mixture was cooled to 26 ° C. and concentrated aqueous ammonia was added. Stirring was continued for 2 hours and the reaction mixture was left overnight. The contents were transferred to a flask and rinsed with tetrahydrofuran (250 ml). The mixture was stirred, the layers separated and the aqueous layers collected. The organic layer was washed with brine (2.5 L) and brine / deionized water (DI) (1 L / 1.5 L). The organic layer was washed with 9.7 M hydrochloric acid (HCl) / deionized water (0.25 L / 2.25 L), followed by 9.7 M hydrochloric acid (HCl) / deionized water (0.5 L / 2.8 L) and 9.7 M hydrochloric acid (HCl) / deionized water / salt ( 0.5 L / 1.5 L / 1.5 L). The combined aqueous layers were washed apart with tetrahydrofuran apart from the organic layers. The combined organic layers were washed with brine, dried over sodium sulfate (855 g) and filtered. The filtrate was evaporated to afford 1011 g of a wet (water) white solid. Methylene chloride was added and removed in vacuo. This procedure was repeated with ethyl acetate (6 L, then 2 L) to give a solid residue (779 g). The residue was slurried with ethyl acetate and heptanes, filtered and dried in a vacuum oven to yield the desired amide (736 g, 98.7%) as a white solid having a melting point of 257 to 260 ° C.
[397] ¹ H NMR (DMSO-d ₆ , 300 MHz) δ 7.75 (1 H, s), 7.60 (2H, s), 7.30 (1 H, s), 7.00 (1 H, s), 1.35 (18 H, s).
[398] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (carboxymethyl) oxazole
[399] To 24.90 g (100 mmol) of the compound of Step A was added 55 ml (407 mmol) of ethyl 4-chloroacetoacetate. The mixture was heated to 130 ° C. under nitrogen for 2 hours. The reaction mixture was cooled to 90 ° C and the volatiles were distilled from the reaction mixture under vacuum until the pot temperature reached 130 ° C. The concentrated residue was cooled to 60 ° C. under vacuum. The vacuum was released and 100 ml of methanol was added to the mixture. The solution was cooled to 25 ° C. and then 50% sodium hydroxide solution (50 ml) was added dropwise. The reaction mixture temperature was raised to 55 ° C. The mixture was stirred for 25 minutes, then concentrated aqueous hydrochloric acid (25 ml, 300 mmol) was added dropwise to the reaction mixture to bring the pH to 7-8. The mixture was filtered and the cake washed with methanol (2 x 50 ml). Methanol was removed under vacuum followed by addition of 1N hydrochloric acid (100 ml) and water (100 ml). A sticky precipitate formed. The precipitate was dissolved by adding 500 ml of a 1: 1 mixture of tert-butyl methyl ether (MTBE) and ethyl acetate. The resulting emulsion was separated into three layers overnight. The top layer containing the desired product identified by HPLC was dried over sodium sulfate and concentrated in vacuo to give 30.8 g of a tan solid. This solid was dissolved in 2: 1 methanol: water (225 ml) at 75 ° C. The stirred mixture was cooled to 25 ° C. for 1 hour and stirred for another 2.5 hours. The mixture was filtered and the cake was washed with a total of 120 ml 2: 1 methanol: water. Vacuum drying at 40 ° C. yielded 21.94 g of a subtitle compound. A portion of the acid, 19.9 g, was recrystallized from 300 ml of 1: 1 heptane: toluene to yield 17.77 g (62% total yield) of the subtitle product as a white solid.
[400] Melting Point 166-68 ℃
[401] ¹ H NMR (DMSO-d ₆ , 300 MHz) δ 12.49 (s, 1H, exchanged for D ₂ O), 7.93 (s, 1H), 7.72 (s, 2H), 7.54 (s, 1H, D ₂ Exchanged with O), 3.56 (s, 2H), 1.41 (s, 18H).
[402] Elemental Analysis for C ₁₉ H ₂₅ NO ₄ :
[403] Theoretical: C, 68.86; H, 7. 60; N, 4.23.
[404] Found: C, 68.86; H, 7.59; N, 4.32.
[405] FDMS 331 (M ⁺ ).
[406] C. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-hydroxyethyl) oxazole
[407] In a 22 L flask, 757 g (2.28 mol) of the compound of Step B were dissolved in tetrahydrofuran. To this solution was added 1M borane tetrahydrofuran (4.8 L) initially very slowly and with cooling in a water bath. After 1 hour the reaction mixture was quenched very slowly due to hydrogen evolution with methanol (650 ml). The mixture was stirred overnight. The solution was placed on a rotary evaporator and evaporated to foam (995 g). The residue was dissolved in tert-butyl methyl ether (11 L) and deionized water (4.9 L), 50% sodium hydroxide (130 ml) was added and stirred, followed by brine (3.6 L). The layers were separated to form three layers. The lower two layers were discarded because no product appeared. The tert-butyl methyl ether layer was washed with a mixture of 1N sodium hydroxide (100 ml), deionized water (2 L) and brine (2 L). The organic layer was dried over sodium sulfate, filtered and evaporated to give 802 g of a viscous residue. Toluene (1.4 L) was added to the residue and the mixture was heated to 80 ° C to give a solution. Heptane (6 L) was added and the solution was heated to 93 ° C and then cooled to 0-10 ° C with an ice bath for 1.5 h. The mixture was filtered and the cake rinsed with 60:40 heptane / toluene (2 L). The solid was dried in a vacuum oven to prepare 670 g of the subtitle product. The solid was recrystallized from toluene (2 L) and heptane (5.5 L) to yield 627 g (87% yield) of the product as a white solid.
[408] Melting point 119 ° C-121 ° C.
[409] ¹ H NMR (CDCl ₃ , 300 MHz) δ 1.48 (s, 18H), 2.8 (t, J = 6.0 Hz, 2H), 3.97 (t, J = 6.0 Hz, 2H), 5.52 (s, 1H), 7.42 (s, 1 H), 7.82 (s, 2 H).
[410] D. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formylphenyloxy) ethyl) oxazole
[411] The compound of step C (204.3 g, 644 mmol), triethylamine (100 ml, 716 mmol) and methylene chloride (1.7 L) were stirred to give a solution. Methanesulfonyl chloride (81.3 g, 710 mmol) was added for 15 minutes and the pot temperature was kept below 31 ° C. using a water bath. The reaction mixture was stirred and cooled to 23 ° C. for 1.5 h. The reaction mixture was poured into a 4 L separatory funnel and the flask was rinsed with methylene chloride (0.5 L). The organic layer was washed with 1N hydrochloric acid (3 × 1 L) and the combined aqueous layers were extracted again with methylene chloride (0.3 L). The combined organic layers were washed with a solution of brine (0.5 L) and deionized water (0.5 L). The organic layer was dried over sodium sulfate, filtered and evaporated to give 254 g of mesylate as an oil foam. Dimethyl sulfoxide (DMSO, 0.7 L) was added to the intermediate mesylate compound to give a solution. In a separate flask, 4-hydroxybenzaldehyde (89.6 g, 734 mmol), potassium t-butoxide (79.98 g, 0.713 mmol) and dimethylsulfoxide (1.2 L) were combined and heated to 45 ° C. to prepare a brown solution. The mesylate compound in dimethyl sulfoxide was added all at once. The reaction mixture was heated to 60-65 ° C. for 15 hours. Additional 0.5 L of dimethyl sulfoxide was added. The reaction temperature was increased to 70 ° C. and maintained for 2 hours. Then 4-hydroxybenzaldehyde (3.92 g) and potassium t-butoxide (3.59 g) were added to the reaction mixture. After 7 hours at 70 ° C. the reaction mixture was cooled to ambient temperature. tert-butyl methyl ether (3.3 L) was added to the reaction mixture. The solution was extracted with 1N sodium hydroxide (4 x 2 L). The aqueous layers were combined and extracted again with tert-butyl methyl ether (2 × 1 L) and discarded. The combined organic layers were washed with deionized water (2 L), deionized water / salt (2 L), and brine (2 L). The organic layer was dried over sodium sulfate, filtered and evaporated to give a dark residue (267.3 g). The residue was dissolved in a mixture of methylene chloride (150 ml) and heptane (100 ml) and passed through a chromatography apparatus equipped with a silica gel (2.5 kg) column. The column was eluted with 1: 1 heptane / methylene chloride (16 L), methylene chloride (12 L), and 6% ethyl acetate / methylene chloride. Fractions containing the main component product were combined and evaporated to yield 196 g of amber oil. The oil was dissolved in chloroform (200 ml) and transferred to a flask with a mechanical stirrer. The flask was rinsed with hexane / chloroform (100 ml / 25 ml) and hexane (100 ml) and the wash was added to the solution. After addition of hexanes (1.8 L), the solution was heated to reflux to give 100 ml of distillate. The mixture was cooled to 35 ° C. for 1.5 h and crystallization occurred. Using an ice / water bath, the solution was cooled to 6 ° C. for 1.5 h. The product was filtered, rinsed with 10% chloroform / hexanes (300 ml) and dried in a vacuum oven to give 153 g (56% yield) of the subtitle product as a white solid.
[412] Melting point 110-112 ° C.
[413] The desired compound in the HPLC analysis was 99.4% (area).
[414] ¹ H NMR (CDCl ₃ , 300 MHz) δ 1.45 (s, 18H), 3.10 (t, 2H, J = 6 Hz), 4.38 (t, 2H, J = 6 Hz), 5.50 (s, 1H), 7.02 (d, J = 7 Hz, 2H), 7.50 (s, 1H), 7.79 (d, J = 7 Hz, 2H), 7.82 (s, 2H), 9.85 (s, 1H).
[415] E. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-ethylaminomethylphenoxy) ethyl) oxazole hydrochloride hemihydrate
[416] To 5.05 g (12 mmol) of the compound of Step D dissolved in 50 ml of dry methanol under nitrogen was added 7.85 ml (120 mmol) of monoethylamine. The solution was stirred for 5 minutes, then 6.8 ml (120 mmol) of acetic acid were added and the mixture was stirred under nitrogen for 30 minutes. 795 mg (12.6 mmol) sodium cyanoborohydride were added and the reaction stirred for 3 hours. Additional 500 mg of sodium cyanoborohydride was added and stirred again for another 1 hour. Ethyl acetate was then added and the mixture was washed with water, saturated sodium bicarbonate and again with water. The organic layer was dried, filtered and then evaporated to afford 5.44 g of crude product, chromatographed on 300 ml silica eluting methylene chloride / methanol / concentrated ammonia (90: 10: 1). Fractions containing the desired product were concentrated in vacuo and then dissolved in diethyl ether. Hydrogen chloride gas was bubbled into the solution to give an oil which was dissolved in acetone and stripped to dryness to give 3,4 g (54%) of the title product as a white foam.
[417] FDMS-M ⁺ 450;
[418] Elemental Analysis for (C ₂₈ H ₃₈ N ₂ O ₃ .HCl.0.5H ₂ O):
[419] Theoretical: C, 67.79; H, 8.13; N, 5.65.
[420] Found: C, 67.97; H, 7.99; N, 5.74.
[421] NMR (CDCl ₃ ) δ 1.40 (t, 3H, J = 7 Hz), 1.49 (s, 18H), 2.92 (q, 2H, J = 4 Hz), 3.30 (t, 2H, J = 7 Hz), 3.95 (t, 2H, J = 7 Hz), 4.31 (t, 2H, J = 7 Hz), 6.10 (bs, 1H), 6.85 (d, 2H, J = 9 Hz), 7.49 (d, 2H, J = 9 Hz), 7.87 (s, 1 H), 8.21 (s, 2 H), 9.59 (bs, 2 H)
[422] <Example 2>
[423] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-dimethylaminomethyl-phenoxy) ethyl) oxazole hydrochloride
[424] The title compound was subjected to 1.26 g (3 mmol) of the compound of Example 1D substantially using the procedure of Example 1E above using 200 mg (3.15 mmol) of sodium cyanoborohydride and 3.37 ml (30 mmol) of 40% aqueous dimethylamine. From). This reaction gave 1.31 g (90%) of the title product as a white foam.
[425] FDMS-M ⁺ 450;
[426] Elemental Analysis for (C ₂₈ H ₃₈ N ₂ O ₃ · HCl):
[427] Theoretical: C, 69.05; H, 8.07; N, 5.75.
[428] Found: C, 68.75; H, 7.94; N, 5.56.
[429] NMR (CDCl ₃ ) δ 1.49 (s, 18H), 2.71 (d, 2H, J = 3 Hz), 3.38 (t, 2H, J = 7 Hz), 4.10 (d, 2H, J = 7 Hz), 4.44 (t, 2H, J = 7 Hz), 6.08 (s, 1H), 6.95 (d, 2H, J = 9 Hz), 7.50 (d, 2H, J = 9 Hz), 7.74 (s, 1H), 8.23 (s, 2 H).
[430] <Example 3>
[431] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethylphenoxy) ethyl) oxazole hydrochloride hydrate
[432] The title compound was prepared from 3.36 g (7.98 mmol) of Example 1D substantially using the procedure of Example 1E above using 0.5 g (7.98 mmol) of sodium cyanoborohydride and 6.9 ml (79.8 mmol) of methylethylamine. Prepared. The organic layer was chromatographed on silica gel using methylene chloride / methanol with a gradient to give the free base (2.79 g, 75%). The free base was dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to give 2.8 g (93%) of the title product.
[433] ¹ H NMR (CDCl ₃ ) δ8.0 (s, 2H), 7.6 (s, 1H), 7.5 (d, J = 9 Hz, 2H), 6.95 (d, J = 9 Hz, 2H), 5.7 (s , 1H), 4.35 (t, J = 7 Hz, 2H), 4.1 (m, 2H), 3.2 (m, 3H), 2.9 (m, 1H), 2.6 (d, J = 4 Hz, 3H), 1.5 (s, 18 H), 1. 45 (t, J = 7 Hz, 3H);
[434] FDMS 464 (M ⁺ -HCl);
[435] _{C 29 H 41 ClN 2 O 3} · elemental analysis of the H ₂ O:
[436] Theoretical: C, 67.10; H, 8. 35; N, 5.40.
[437] Found: C, 66.99; H, 7.96; N, 5.29.
[438] <Example 4>
[439] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-dimethylaminomethyl-phenoxy) ethyl) oxazole hydrochloride
[440] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-formylphenoxy) ethyl) oxazole
[441] To 4.44 g (14 mmol) of the compound of Example 1C dissolved in tetrahydrofuran (THF) 1.94 g (16 mmol) of 3-hydroxybenzaldehyde and 4.18 g (16 mmol) of triphenylphosphine (PPh ₃ ) under nitrogen Was added. The solution was cooled to −50 ° C. and a solution of 2.51 ml (16 mmol) of diethyldiazodicarboxylate (DEAD) in 15 ml of tetrahydrofuran was added under stirring for 10 minutes. The crude was removed and the reaction stirred under nitrogen for 4 hours. Hydrogen peroxide (0.89 ml, 30%) was added and the reaction stirred for 15 minutes, stripped, dissolved in 40 ml of methylene chloride and placed in the freezer. The diethoxycarbonylhydrazine was then filtered and the filtrate was chromatographed by eluting with a 5 to 20% acetone / hexane gradient for 30 minutes. Appropriate fractions were combined and stripped to yield 3.2 g (54%) of the subtitle product.
[442] NMR (CDCl ₃ ) δ 1.49 (s, 18H), 3.10 (t, 2H, J = 7 Hz), 4.35 (t, 2H, J = 7 Hz), 5.50 (s, 1H), 7.20 (m, 1H ), 7.44 (m, 3H), 7.51 (s, 1H), 7.84 (s, 2H), 9.97 (s, 1H).
[443] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-dimethylaminomethylphenoxy) ethyl) oxazole hydrochloride
[444] The title compound was prepared from 3.2 g (7.6 mmol) of the compound of Step A substantially following the procedure of Example 1E above using 503 mg (8.0 mmol) of sodium cyanoborohydride and 9.5 ml (76 mmol) of dimethylamine. This reaction produced 1.82 g (49%) of white foam and was triturated with methylene chloride / isopropyl ether to yield 1.25 g of subtitle product.
[445] FDMS-M ⁺ 450;
[446] Elemental Analysis for (C ₂₈ H ₃₈ N ₂ O ₃ · HCl):
[447] Theoretical: C, 69.05; H, 8.07; N, 5.75.
[448] Found: C, 69.31; H, 8.13; N, 5.84.
[449] NMR (CDCl ₃ ) δ 1.50 (s, 18H), 2.77 (d, 2H, J = 5 Hz), 3.33 (t, 2H, J = 7 Hz), 4.15 (d, 2H, J = 4 Hz), 4.48 (t, 2H, J = 7 Hz), 5.95 (s, 1H), 6.98 (dd, 1H, J = 2 Hz, 9 Hz), 7.12 (d, 1H, J = 9 Hz), 7.32 (t, 1H, J = 9 Hz, 7.53 (d, 1H, J = 2 Hz), 7.88 (s, 1H), 8.16 (s, 2H).
[450] <Example 5>
[451] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-n-propylaminomethyl-phenoxy) ethyl) oxazole hydrochloride
[452] The title compound was prepared from 3.0 g (7.13 mmol) of Example 1D substantially using the procedure of Example 1E above using 471 mg sodium cyanoborohydride and 5.82 ml (71.3 mmol) monopropylamine. This reaction gave 1.67 g (47%) of the title product as a white foam.
[453] FDMS-M ⁺ 464;
[454] Elemental Analysis for (C ₂₈ H ₃₈ N ₂ O ₃ · HCl):
[455] Theoretical: C, 69.51; H, 8. 25; N, 5.59.
[456] Found: C, 69.80; H, 8. 24; N, 5.46.
[457] NMR (CDCl ₃ ) δ 0.92 (t, 3H, J = 7 Hz), 1.49 (s, 18H), 1.86 (m, 2H, J = 7 Hz), 2.71 (m, 2H, J = 7 Hz), 3.28 (t, 2H, J = 7 Hz), 3.94 (t, 2H, J = 7 Hz), 4.30 (t, 2H, J = 7 Hz), 6.00 (s, 1H), 6.87 (d, 2H, J = 9 Hz), 7.50 (d, 2H, J = 9 Hz), 7.74 (s, 1H), 8.17 (s, 2H), 9.70 (bs, 2H).
[458] <Example 6>
[459] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-n-hexylaminomethyl-phenoxy) ethyl) oxazole hydrochloride
[460] The title compound was practically prepared as described in Example 1E, except using N-hexylamine. The reaction was concentrated in vacuo and then treated with 1: 1 ethyl acetate: water (100 ml). The phases were separated and the organics washed with aqueous saturated sodium bicarbonate (50 ml) followed by brine (50 ml). The organics were concentrated in vacuo and then treated with diethyl ether and silica gel (10 g) and the resulting material was concentrated in vacuo to a flowable powder. Powder was mixed with methylene chloride (3 x 200 ml), methylene chloride: 1% methanol (5 x 100 ml), 94: 5: 1 methylene chloride: methanol: ammonium hydroxide (10 x 100 ml), 89: 10: 1 Methylene chloride: methanol: ammonium hydroxide (4 x 250 ml) was eluted and subjected to silica gel flash chromatography. Fractions containing the desired product were combined and concentrated in vacuo to yield 2.37 g of oil. The oil was treated with chloroform (75 ml) followed by hydrochloric acid gas. The resulting solution was concentrated to foam under vacuum and treated with hot methylene chloride (10 ml) followed by diisopropyl ether (10 ml) and concentrated until turbidity was observed. The cloudy solution was left in the freezer for approximately 2.5 hours. Insolubles were collected by filtration, washed with diisopropyl ether and dried in a 40 ° C. vacuum oven overnight to yield 1.46 g of the title compound.
[461] Mass spectrum (FDMS): m / z 506 (M).
[462] ¹ H NMR (CDCl ₃ ) δ8.23 (s, 2H), 7.80 (s, 1H), 7.49 (d, J = 8.3 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 6.07 (s , 1H), 4.32 (m, 2H), 3.93 (m, 2H), 3.32 (m, 2H), 2.75 (m, 2H), 1.85 (m, 2H), 1.50 (m, 18H), 1.24 (m, 6H), 0.82 (t, J = 6.6 Hz, 3H).
[463] Elemental Analysis for C ₃₂ H ₄₇ ClN ₂ O ₃ :
[464] Theoretical: C, 70.76; H, 8. 72; N, 5.16.
[465] Found: C, 70.68; H, 8.61; N, 5.16.
[466] <Example 7>
[467] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-diethylaminomethyl-phenoxy) ethyl) oxazole hydrochloride dihydrate
[468] The title compound was purified from 4.21 g (10 mmol) of Example 1D substantially using the procedure of Example 1E using 0.63 g (10 mmol) of sodium cyanoborohydride and diethylamine (10.3 ml, 100 mmol). Prepared. The reaction was continued for 21 hours. The organic layer was chromatographed on silica gel using gradient methylene chloride / methanol to give the free base which was then dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to yield 2.68 g (52%) of the title compound. .
[469] ¹ H NMR (CDCl ₃ ) δ 8.05 (s, 2H), 7.6 (s, 1H), 7.55 (d, J = 9 Hz, 2H), 6.95 (d, J = 9 Hz, 2H), 5.8 (s , 1H), 4.4 (t, J = 7 Hz, 2H), 4.1 (d, J = 5 Hz, 2H), 3.25 (t, J = 7 Hz, 2H), 3.0 (m, 4H), 1.5 (s , 18H), 1.4 (t, J = 7 Hz, 6H);
[470] FDMS 478 (M ⁺ -HCl);
[471] Elemental Analysis for C ₃₀ H ₄₃ ClN ₂ O ₃ · 2H ₂ O:
[472] Theoretical: C, 64.32; H, 8. 64; N, 5.00.
[473] Found: C, 63.94; H, 8. 46; N, 4.80.
[474] <Example 8>
[475] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-n-propyl-N-methylaminomethylphenoxy) ethyl) oxazole hydrochloride
[476] The title compound was prepared substantially as described in Example 1E, except using N-methyl-Nn-propylamine, and a gradient from 0 to 10% (methanol: 1% ammonium hydroxide): chloroform for 30 minutes. Chromatography. Fractions containing the desired product were concentrated in vacuo, treated with chloroform (100 ml) and magnesium sulfate and filtered, then the filtrate was saturated with hydrogen chloride gas. The solution was concentrated in vacuo to afford 3.40 g (68%) of the title compound foam.
[477] Mass spectrum (FDMS): m / z 478 (M).
[478]
[479] _{C 30 H 43 ClN 2 O 3} · elemental analysis of the H ₂ O:
[480] Theoretical: C, 67.58; H, 8.51; N, 5.25.
[481] Found: C, 67.65; H, 8.34; N, 5.33.
[482] <Example 9>
[483] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-n-propyl-N-ethylaminomethylphenoxy) ethyl) oxazole hydrochloride
[484] A solution of N-ethyl-N-propylamine (29.5 mmol, 2.58 g) in chloroform (10 ml) was saturated with hydrogen chloride gas. The solution was concentrated in vacuo followed by ethanol (11 ml), triethylamine (29.5 mmol, 2.99 g), titanium IV isopropoxide (29.5 mmol, 8.40 g) and prepared as described in Example 1D above. Treated with 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formylphenoxy) ethyl) oxazole (14.8 mmol, 6.22 g). The suspension was stirred for 4 hours at room temperature and carefully treated to avoid foaming with sodium borohydride (22.2 mmol, 0.84 g). The reaction was stirred for approximately 3 days and then treated with 2N ammonium hydroxide (23 ml). To this mixture was added methylene chloride (150 ml) and diatomaceous earth (20 g) and the mixture was filtered through a pad of diatomaceous earth and washed with methylene chloride (100 ml). The filtrate was washed with brine (1 x 50 ml) and the organic layer was concentrated in vacuo to an oil, treated with chloroform and prechromatographic. The material was eluted for 30 minutes with a 0 to 10% (1% ammonium hydroxide: methanol): chloroform gradient. Fractions containing the desired product were concentrated in vacuo to oil. The oil was treated with chloroform and saturated with hydrogen chloride gas. This solution was concentrated in vacuo to give 4.78 g (61%) of the title compound.
[485] Mass spectrum (FDMS): m / z 492 (M-HCl).
[486]
[487] Elemental Analysis for C ₃₁ H ₄₅ ClN ₂ O ₃ :
[488] Theoretical: C, 70.36; H, 8.57; N, 5.29.
[489] Found: C, 70.08; H, 8.32; N, 5.30.
[490] <Example 10>
[491] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (2,4-bis (methylethylaminomethyl) phenoxy) ethyl) oxazole dihydrochloride
[492] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (2,4-bis-formylphenoxy) ethyl) oxazole
[493] In a flask, tetrahydrofuran was mixed with 4.75 g (15 mmol) of compound of Example 1C, 2.36 g (15.75 mmol) of 3-formyl-4-hydroxybenzaldehyde and 3.93 g (15 mmol) of triphenylphosphine under nitrogen. It was dissolved in 45 ml. The solution was cooled to −10 ° C. and a solution of 2.36 ml (15 mmol) of diethyl azodicarboxylate in 15 ml of tetrahydrofuran was added for 10 minutes with stirring. The reaction exothermed to + 1 ° C. The crude was removed and reacted with stirring under nitrogen for 18 hours. The reaction was then stripped and dissolved in the minimum amount of methylene chloride and placed in the freezer. The diethoxycarbonylhydrazine was then filtered off and the filtrate was chromatographed with two columns of Prep 500 eluting with a 0 to 20% ethyl acetate / toluene gradient for 30 minutes. Appropriate fractions were combined and stripped to yield 3.3 g (49%) of product which was used without further purification.
[494]
[495] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (2,4-bis (methylethylaminomethyl) phenoxy) ethyl) oxazole dihydrochloride hydroxide Manufacture of Rate
[496] The title compound hydrochloride was substantially prepared according to the procedure of Example 9 using 4.0 ml (13.4 mmol) titanium IV isopropoxide and 1.15 ml (13.4 mmol) methylethylamine and 0.38 g (10 mmol) sodium borohydride. Prepared from 1.5 g (3.34 mmol) of the product of Step A. The organics were chromatographed on 100 ml silica eluting with methylene chloride / methanol and concentrated ammonia (90: 10: 1). The appropriate fractions were concentrated and dissolved in methylene chloride / isopropyl ether. Bubbling hydrogen chloride gas and the resulting residue was triturated with isopropyl ether to give 1.10 g (54%) of the title product as a white foam.
[497] FDMS-M ⁺ 536;
[498] Elemental Analysis for (C ₃₃ H ₄₉ N ₃ O ₃ 2HClH ₂ O):
[499] Theoretical: C, 63.45; H, 8.52; N, 6.72.
[500] Found: C, 63.80; H, 8.53; N, 6.49.
[501]
[502] <Example 11>
[503] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-hydroxyethyl) ethylaminomethylphenoxy) ethyl) oxazole hydrochloride
[504] To a solution of N-ethylethanolamine (1.95 ml, 20 mmol) in ethanol (25 ml) was added titanium IV isopropoxide (5.9 ml, 20 mmol) with stirring, followed by the compound of Example 1D (4.21 g , 10 mmol) was added. The reaction was stirred for 4 hours and sodium borohydride (0.57 g, 15 mmol) was added. After 20 h at rt, the reaction was poured into 75 ml 2N ammonium hydroxide and diluted with methylene chloride. The mixture was filtered through diatomaceous earth and the filtrate was extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel with gradientd methylene chloride / methanol to give the free base (3.56 g, 72%). The free base was dissolved in methylene chloride (86 ml), treated with hydrogen chloride gas and evaporated to afford the desired product (3.92 g, 100%).
[505]
[506] FD MS 494 (M ⁺ -HCl);
[507] _{(C 30 H 43 ClN 2 O} 4 · 0.5H 2 O) Elemental Analysis for:
[508] Theoretical: C, 66.71; H, 8.21; N, 5.19.
[509] Found: C, 66.47; H, 8. 10; N, 5.20.
[510] <Example 12>
[511] 2- (3,5-di-t-butyl-4-methoxyphenyl) -4- (2- (4-N-bis [hydroxyethyl] aminomethylphenoxy) ethyl) oxazole hydrochloride
[512] The title compound was prepared substantially as described in Example 11 except for using diethanolamine. The material was pre chromatographed by eluting with a gradient of 0 to 10% (1% ammonium hydroxide / methanol): chloroform for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to afford an oil. The oil was treated with chloroform and then with hydrogen chloride gas and concentrated in vacuo to yield 817 mg of the title compound as a foam.
[513] Mass spectrum (FDMS): m / z 510 (M-HCl).
[514]
[515] Elemental Analysis for C ₃₀ H ₄₃ ClN ₂ O ₅ + 0.3 mol H ₂ O:
[516] Theoretical: C, 65.21; H, 7.95; N, 5.07.
[517] Found: C, 65.18; H, 7.95; N, 4.67.
[518] <Example 13>
[519] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- [N-methyl-N- (3-piperidin-3-yl) propyl) aminomethyl ] Phenoxy) ethyl) oxazole dihydrochloride
[520] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-aminomethylphenoxy) ethyl) oxazole
[521] The subtitle compound was prepared substantially as described in Example 11 except for using the methylamine hydrochloride salt. The crude material was prechromatographic. The material was eluted for 30 minutes with a 0 to 10% (1% ammonium hydroxide: methanol): chloroform gradient. Fractions containing the desired product were reduced in vacuo, dried over sodium sulfate, filtered and concentrated in vacuo to yield 6.74 g (62%) of the title compound.
[522] Mass spectrum (FDMS): m / z 436 (M).
[523]
[524] Elemental Analysis for C ₂₇ H ₃₆ N ₂ O ₃ :
[525] Theoretical: C, 74.28; H, 8.31; N, 6.42.
[526] Found: C, 74.39; H, 8.51; N, 6.47.
[527] B. 2-((3,5-di-t-butyl-4-hydroxyphenyl) -4- [N-methyl-N- (3-N'-tert-butoxycarbonylpiperid-3-yl Preparation of (propyl) aminomethyl] phenoxy) ethyl) oxazole
[528] A red solution of the compound of step A (9.2 mmol, 4.01 g) in dimethylformamide (dimethylformamide, 18 ml) was treated with 60% (w / w) sodium hydride (20.2 mmol, 808 mg). The suspension is stirred at 24 ° C. for 30 minutes and then with a solution of N-tert-butoxycarbonyl-3- (3-bromopropyl) piperidine (8.4 mmol, 2.56 g) in dimethylformamide (5 ml). Treated. Thereafter, the suspension was heated to 80 ° C. for 4 hours and then cooled to 24 ° C. The reaction was treated with 10% aqueous sodium hydrogen sulfate (25 ml), water (10 ml) and 3/2 ethyl acetate: hexane (50 ml). The phases were separated and the aqueous layer was extracted with 3: 2 ethyl acetate: hexanes (2 × 50 ml). The combined organics were washed with brine (2 × 50 ml), dried over sodium sulphate, filtered and concentrated in vacuo to give 6.67 g of oil. The crude material was prechromatographic. The material was eluted for 30 minutes with a 0 to 10% (1% ammonium hydroxide: methanol): chloroform gradient. Fractions containing the desired product were reduced in vacuo, dried over sodium sulfate, filtered and concentrated in vacuo to yield 4.19 g of the title compound. The material contained some impurities and the next step was carried out without further purification.
[529] Mass spectrum (FDMS): m / z 662 (M + l).
[530]
[531] C. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- [N-methyl-N- (3- (N'-tert-butoxycarbonyl) Preparation of -piperid-3-yl) propyl) aminomethyl] phenoxy) ethyl) oxazole hydrochloride
[532] A solution of the compound of step B (3.15 mmol, 2.09 g) in diethyl ether (20 ml) was treated with hydrogen chloride gas for approximately 10 minutes. The resulting thick suspension was stirred for another 20 minutes, filtered and washed with diethyl ether (20 ml) to give 2.01 g (91%) of the subtitle compound.
[533] Mass spectrum (FDMS): m / z 661 (M).
[534]
[535] Elemental Analysis for C ₄₀ H ₆₀ ClN ₃ O ₅ :
[536] Theoretical: C, 68.89; H, 8.53; N, 6.03.
[537] Found: C, 68.65; H, 8. 45; N, 6.02.
[538] D. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- [N-methyl-N- (3- (piperidin-3-yl) propyl Preparation of Aminomethyl] phenoxy) ethyl) oxazole dihydrochloride
[539] To a solution of the compound of the compound of step C (3.0 mmol, 2.01 g) in chloroform (20 ml) was added thiophenol (6.07 mmol, 0.67 g). Hydrogen chloride gas was then passed through this solution for approximately 30 minutes and then stirred at 24 ° C. overnight and concentrated to a foam in vacuo. The material was placed in hot methylene chloride (10 ml) and then tetrahydrofuran (15 ml) was added while heating the solution. The solution was boiled until the total volume was 12 ml, cooled to approximately −22 ° C. and tetrahydrofuran (10 ml) was added, resulting in a precipitate. The suspension was filtered and the insolubles were transferred to methylene chloride and the volume reduced to approximately 5 ml. Tetrahydrofuran (20 ml) was added and the solution boiled down to approximately 5 ml. Thereafter, diethyl ether (20 ml) was added to the hot solution to form a gum. The suspension was cooled to 24 ° C., the gum was softened and the insolubles were collected by filtration and washed with diethyl ether (20 ml). The insoluble was resuspended with stirring in hot diethyl ether (150 ml). After heating for approximately 30 minutes (keeping volume from 100 to 150 ml) insolubles were collected by filtration and washed with hot diethyl ether (100 ml). The insolubles were dried overnight in a 60 ° C. vacuum oven to yield 1.32 g (72%) of the title compound.
[540] Mass spectrum (FDMS): m / z 562 (M + l).
[541]
[542] Elemental Analysis for C ₃₅ H ₅₃ Cl ₂ N ₃ O ₃ :
[543] Theoretical: C, 66.23; H, 8.42; N, 6.62.
[544] Found: C, 66.47; H, 8.67; N, 6.39.
[545] <Example 14>
[546] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminoethylphenoxy) ethyl) oxazole hydrochloride heptahydrate
[547] A. Preparation of N-Formyl-N-ethyl-p-hydroxyphenethylamine
[548] To a suspension of 1,1′-carbonyldiimidazole (326 mmol, 52.81 g) in tetrahydrofuran (164 ml) cooled to 0 ° C. was added dropwise 96% formic acid (326 mmol, 14.99 g) for 24 minutes. The reaction was stirred at 0 ° C. for 30 minutes and then a thin suspension of N-ethyl-p-hydroxyphenethylamine (102 mmol, 16.88 g) in tetrahydrofuran (66 ml) was added for 10 minutes. The reaction was then stirred at 22 ° C. for 170 minutes and treated with methanol (10 ml). After stirring for 90 minutes, the reaction was concentrated in vacuo to an oil containing crystals. The mixture was taken up in methylene chloride and pre chromatographed for 30 minutes eluting with a 0 to 5% methanol: methylene chloride gradient. Fractions containing the title compound were combined and concentrated in vacuo to afford 13.46 g of oil with gradual crystallization. Fractions containing the title compound and impurities were subjected to preliminary column chromatography again under the same conditions described above to afford 2.61 g of additional title compound.
[549] Melting Point (℃): 85
[550] Mass spectrum (FDMS): m / z 193 (M).
[551]
[552] Elemental Analysis for C ₁₁ H ₁₅ NO ₂ :
[553] Theoretical: C, 68.37; H, 7. 82; N, 7.25.
[554] Found: C, 68.56; H, 7.81; N, 7.49.
[555] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-formyl-N-ethylaminoethylphenoxy) ethyl) oxazole
[556] The title compound was substantially described in Example 4, except that N-formyl-N-ethyl-p-hydroxyphenethylamine and 0.7 M (alcohol (millimolar) / tetrahydrofuran (ml)) reaction solution were used. As prepared. After stirring at 24 ° C. for approximately 24 hours, the reaction was concentrated in vacuo. The filtrate was concentrated in vacuo to an oil, treated with ethyl acetate and prechromatographic. The material was eluted with 45% ethyl acetate. Fractions containing the desired product were concentrated in vacuo and pre chromatographed again. The material was eluted with a 0 to 20% ethyl acetate / (93% chloroform: hexanes) gradient for 30 minutes. Fractions containing the desired product were concentrated in vacuo and pre chromatographed again. The material was eluted with a 5 to 30% acetone / hexanes gradient for 30 minutes. Fractions containing the desired product were concentrated in vacuo to yield 3.01 g (19%) of the subtitle compound as a foam.
[557] Mass spectrum (FDMS): m / z 493 (M + l).
[558]
[559] Elemental Analysis for C ₃₀ H ₄₀ N ₂ O ₄ :
[560] Theoretical: C, 73.14; H, 8. 18; N, 5.69.
[561] Found: C, 73.30; H, 8. 44; N, 5.90.
[562] C. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminoethylphenoxy) ethyl) oxazole
[563] Sulfuric acid (6.0 mmol, 0.597 g) was carefully added dropwise for 8 minutes to a cold suspension of lithium aluminum hydride (12.2 mmol, 0.462 g) in tetrahydrofuran (THF, 18 ml). After the addition was complete, the ice bath was removed. After approximately 1 hour of addition, the reaction was cooled to 0 ° C. and then a solution of the compound of step B in tetrahydrofuran (4 ml) was added for 10 minutes. The reaction was stirred at 24 ° C. for 3 hours and then quenched with water (12.2 mmol, 214 μL). After this time chloroform (200 ml) was added and 5N hydrochloric acid (50 ml) was added. The phases were separated and the aqueous layer was then extracted with chloroform (2 x 50 ml). The combined organic phases were washed with brine (1 x 50 ml), dried over sodium chloride, filtered and concentrated in vacuo to yield 5.8 g of oil containing some solids. The material was treated with ethyl acetate (250 ml) and then washed with saturated aqueous sodium bicarbonate (2 x 50 ml). The organics were dried over sodium sulphate, filtered and concentrated in vacuo to yield 2.77 g of oil. The material was treated with chloroform and prechromatographic. The material was eluted for 30 minutes with a 0 to 10% (1% ammonium hydroxide: methanol): chloroform gradient. Fractions containing the desired product were concentrated in vacuo to oil. This material was placed in chloroform and saturated with hydrogen chloride gas. The solution was concentrated in vacuo to yield 1.35 g (43%) of the title compound as a foam.
[564] Mass spectrum (FDMS): m / z 478 (M + l).
[565]
[566] Elemental Analysis for _{C 30 H 40 N 2 O 4} · 0.7H 2 O:
[567] Theoretical: C, 68.28; H, 8. 48; N, 5.31.
[568] Found: C, 68.20; H, 8.41; N, 5.35.
[569] <Example 15>
[570] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-ethyl-N-methylaminobutyl) phenoxyethyl) oxazole hydrochloride
[571] A. Preparation of 4- (4-hydroxyphenyl) butyl bromide
[572] A solution of triphenylphosphine (144.1 mmol, 37.80 g) in methylene chloride (556 ml) was treated with bromine (144.1 mmol, 23.03 g) until light yellow persisted. After stirring for approximately 15 minutes, a solution of 4- (4-hydroxyphenyl) butanol (96.1 mmol, 15.97 g) and imidazole (192.2 mmol, 13.08 g) in methylene chloride (355 ml) was added for 15 minutes. After approximately 4 hours, the reaction suspension was filtered and the volume of filtrate was reduced. Silica gel was added to the reduced filtrate to reduce the suspension to dryness. This material was filtered off and the first six fractions eluted with 10% ethyl acetate: hexanes. Fractions 7-12 were eluted with 20% ethyl acetate: hexanes. Fractions 7-10 were combined, reduced in volume, dried over sodium sulfate, filtered and concentrated in vacuo to yield 19.32 g (88%) of the title compound as an oil.
[573] Mass spectrum (FDMS): m / z 230 (M + l).
[574]
[575] Elemental Analysis for C ₁₀ H ₁₃ BrO:
[576] Theoretical: C, 52.42; H, 5.72.
[577] Found: C, 52.24; H, 5.61.
[578] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-bromobutyl) phenoxyethyl) oxazole
[579] The title compound was prepared substantially as described in Example 4 except for using the compound of Step A. The reaction was concentrated to oil under vacuum. The oil was treated with chloroform (25 ml), softened, then treated with diatomaceous earth and filtered through a pad of diatomaceous earth. The volume of the filtrate was reduced and then pre chromatographed. The material was eluted with 20 to 35% diethyl ether: hexanes gradient for 30 minutes. Fractions 4-15 were combined, concentrated in vacuo and chromatographed again by eluting with 20 to 35% diethyl ether: hexanes gradient for 30 minutes. Fractions 8-16 were combined, concentrated in vacuo and chromatographed again eluting with a gradient of 5 to 20% ethyl acetate: (33% chloroform: 67% hexane) for 30 minutes. Fractions 7-9 were combined, dried over sodium sulfate, filtered and concentrated in vacuo to yield 10.51 g (49%) of the title compound.
[580] Mass spectrum (FDMS): m / z 529 (M + l).
[581]
[582] Elemental Analysis for C ₂₉ H ₃₈ BrNO ₃ :
[583] Theoretical: C, 65.90; H, 7. 25; N, 2.65.
[584] Found: C, 66.14; H, 7. 26; N, 2.36.
[585] C. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-ethyl-N-methylaminobutyl) phenoxyethyl) oxazole hydrochloride
[586] A solution of N-methylethylamine (7.8 mmol, 0.46 g) in dimethylformamide (21 ml) was treated with sodium hydride (7.8 mmol, 0.68 g). The suspension was heated to 35 ° C. for 15 minutes. The suspension was then treated with a solution of the compound of step B (8.5 mmol, 4.51 g) in dimethylformamide (21 ml). The suspension was then heated to 70 ° C. for approximately 4.5 hours and additional N-methylethylamine (15.6 mmol, 0.92 g) was added. After 45 minutes the reaction was cooled to 22 ° C. and treated with ethyl acetate (50 ml), hexane (25 ml) and 10% aqueous sodium sulfate (950 ml). The phases were separated and the aqueous phase was extracted with 2: 1 ethyl acetate: hexanes (3 x 75 ml). The combined organics were washed with brine (2 × 100 ml), dried over sodium sulphate, filtered and concentrated in vacuo to give 4.16 g of oil. The oil was treated with chloroform, filtered through a pad of diatom silica and washed with chloroform. The filtrate was preparative silica gel chromatography. The material was eluted for 30 minutes with a 0 to 10% (1% ammonium hydroxide: methanol): chloroform gradient. Fractions containing the desired product were combined, concentrated in vacuo, placed in chloroform (100 ml) and washed with 1: 1 saturated aqueous sodium bicarbonate: water (50 ml) followed by brine (50 ml). The organics were dried over sodium sulfate, filtered and concentrated in vacuo to yield 1.6 g of oil. The oil was treated with chloroform (50 ml) and then saturated with hydrogen chloride gas. This solution was concentrated to foam under vacuum. The foam was treated with tetrahydrofuran (THF) and boiled in a stream bath with the slow addition of diisopropyl ether. Tetrahydrofuran was boiled off to give an oily product. The remaining solvent was decanted and isopropyl ether (10 ml) was added. The biphasic solution was boiled in a stream bath and the solvent was decanted and the remaining material was placed in vacuo overnight to yield 1.38 g of the title compound as a foam.
[587] Mass spectrum (FDMS): m / z 506 (M).
[588]
[589] Elemental Analysis for C ₃₂ H ₄₇ ClN ₂ O ₃ :
[590] Theoretical: C, 70.76; H, 8. 72; N, 5.16.
[591] Found: C, 70.52; H, 8.56; N, 5.41.
[592] <Example 16>
[593] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-N-ethyl-N-methylaminopropyl) phenoxy) ethyl) oxazole hydrochloride
[594] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-cyanoethyl) phenoxyethyl) oxazole
[595] The title compound was prepared substantially as described in Example 4 except using 3- (4-hydroxyphenyl) propionitrile. The reaction was concentrated to oil under vacuum. The oil was treated with chloroform (75 ml), softened and filtered. The filtrate was washed with saturated aqueous sodium bicarbonate (2 × 250 ml) and 10% sodium hydrogen sulfate (1 × 250 ml). The organic layer was dried over sodium sulfate, filtered and concentrated in vacuo to afford a dark oil. The oil was treated with methylene chloride and preparative silica gel chromatography. The material was eluted with a 10 to 25% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 29.57 g of oil. The material was eluted with 15 to 35% diethyl ether: hexanes gradient for 30 minutes to perform preparative silica gel chromatography again. Fractions containing the title compound were combined and concentrated in vacuo to yield 20.57 g of foam. The material was eluted with a 10 to 30% acetone: hexane gradient for 30 minutes and again subjected to preparative silica gel chromatography. Fractions containing the title compound were combined and concentrated in vacuo to yield 14.71 g of foam. This material contained some impurities and was used in the next step without further purification.
[596] Mass spectrum (FDMS): m / z 446 (M).
[597]
[598] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-formylethyl) phenoxyethyl) oxazole
[599] To a -78 ° C cooled solution of the compound of step A (32.9 mmol, 14.68 g) in toluene (105 ml) was added a 1.0 molar solution of diisobutylaluminum hydride (42.7 mmol, 42.7 ml) for 17 minutes. The reaction was then stirred at 22 ° C. for 1 hour and quenched with methanol (4.1 ml). The suspension was cooled to 0 ° C. and treated with a saturated solution of ammonium hydroxide (300 ml). After stirring for 1.5 hours, the reaction was treated with 50% sulfuric acid until a biphasic solution was formed. The mixture was then treated with ethyl acetate (250 ml) and the phases separated. The aqueous phase was extracted with ethyl acetate (3 x 100 ml). The combined organic phases were washed with brine (2 × 200 ml), dried over sodium sulphate, filtered and concentrated in vacuo to an oil. The oil was subjected to preparative silica gel chromatography. The material was eluted with a 0 to 10% methanol: toluene gradient for 30 minutes. Fractions containing the subtitle compound were combined and concentrated in vacuo to yield 11.76 g of oil. This material was used for the next step without further purification.
[600] Mass spectrum (FDMS): m / z 449 (M).
[601]
[602] C. of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-N-ethyl-N-methylaminopropyl) phenoxy) ethyl) oxazole hydrochloride Produce
[603] The title compound was prepared substantially as described in Example 4 except for using the compound of Step B and N-methylethylamine. The material was eluted with 0 to 5% (1% ammonium hydroxide: methanol): chloroform gradient for 30 min and preparative silica gel chromatography. The remaining fractions were dissolved in 5% (1% ammonium hydroxide: methanol): chloroform. Fractions containing the desired product were combined and concentrated in vacuo, placed in chloroform (100 ml) and washed with saturated sodium bicarbonate (10 ml) and water (15 ml) followed by water (25 ml). The organic layer was dried over sodium sulfate and filtered. The filtrate was saturated with hydrogen chloride gas and concentrated in vacuo to yield 1.61 g of the title compound as a foam.
[604] Mass spectrum (FDMS): m / z 492 (M-HCl).
[605]
[606] Elemental Analysis for C ₃₁ H ₄₅ ClN ₂ O ₃ + 0.2 mol H ₂ O:
[607] Theoretical: C, 69.89; H, 8.58; N, 5.26.
[608] Found: C, 69.88; H, 8.73; N, 5.32.
[609] <Example 17>
[610] 2- (3,5-di-t-butyl-4-methoxyphenyl) -4- (2- (4-N-ethyl-N-methylaminomethylphenoxy) ethyl) oxazole hydrochloride
[611] A. Preparation of 2- (3,5-di-t-butyl-4-methoxyphenyl) -4- (2- (4-formylphenoxy) ethyl) oxazole
[612] A solution of the compound of Example 1D (8.4 mmol, 3.54 g) and methyl iodide (67.3 mmol, 9.54 g) in tetrahydrofuran (40 ml) and dimethylformamide (4 ml) was dissolved in sodium hydride (60 weight / Weight percent, 16.8 mmol, 0.67 g). After stirring for 31 h at 22 ° C., the reaction was treated with water (10 ml) and the pH was adjusted to 12.6-5.4 with 1N hydrochloric acid. Tetrahydrofuran was removed from the head phase solution to reduce volume, followed by addition of ethyl acetate (100 ml) followed by 10% aqueous sodium hydrogen sulfate (50 ml). The phases were separated and the organic phase was dried over sodium sulphate and filtered. The filtrate was subjected to preparative silica gel chromatography eluting with a gradient of 20 to 45% ethyl acetate: hexanes for 30 minutes. Fractions containing the subtitle compound were combined and concentrated in vacuo to yield 3.57 g of oil. The material was used for the next step without further purification.
[613] Mass spectrum (FDMS): m / z 435 (M).
[614]
[615] B. Preparation of 2- (3,5-di-t-butyl-4-methoxyphenyl) -4- (2- (4-N-ethyl-N-methylaminomethylphenoxy) ethyl) oxazole hydrochloride
[616] The title compound was prepared substantially as described in Example 11 except for using the compound of Step A. The filtrate was pre chromatographed by eluting with a gradient of 0 to 10% (1% ammonium hydroxide: methanol): chloroform for 30 minutes. Fractions containing the title compound were combined and concentrated to foam under vacuum. The foam was treated with chloroform and then saturated with hydrogen chloride gas. This solution was concentrated in vacuo to yield 2.2 g of a subtitle compound which is a foam.
[617] Mass spectrum (FDMS): m / z 478 (M-HCl).
[618]
[619] Elemental Analysis for C ₃₀ H ₄₃ ClN ₂ O ₃ + 0.2 mol H ₂ O:
[620] Theoretical: C, 69.46; H, 8.43; N, 5.40.
[621] Found: C, 69.23; H, 8. 47; N, 5.53.
[622] <Example 18>
[623] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-dimethylaminobutyryl) phenyloxy) ethyl) oxazole hydrochloride
[624] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-chlorobutyryl) phenyloxy) ethyl) oxazole
[625] 4-Chloro-4'-hydroxybutyrophenone (3.56 g, 17.92 mmol) and triphenylphosphine (576 g) with stirring in a solution of the compound of Example 1C (5.68 g, 17.92 mmol) in tetrahydrofuran (54 ml) 5.16 g, 19.71 mmol) was added. After cooling to 20 ° C., a solution of diethylazodicarboxylate (3.1 ml, 19.71 mmol) in tetrahydrofuran (18 ml) was added dropwise over 15 minutes. The reaction was warmed to rt and stirred for 5 h, during which time it was diluted with diethyl ether and extracted with water and brine. The organic layer was dried over sodium sulphate, evaporated to dryness and chromatographed on silica gel using gradient hexane-acetone to give the intermediate chloroketone (4.77 g, 53%).
[626]
[627] FD MS 497 (M ⁺ ).
[628] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-dimethylaminobutyryl) phenyloxy) ethyl) oxazole hydrochloride
[629] To a solution of chloroketone (5.09 g, 10.2 mmol) in acetone (51 ml) was added sodium iodide (7.66 g, 51 mmol) with stirring. The reaction was heated to 50 ° C. for 28 hours, evaporated to dryness and dissolved again in methylene chloride and water. The organic layer was extracted with brine, dried over sodium sulfate and evaporated to dryness to yield the intermediate iodoketone, which was used without further purification. Iodoketone was dissolved in toluene (30 ml), cooled to 0 ° C. and treated with anhydrous dimethylamine (0.79 ml, 12 mmol). The reaction was heated to 80 ° C. for 3 hours and then cooled to room temperature. The white precipitate was filtered off and the filtrate was diluted with ethyl acetate and saturated sodium bicarbonate. The organic layer was extracted with 0.1 N sodium thiosulfate and brine, dried over sodium sulfate, evaporated to dryness and chromatographed on silica gel with gradient methylene chloride / methanol to free base (1.82 g, 35%). Obtained. The free base was dissolved in methylene chloride (50 ml), treated with hydrogen chloride gas and evaporated to afford the desired product (1.87 g, 96%).
[630]
[631] FDMS 506 (M ⁺ -HCl).
[632] Elemental Analysis for C ₃₁ H ₄₃ ClN ₂ O ₄ :
[633] Theoretical: C, 68.55; H, 7.98; N, 5.16.
[634] Found: C, 68.36; H, 7.90; N, 5.34.
[635] <Example 19>
[636] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (1-dimethylaminoethyl) phenyloxy) ethyl) oxazole hydrochloride monohydrate
[637] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-acetylphenyloxy) ethyl) oxazole
[638] To a solution of 10 g (31.5 mmol) of the compound of Example 1C in tetrahydrofuran (95 ml) was added 4-hydroxyacetophenone (4.29 g, 31.5 mmol) and triphenylphosphine (9.09 g, 34.7 mmol) with stirring. Added. After cooling to −20 ° C., a solution of diethylazodicarboxylate (5.5 ml, 34.7 mmol) in tetrahydrofuran (31 ml) was added dropwise over 15 minutes. The reaction was warmed to rt and stirred for 2.5 h, during which time it was diluted with diethyl ether and extracted with water and brine. The organic layer was dried over sodium sulphate, evaporated to dryness and chromatographed on silica gel with gradient toluene-ethyl acetate to afford the subtitle compound (8.5 g, 62%).
[639]
[640] FDMS 435 (M ⁺ ).
[641] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (1-dimethylaminoethyl) phenyloxy) ethyl) oxazole hydrochloride
[642] The title compound was heated to 60 ° C. for 24 hours substantially using the compound of Step A, 1.23 g (19.5 mmol) and dimethylamine (19.4 ml, 293 mmol) sodium cyanoborohydride for 24 hours according to the procedure of Example 1E. Prepared. The organic layer was chromatographed on silica gel using gradient methylene chloride / methanol to give the free base, dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to give 8.31 g (80%) of the title compound. .
[643]
[644] FDMS 464 (M ⁺ -HCl).
[645] _{C 29 H 41 ClN 2 O 3} · elemental analysis of the H ₂ O:
[646] Theoretical: C, 67.10; H, 8. 35; N, 5.40.
[647] Found: C, 67.00; H, 8.04; N, 5.24.
[648] <Example 20>
[649] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-3-methylphenoxy) ethyl) oxazole hydrochloride Hydrate
[650] A. Preparation of 3-methyl-allyloxybenzene
[651] 10.4 ml (100 mmol) m-cresol, 10.8 ml (125 mmol) allyl bromide and 16.56 g (120 mmol) potassium carbonate were added with stirring in 50 ml of acetone and refluxed with stirring under nitrogen for 18 hours. The reaction was cooled, the insoluble inorganics were filtered off and the filtrate was stripped to give 14.0 g (95%) of the subtitle compound which was used without further purification.
[652]
[653] B. Preparation of 4-allyloxy-2-methylbenzaldehyde
[654] 19.4 ml (158 mmol) N-methyl formaniline were cooled to 13 ° C. and started to solidify. 13.7 ml (147 mmol) of phosphorus oxychloride was added with stirring under nitrogen. After 25 minutes, the temperature was 45 ° C. and the reaction began to solidify again. 14 g (95 mmol) of the compound of Step A were added and the mixture was stirred and heated in a 70 ° C. oil bath. The reaction exothermed to 95 ° C. Stirring was continued under nitrogen for 30 minutes. When the bath was removed and the temperature reached 35 ° C., the mixture was dissolved in chloroform. Ice was added and the layers separated and washed once with water, twice with saturated sodium bicarbonate, once again with water and once with brine. The organic layer was chromatographed on 450 ml silica eluting with chloroform to give 13.54 g (81%) of the subtitle compound which was used without further purification.
[655]
[656] C. Preparation of 2-methyl-4-hydroxybenzaldehyde
[657] 13.54 g (76.9 mmol) of the compound of Step B, 1.72 g (7.69 mmol) of palladium acetate and 12.09 g (46.2 mmol) of triphenylphosphine were mixed in a 250 ml flask. 3.2 ml (84.6 mmol) of formic acid were added and the reaction was vortexed. Within 15 seconds, the reaction foamed, exothermed and formed a gum, dissolved in ethyl acetate, washed once with sodium bicarbonate and once with brine. The organic layer was chromatographed on 350 ml silica eluting with 20% then 40% ethyl acetate / hexanes. The fractions were combined and the product was recrystallized from methylene chloride / hexanes to give 3.61 g (35%) of product which was used without further purification.
[658]
[659] D. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-3-methylphenyloxy) ethyl) oxazole
[660] The subtitle compound was substantially prepared according to the procedure of Example 4A using 3.61 g (26.5 mmol) of the compound of Step C, 6.62 g (25.2 mmol) of triphenylphosphine and 3.97 ml (25.2 mmol) of diethylazodicarboxylate. Prepared from 8.0 g (25.2 mmol) of the compound of Example 1C. The crude product was chromatographed on silica eluting methylene chloride. Appropriate fractions were combined and stripped to afford 5.05 g (46%) of the subtitle product which was used without further purification.
[661]
[662] E. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-3-methylphenoxy) ethyl) oxazole Preparation of Hydrochloride Hydrate
[663] The title compound is substantially 4.54 g of the compound of Step D using 8.9 ml (104 mmol) methylethylamine, 5.59 ml (104 mmol) acetic acid and 693 mg (11 mmol) sodium cyanoborohydride substantially according to Example 1E above. (10.4 mmol). This reaction provided 1.89 g (35%) of the title compound as a white foam.
[664] FDMS-M ⁺ 478;
[665] Elemental Analysis for (C ₃₀ H ₄₂ N ₂ O ₃ .HCl.0.75H ₂ O):
[666] Theoretical: C, 68.02; H, 8. 48; N, 5.35.
[667] Found: C, 68.16; H, 8. 48; N, 5.30.
[668]
[669] <Example 21>
[670] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-chloro-4-N-methyl-N-ethylaminomethylphenoxy) ethyl) oxazole hydrochloride Hemihydrate
[671] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-chloro-4-formylphenoxy) ethyl) oxazole
[672] Subsidiary compound substantially using Example 3.60 g (23 mmol) 2-chloro-4-hydroxybenzaldehyde, 6.03 g (23 mmol) triphenylphosphine and 3.62 ml (23 mmol) diethylazodicarboxylate Prepared from 6.34 g (20 mmol) of the compound of Example 1C according to the procedure of 4A. The crude product was chromatographed by eluting methylene chloride. The appropriate fractions were combined and stripped to give 5.64 g (62%) of the subtitle product which was used without further purification.
[673]
[674] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-chloro-4-N-methyl-N-ethylaminomethylphenoxy) ethyl) oxazole Preparation of Hydrochloride Hemihydrate
[675] The title compound was purified using 6.54 ml (100 mmol) of methylethylamine, 5.75 ml (100 mmol) acetic acid and 661 mg (10.5 mmol) of sodium cyanoborohydride substantially in accordance with the procedure of Example 1E. Prepared from g (10 mmol). This reaction gave 1.24 g (23%) of the title product as a white foam.
[676] FDMS-M ⁺ 498;
[677] Elemental Analysis for (C ₂₉ H ₃₉ N ₂ O ₃ ClHCl0.5H ₂ O):
[678] Theoretical: C, 63.96; H, 7.59; N, 5.14.
[679] Found: C, 63.83; H, 7.83; N, 5.10.
[680]
[681] <Example 22>
[682] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-hydroxy-4-N-methyl-N-ethylaminomethylphenoxy) ethyl) oxazole hydro Chloride hemihydrate
[683] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (3-hydroxy-4-formylphenoxy) ethyl) oxazole
[684] Subsidiary compound substantially using Example 2A using 6.35 g (46 mmol) of 2,4-dihydroxybenzaldehyde, 12.05 g (46 mmol) of triphenylporpine and 7.24 ml (46 mmol) of diethylazodicarboxylate Prepared from 12.68 g (40 mmol) of the compound of Example 1C according to the procedure of. The crude product was chromatographed on silica eluting methylene chloride. The appropriate fractions were combined and the solvent stripped to yield 9.2 g (53%) of the subtitle product which was used without further purification.
[685]
[686] B. 2- (3,5-Di-t-butyl-4-hydroxyphenyl) -4- (2- (3-hydroxy-4-N-methyl-N-ethylaminomethylphenoxy) ethyl) oxa Preparation of Sol Hydrochloride Hemihydrate
[687] The title compound was purified substantially using the procedure of Example 1E, using 4.76 ml (72.8 mmol) of methylethylamine, 4.16 ml (72.8 mmol) of acetic acid, and 481 mg (7.64 mmol) of sodium cyanoborohydride. Prepared from 3.18 g (7.28 mmol) and the reaction proceeded for 2 days. This reaction gives 1.23 g (33%) of the title product as a white foam.
[688] FDMS-M ⁺ 480;
[689] _{(C 29 H 40 N 2 O} 4 · HCl · 0.5H 2 O) Elemental Analysis for:
[690] Theoretical: C, 66.21; H, 8.05; N, 5.32.
[691] Found: C, 66.01; H, 8.49; N, 5.09.
[692]
[693] <Example 23>
[694] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-3,5-dimethylphenyloxy) ethyloxazole hydro Chloride hydrate
[695] A. Preparation of 3,5-dimethyl-allyloxy benzene
[696] 12.2 g (100 mmol) of 3,5-dimethylphenol, 10.8 ml (125 mmol) of allyl bromide and 16.56 g (120 mmol) of potassium carbonate were dissolved and stirred at 50 ml of acetone for 18 hours under nitrogen. The reaction was cooled, the insoluble inorganics were filtered off and the filtrate was stripped to give 16.2 g (100%) of the subtitle product which was used without further purification.
[697]
[698] B. Preparation of 4-allyloxy-2,6-dimethyl-benzaldehyde
[699] 20.5 ml (166 mmol) of N-methyl formaniline were cooled to 13 ° C. and started to solidify. 14.4 ml (155 mmol) of phosphorus oxychloride were added with stirring under nitrogen. After 25 minutes, the temperature was 45 ° C. 16.2 g (100 mmol) of 3,5-dimethylallyloxy benzene prepared as described above were added with stirring and heated in a 70 ° C. oil bath. The reaction was exothermic to 93 ° C. and stirred under nitrogen for 30 minutes. When the bath was removed and the temperature reached 35 ° C., the product was dissolved in chloroform. Ice was added and the layers separated and washed once with water, twice with sodium bicarbonate, once again with water and once with brine. The product was chromatographed on 450 ml silica eluting with chloroform to yield 9.67 g (51%) of the subtitle product which was used without further purification.
[700]
[701] C. Preparation of 2,6-dimethyl-4-hydroxy-benzaldehyde
[702] 9.67 g (50.9 mmol) of 4-allyloxy-2,6-dimethyl-benzaldehyde, 1.14 g (5.09 mmol) of palladium II acetate and 8.00 g (30.5 mmol) of triphenylphosphine were mixed in a flask. 2.11 ml (56 mmol) of formic acid were added and the mixture was vortexed in an 80 ° C. oil bath. Within 15 seconds, the reaction exothermic and turned very black. The gum was dissolved in ethyl acetate, washed once with sodium bicarbonate and once with water, once with brine, then chromatographed on 350 ml silica eluting with 20% then 40% ethyl acetate / hexanes. The fractions were combined and the product was determined from methylene chloride / hexanes to yield 3.90 g (51%) of the subtitle product which was used without further purification.
[703]
[704] D. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-3,5-dimethylphenyloxy) ethyl) oxazole
[705] The title compound was substantially prepared in Example 4A using 3.9 g (26 mmol) of dimethyl-4-hydroxybenzaldehyde, 6.49 g (24.8 mmol) of triphenylphosphine and 3.90 ml (24.8 mmol) of diethylazodicarboxylate. Prepared from 7.85 g (24.8 mmol) of the compound of Example 1C according to the procedure of. The reaction was stirred under nitrogen for 18 hours. 1.38 ml (30%) hydrogen peroxide were added and the reaction stirred for an additional 30 minutes, stripped, dissolved in 40 ml of methylene chloride and placed in the freezer. The diethoxycarbonylhydrazine was then filtered off and the filtrate was chromatographed on silica eluting with methylene chloride. Appropriate fractions were combined and stripped to yield 6.73 g (60%) of the subtitle product which was used without further purification.
[706]
[707] E. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-methylaminomethyl-3,5-dimethylphenyloxy) ethyl) Preparation of Oxazole Hydrochloride Monohydrate
[708] 5.02 g (11.2) of the title compound as 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-3,5-dimethylphenyloxy) ethyl) oxazole Mmol), 9.59 ml (112 mmol) methylethylamine, 6.40 ml (112 mmol) acetic acid and 741 mg (11.76 mmol) sodium cyanoborohydride were prepared substantially in accordance with Example 1E above. Ethyl acetate was added and the mixture was washed once with water, once with saturated sodium bicarbonate, twice with water and once with brine. The mixture was dried, chromatographed by stripping the organics and eluting with 92: 8 methylene chloride / methanol. Fractions were combined and the organics stripped and dissolved in methylene chloride / isopropyl ether. Hydrogen chloride gas was bubbled into this solution and the mixture was concentrated and triturated with isopropyl ether to give 4.47 g (69%) of a white foam.
[709] FDMS-M + 492;
[710] Elemental Analysis for _{C 31 H 44 N 2 O 3} · HCl · H 2 O:
[711] Theoretical: C, 68.05; H, 8. 66; N, 5.12.
[712] Found: C, 68.06; H, 8. 84; N, 4.77.
[713]
[714] <Example 24>
[715] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-2-chlorophenyloxy) ethyl) oxazole hydrochloride
[716] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-2-chlorophenyloxy) ethyl) oxazole
[717] The subsidiary compound was substantially prepared according to the procedure of Example 4A, above 3.17 g (10 mmol) of the compound of Example 1C, 1.72 g (11 mmol) of 3-chloro-4-hydroxybenzaldehyde, 2.62 g (10 mmol) of triphenylphosphine ) And 1.57 ml (10 mmol) of diethylazodicarboxylate. The reaction was chromatographed by eluting 4% methanol / methylene chloride. The appropriate fractions were combined and stripped to yield 3.51 g (77%) of product, which was used without further purification.
[718]
[719] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-2-chlorophenyloxy) ethyl) oxazole Preparation of Hydrochloride
[720] 0.66 ml (7.7 mmol) of methylethylamine, 2.28 ml (7.7 mmol) of titanium IV isopropoxide and 220 mg (5.74 mmol) of sodium borohydride were used, except for reducing the title compound with stirring for 18 hours. Was prepared substantially from 1.75 g of the compound of Step A according to the procedure of Example 9. Ammonia (6.3 ml, 2N) was added to give a thick suspension. Methylene chloride and diatomaceous earth were added and the suspension was filtered through diatomaceous earth. The filtrate was washed once with brine, dried and the organics stripped and chromatographed by elution with 90: 5: 0.5 methylene chloride / methanol / concentrated ammonia. Fractions were combined and the solvent stripped and dissolved in methylene chloride / isopropyl ether. Bubbling hydrogen chloride gas and concentrating the material and triturating with isopropyl ether gave 1.21 g (59%) of a white foam.
[721] FDMS-M ⁺ 498;
[722] Elemental Analysis for C ₂₉ H ₃₉ N ₂ O ₃ ClHCl:
[723] Theoretical: C, 65.04; H, 7.53; N, 5.23.
[724] Found: C, 65.30; H, 7.72; N, 5.22.
[725] NMR (CDCl ₃ ), δ 1.48 (m, 21H), 2.63 (d, 3H, J = 5 Hz), 2.88-2.92 (m, 1H), 3.15 (m, 3H, J = 5 Hz), 3.97- 4.16 (m, 2H), 4.34 (t, 2H, J = 5 Hz), 5.53 (s, 1H), 7.03 (d, 1H, J = 9 Hz), 7.48 (d, 1H, J = 2 Hz), 7.60 (s, 1 H), 7.65 (dd, 1 H, J = 2 Hz, 9 Hz), 7.85 (s, 1 H).
[726] <Example 25>
[727] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-1-naphthyloxy) ethyl) oxazole hydrochloride Hemihydrate
[728] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-1-naphthyloxy) ethyl) oxazole
[729] Subsidiary compounds were substantially prepared using 4.95 g (28.75 mmol) of 4-hydroxy-1-naphthalaldehyde, 7.53 g (28.75 mmol) of triphenylphosphine and 4.52 ml (28.75 mmol) of diethylazodicarboxylate. Prepared from 7.925 g (25 mmol) of the compound of Example 1C according to the procedure of Example 4A. The crude product was chromatographed with methylene chloride. The appropriate fractions were combined and stripped to yield 4.08 g (35%) of product, which was used without further purification.
[730]
[731] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethyl-1-naphthyloxy) ethyl) oxazole Preparation of Hydrochloride Hemihydrate
[732] The title compound was purified substantially using the procedure of Example 1E, using 4.74 ml (72.4 mmol) of methylethylamine, 4.14 ml (12.4 mmol) of acetic acid and 480 mg (7.6 mmol) of sodium cyanoborohydride. Prepared from 3.41 g (7.24 mmol). The crude product was chromatographed by eluting methylene chloride / methanol / 1% concentrated ammonia from 100: 0: 0 to 90: 10: 1 for 10 minutes. The crude product was dissolved in methylene chloride / isopropyl ether and treated with hydrogen chloride gas and the resulting oil was triturated with isopropyl ether to give 1.84 g (46%) of white foam.
[733] FDMS-M ⁺ 514;
[734] Elemental Analysis for C ₃₃ H ₄₂ N ₂ O ₃ HCl0.5H ₂ O:
[735] Theoretical: C, 70.76; H, 7.92; N, 5.00.
[736] Found: C, 70.52; H, 8.22; N, 4.72.
[737]
[738] <Example 26>
[739] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (morpholin-4-yl-methyl) phenyloxy) ethyl) oxazole hydrochloride
[740] The title compound was prepared using morpholine (8.72 ml, 100 mmol) and sodium cyanoborohydride (0.63 g, 10 mmol) substantially in accordance with the procedure of Example 1E above (4.21 g, 10 mmol). From). Methanol was evaporated and the residue was dissolved in ethyl acetate and saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness, and chromatographed on silica gel with gradient hexane-isopropanol to give the free base (3.68 g, 75%). The free base was dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to afford the desired product (3.68 g, 93%).
[741]
[742] FDMS 492 (M ⁺ -HCl);
[743] Elemental Analysis for C ₃₀ H ₄₁ ClN ₂ O ₄ :
[744] Theoretical: C, 68.10; H, 7.81; N, 5.29.
[745] Found: C, 67.93; H, 7.73; N, 5.17.
[746] <Example 27>
[747] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-methylpiperazin-1-yl-methyl) phenyloxy) ethyl) oxazole dihydro Chloride
[748] The title compound was purified using N-methylpiperazine (13.3 ml, 120 mmol) and sodium cyanoborohydride (0.75 g, 12 mmol) substantially in 5.05 g of the compound of Example 1D following the procedure of Example 1E. 12 mmol). Methanol was evaporated and the residue was dissolved in ethyl acetate and saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness, and chromatographed on silica gel with gradientd methylene chloride / methanol to give the free base (4.53 g, 75%). The free base was dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to afford the desired product (4.53 g, 87%).
[749]
[750] FDMS 505 (M ⁺ -HCl);
[751] Elemental Analysis for C ₃₁ H ₄₅ Cl ₂ N ₃ O ₃ :
[752] Theoretical: C, 64.35; H, 7. 84; N, 7.26.
[753] Found: C, 64.07; H, 7.67; N, 7.32.
[754] <Example 28>
[755] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-acetylpiperazin-1-yl-methyl) phenyloxy) ethyl) oxazole hydrochloride
[756] The title compound was synthesized using N-acetylpiperazine (12.82 g, 100 mmol) and sodium cyanoborohydride (0.63 g, 10 mmol) substantially in accordance with the procedure of Example 1E (4.21 g, 10 mmol). Methanol was evaporated and the residue was dissolved in ethyl acetate and saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness and chromatographed on silica gel with gradientd methylene chloride / methanol to give the free base (3.96 g, 74%). The free base was dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to afford the desired product (3.94 g, 93%).
[757]
[758] FDMS 533 (M ⁺ -HCl);
[759] Elemental Analysis for _{C 32 H 44 ClN 3 O 4} · 1.2H 2 O:
[760] Theoretical: C, 64.95; H, 7.90; N, 7.10.
[761] Found: C, 64.67; H, 7.51; N, 6.97.
[762] <Example 29>
[763] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-thiomorpholinylmethylphenoxy) ethyl) oxazole
[764] The title compound was prepared from the compound of Example 1D substantially following the procedure of Example 11 above except for using thiomorpholine and the reaction was performed at room temperature. The material was eluted with a gradient from 0 to 3% (1% ammonium hydroxide: methanol): chloroform for 30 minutes. Fractions containing the desired product were concentrated in vacuo to oil. The oil was treated with chloroform and saturated with hydrogen chloride gas. This solution was concentrated in vacuo to afford 3.64 g of the title compound. 1.50 g of this material was placed in a solution with tetrahydrofuran (20 ml), the solution was boiled until approximately 10 ml, then additional tetrahydrofuran (20 ml) was added and the crystals collected by filtration. The crystals were dried overnight in a 60 ° C. vacuum oven to yield 1.27 g of the title compound.
[765] Mass spectrum (FDMS): m / z 508 (M-HCl).
[766]
[767] Elemental Analysis for C ₃₀ H ₄₁ ClN ₂ O ₃ S:
[768] Theoretical: C, 66.09; H, 7. 58; N, 5.14.
[769] Found: C, 66.36; H, 7. 82; N, 4.85.
[770] <Example 30>
[771] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (piperazin-1-yl-methyl) phenoxy) ethyl) oxazole dihydrochloride hydrate
[772] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (4-acetylpiperazin-1-yl-)-prepared as described in Example 28 above Methyl) phenyloxy) ethyl) oxazole hydrochloride was dissolved in 4N hydrochloric acid and stirred at 80 ° C. for 1.5 h. The reaction was then diluted with ethyl acetate and neutralized with saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness, and chromatographed on silica gel using a gradient of methylene chloride / methanol / ammonium hydroxide to give the free base (0.67 g, 75%). . The free base (1.29 g, 2.62 mmol) was dissolved in methylene chloride, treated with hydrogen chloride gas and evaporated to give the desired product (1.35 g, 91%).
[773]
[774] FDMS 491 (M ⁺ -HCl).
[775] Elemental Analysis for C ₃₀ H ₄₃ Cl ₂ N ₃ O ₃ 1.4H ₂ O:
[776] Theoretical: C, 61.09; H, 7.83; N, 7.12.
[777] Found: C, 60.71; H, 7. 43; N, 7.02.
[778] <Example 31>
[779] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (imidazol-1-yl-methyl) phenoxy) ethyl) oxazole hydrochloride monohydrate
[780] A. Preparation of N-p-methoxybenzylimidazole
[781] To the solution in imidazole (25.53 g, 375 mmol) in acetonitrile (625 ml) was added p-methoxybenzyl chloride (16.95 ml, 125 mmol) with stirring. The reaction was refluxed for 16 hours, evaporated to dryness and redissolved in methylene chloride and saturated sodium bicarbonate. The organic layer was extracted twice with water. Standard acid / base finishing gave N-p-methoxybenzylimidazole (16.3 g, 69%), which was used without further purification.
[782]
[783] B. Preparation of N-p-hydroxybenzylimidazole
[784] To a solution of the compound of step A (16.3 g, 86.1 mmol) in methylene chloride (860 ml) cooled to 5 ° C. was added dropwise boron tribromide (32.6 ml, 344.4 mmol) for 15 minutes. After 2 h at 5 ° C., the reaction was quenched by the dropwise addition of methanol, evaporated to dryness and redissolved in methanol, water and methylene chloride. The pH was adjusted to 8.4 with sodium hydroxide. The organic layer was dried over sodium sulfate and evaporated to dryness to afford N-p-hydroxybenzylimidazole (13.6 g, 91%), which was used without further purification.
[785]
[786] C. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (imidazol-1-ylmethyl) phenoxy) ethyl) oxazole hydrochloride monohydrate Manufacture of Rate
[787] The title compound was purified using the compound of Step B (13.6 g, 78.1 mmol) and triphenylphosphine (22.5 g, 85.9 mmol) substantially in accordance with the procedure of Example 4A (24.75 g, 78.1 mmol) Prepared from. The filtrate is extracted with water and brine, the organic layer is dried over sodium sulfate, evaporated to dryness, chromatographed on silica gel with gradientd methylene chloride-isopropanol and triturated with hot diethyl ether to give the free base (2.51 g, 7%). The free base was dissolved in methylene chloride (65 ml), treated with hydrogen chloride gas and evaporated to afford the desired product (2.63 g, 97%).
[788]
[789] Elemental Analysis for _{C 29 H 36 ClN 3 O 3} · H 2 O:
[790] Theoretical: C, 65.96; H, 7. 25; N, 7.96.
[791] Found: C, 65.75; H, 7.07; N, 8.09.
[792] <Example 32>
[793] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4,5-dihydro-1H-imidazol-1-ylmethyl) phenoxy) ethyloxazole hydro Chloride
[794] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-cyanomethylphenoxy) ethyl) oxazole
[795] Diethylazodicarboxylate was added to the compound of Example 1C, 4-hydroxybenzyl cyanide, triphenylphosphine and 0.7 M (alcohol (millimolar) alcohol / tetrahydrofuran (ml)) reaction solution. After stirring at 24 ° C. for approximately 24 hours, the reaction was concentrated in vacuo to a brown oil. The material was treated with chloroform (30 ml), softened and the insolubles were filtered off and washed with chloroform (20 ml). The filtrate was concentrated in vacuo to an oil, treated with toluene and prechromatographic. The material was eluted with a 0 to 10% methanol / toluene gradient for 30 minutes. Fractions containing the desired product were concentrated in vacuo to yield 12.18 g (88%) of the subtitle compound.
[796] Mass spectrum (FDMS): m / z 432 (M).
[797]
[798] Elemental Analysis for C ₂₇ H ₃₂ N ₂ O ₃ :
[799] Theoretical: C, 74.97; H, 7. 46; N, 6.48.
[800] Found: C, 75.17; H, 7.41; N, 6.21.
[801] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4,5-dihydro-1H-imidazol-2-ylmethyl) phenoxy) ethyloxa Preparation of Sol Hydrochloride
[802] Hydrogen chloride gas was bubbled into a solution of the compound of step A in ethanol (2 ml) and diethyl ether (50 ml) at −10 ° C. for 30 minutes. The reaction was kept at 0 ° C. After 4 days, the supernatant was decanted and then pure ethanol (50 ml) and diethyl ether (50 ml) were added. The reaction was cooled to 0 ° C. and then hydrogen chloride gas was passed through the solution for approximately 4 hours. After stirring at 0 ° C. for 4 hours, the reaction was concentrated to foam under vacuum. The foam was then placed in pure ethanol (50 ml) and then treated with ethylene diamine (48 mmol, 2.88 g). The resulting suspension was refluxed for approximately 32 hours, filtered while hot and the insolubles were washed with ethanol (20 ml). The filtrate was concentrated in vacuo to oil. The oil was treated with chloroform (100 ml) and washed with saturated sodium bicarbonate (2 x 50 ml) and brine (1 x 50 ml). The organics were dried over sodium sulphate, filtered and concentrated in vacuo to afford 8.38 g of foam. The material was chromatographed in chloroform. The material was eluted with a 10% (1% ammonium hydroxide / methanol): chloroform gradient for 30 minutes. The remaining material was eluted with 10% (1% ammonium hydroxide / methanol): chloroform. Fractions containing the desired product were concentrated to foam under vacuum. The material was placed in methylene chloride (100 ml) and washed with saturated sodium bicarbonate (2 x 50 ml) and (1 x 50 ml). The organics were dried over sodium sulfate, filtered and then hydrogen chloride gas passed through the solution. This solution was concentrated in vacuo to give a foam. A portion of the foam (1.26 g) was treated with methylene chloride (20 ml) and isopropyl ether (10 ml) and then the total volume boiled to approximately 20 ml. The cloudy solution was cooled to -10 ° C for approximately 1 hour and then decanted. The remaining oil was concentrated in vacuo to yield 1.08 g of foam.
[803] Mass spectrum (FDMS): m / z 476 (M + l).
[804] ¹ H NMR (CDCl ₃ ): δ 7.85 (s, 2H), 7.55 (s, 1H), 7.47 (d, J = 8.5 Hz, 2H), 6.78 (d, J = 8.5 Hz, 2H), 5.59 ( s, 1H), 4.19 (t, J = 6.4 Hz, 2H) 3.96 (s, 2H), 3.80 (s, 4H), 3.04 (t, J = 6.4 Hz, 2H), 1.46 (s, 18H).
[805] Elemental Analysis for _{C 29 H 38 ClN 3 O 3} · C 6 H 14 O:
[806] Theoretical: C, 74.97; H, 7. 46; N, 6.48.
[807] Found: C, 75.17; H, 7.41; N, 6.21.
[808] <Example 33>
[809] 6- [2-[(3,5-di-t-butyl-4-hydroxyphenyl) -4-oxazolyl] ethoxy] -1,2,3,4-tetrahydroisoquinoline hydrochloride
[810] A. Preparation of N-tert-butoxycarbonyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline
[811] Suspension in 6-hydroxy-1,2,3,4-tetrahydroisoquinoline oxalate (0.17 mol, 40.04 g) in methanol (150 ml) and tetrahydrofuran (420 ml) was added to diisopropylethylamine (0.38 Mole, 48.50 g), followed by a solution of di-tert-butyl dicarbonate (0.13 mole, 27.30 g) in tetrahydrofuran (10 ml). After stirring at room temperature for approximately 4 hours, the material was treated with methylene chloride (500 ml), brine (250 ml) and 10% aqueous sodium sulfate (250 ml). The phases were separated and the organic phase was washed with 10% aqueous sodium sulfate (3 × 250 ml), brine (1 × 250 ml) then dried over sodium sulfate, filtered and concentrated to a solid in vacuo. The material was treated with methylene chloride and chromatographed by eluting with a gradient of 0 to 35% (ethyl acetate / hexane) for 30 minutes. Fractions containing the desired product were concentrated in vacuo to afford 27.63 g (66%) of the subtitle compound.
[812] Mass spectrum (FDMS): m / z 249 (M), 148 (M-101).
[813]
[814] Elemental Analysis for C ₁₄ H ₁₉ NO ₃ :
[815] Theoretical: C, 67.45; H, 7.68; N, 5.62.
[816] Found: C, 67.74; H, 7.53; N, 5.59.
[817] B. 6- [2-[(3,5-Di-tert-butyl-4-hydroxyphenyl) -4-oxazolyl] ethoxy] -2-tert-butoxycarbonyl-1,2,3, Preparation of 4-tetrahydroisoquinoline
[818] The title compound was prepared substantially as described in Example 4A, except that the compound of Step A and the 0.7M reaction solution were used. At approximately 3.8 hours, the reaction was concentrated to oil under vacuum. The oil was treated with methylene chloride (10 ml) and insolubles were collected by filtration and washed with methylene chloride (10 ml). The filtrate was treated with methylene chloride (25 ml) and washed with 0.1N sodium hydroxide (3 x 50 ml) and 10% aqueous sodium sulfate (2 x 50 ml). The organics were concentrated to foam under vacuum, treated with ethyl acetate and prechromatographic. Eluted with a 10 to 40% (ethyl acetate / hexanes) gradient for 30 minutes. Fractions containing the title compound were combined, concentrated in vacuo and chromatographed. The material was eluted with a 10 to 25% acetone: hexane gradient for 30 minutes. Fractions containing the desired product were concentrated in vacuo to yield 5.60 g (56%) of the subtitle compound as a foam.
[819] Mass spectrum (FDMS): m / z 548 (M).
[820]
[821] C. of 6- [2-[(3,5-di-tert-butyl-4-hydroxyphenyl) -4-oxazolyl] ethoxy] -1,2,3,4-tetrahydroisoquinoline hydrochloride Produce
[822] The solution of the compound of step B (9.8 mmol, 5.60 g) in methylene chloride (33 ml) was treated with thiophenol (98.1 mmol, 10.81 g). The reaction was cooled to -10 ° C and then treated with trifluoroacetic acid (98.1 mmol, 8.26 g). After approximately 1.5 hours, the reaction was warmed to 24 ° C. After stirring for 5.5 h at 24 ° C., the reaction was concentrated in vacuo, treated with chloroform and chromatographed. The material was eluted from 0 to 10% (1% ammonium hydroxide / methanol): chloroform gradient for 15 minutes. The volume of the fraction containing the desired product was reduced, washed with water (50 ml), dried over sodium sulphate, filtered and concentrated in vacuo to afford an oil. The material was placed in chloroform and then saturated with hydrogen chloride gas. This solution was concentrated in vacuo to afford 2.40 g of the title compound. This material was recrystallized from 3: 1 diisopropyl ether: methylene chloride to give 760 mg of the title compound.
[823] Mass spectrum (ion injection MS): m / z 449 (M + l).
[824]
[825] <Example 34>
[826] 6- [2-[(3,5-di-tert-butyl-4-hydroxyphenyl) -4-oxazolyl] ethoxy] isoquinoline hydrochloride monohydrate
[827] The title compound was poured into compound of Example 1C (19.1 mmol, 6.07 g), triphenylphosphine (21.1 mmol, 5.52 g) and 6-hydroxyisoquinoline (21.1 mmol, 3.07 g) in tetrahydrofuran (43 ml). Prepared by addition of diethylazodicarboxylate (21.1 mmol, 3.67 g) at −10 ° C. (ice / acetone bath) for 11 minutes. After the addition was complete, the reaction was stirred at room temperature. At approximately 3.8 hours the reaction was concentrated to oil under vacuum. The oil was poured into chloroform and then chromatographed. The material was eluted with a 70 to 85% ethyl acetate / hexanes gradient for 30 minutes. Fractions containing the desired product were combined, reduced in volume and chromatographed. The material was eluted with a 0 to 15% methanol / toluene gradient for 30 minutes. Fractions containing the desired product were combined and concentrated to solid under vacuum. The solid was treated with chloroform (100 ml) and hydrogen chloride gas was passed through this solution and then concentrated to a yellow foam under vacuum. The foam was softened in diisopropyl ether (100 ml) and then filtered. Insolubles were treated with toluene (100 ml), heated to boiling, filtered hot and washed with toluene (50 ml).
[828] These insolubles were crystallized from methylene chloride. The crystals were treated with chloroform (60 ml) followed by hydrogen chloride gas and concentrated to foam under vacuum. The material was triturated in toluene (100 ml), filtered and insolubles were collected by filtration to give 1.38 g of product.
[829] Mass spectrometry (ion spray): m / z 444 (M-HCl).
[830]
[831] _{C 28 H 33 ClN 2 O 3} · Elemental Analysis for 1.0H ₂ O:
[832] Theoretical: C, 67.38; H, 7.07; N, 5.61.
[833] Found: C, 67.60; H, 6.87; N, 5.35.
[834] <Example 35>
[835] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (5-N-ethyl-N-methylaminomethylpyrid-2-yl-oxy) ethyl) oxazole Dihydrochloride
[836] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (5-formylpyrid-2-yl-oxy) ethyl) oxazole
[837] The title compound was prepared substantially as described in Example 4 except for using 2-pyridone-5-carboxaldehyde. After stirring at 24 ° C. for approximately 15.5 hours, the reaction was treated with water (2.1 equiv, 870 51) and stirred for 10 minutes and then concentrated in vacuo to give a foam. The foam was chromatographed by eluting with a 50 to 65% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the desired product were combined and concentrated in vacuo to afford a purple solid. The solid was treated with diethyl ether, softened, stirred for approximately 4 hours and then filtered. The filtrate was concentrated in vacuo to give a purple foam. The foams were chromatographed by eluting with 20 to 35% acetone / hexane gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 2.28 g of subtitle compound as a foam. This material was used in the next step without further purification.
[838] Mass spectrometry (FDMS): m / z 422 (M).
[839]
[840] B. 2- (3,5-Di-t-butyl-4-hydroxyphenyl) -4- (2- (5-N-ethyl-N-methylaminomethyl-pyrid-2-yl-oxy) ethyl Preparation of Oxazole Dihydrochloride
[841] The title compound was prepared from the compound of Step A substantially following the procedure of Example 11. The material was chromatographed by eluting with a gradient of 0 to 5% (1% ammonium hydroxide: methanol): chloroform for 30 minutes. The remaining fractions were eluted with 5% (1% ammonium hydroxide: methanol): chloroform. Fractions containing the title compound were combined and concentrated in vacuo to afford an oil. The oil was treated with chloroform followed by hydrogen chloride gas to form crystals. The crystals were collected by filtration and washed with chloroform to give 1.44 g. The material was recrystallized from methanol: tetrahydrofuran to give 1.25 g of the title compound.
[842] Melting Point (℃): 237-239
[843] Mass spectrometry (FDMS); m / z 465 (M-2HCl).
[844]
[845] Elemental Analysis for C ₂₈ H ₄₁ Cl ₂ N ₃ O ₃ :
[846] Theoretical: C, 62.45; H, 7.67; N, 7.80.
[847] Found: C, 62.46; H, 7.71; N, 7.79.
[848] <Example 36>
[849] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethylphenylthio) ethyl) oxazole hydrochloride monohydrate
[850] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formylphenylthio) ethyl) oxazole
[851] The subtitle compound was prepared by dissolving 3.84 g (14.6 mmol) of triphenylphosphine in 45 ml of tetrahydrofuran, cooling to −9 ° C. and adding 2.3 ml (14.6 mmol) of diethylazodicarboxylate under nitrogen. The reaction exothermed to −1 ° C., cooled to −6 ° C. and added 4.64 g (14.6 mmol) of the compound of Example 1C. The dark red solution was stirred for 15 minutes at which time 2.22 g (16.1 mmol) of 4-mercaptobenzaldehyde (Tet. Lett. 25, (17), 1753-1756, 1984) were added and the reaction stirred for 18 hours. The reaction was stripped and chromatographed for 30 minutes eluting with a 10% to 50% ethyl acetate / hexanes gradient. Appropriate fractions were combined and stripped to yield 3.48 g (54%) of product, which was used without further purification.
[852] NMR (CDCl ₃ ), δ 1.46 (t, 3H, J = 9 Hz), 1.50 (s, 18H), 2.64 (d, 2H, J = 5 Hz), 2.88-2.97 (m, 1H), 3.17 ( t, 2H, J = 9 Hz, 3.51 (t, 2H, J = 9 Hz), 3.97-32 (m, 2H), 6.05 (s, 1H), 7.46 (d, 2H, J = 9 Hz), 7.56 (d, 2H, J = 9 Hz), 7.65 (s, 1H), 8.21 (s, 2H).
[853] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethylphenylthio) ethyl) oxazole hydrochloride monohydrate Manufacture
[854] 1.72 ml (20 mmol) of methylethylamine and 5.92 ml (20 mmol) of titanium tetraisopropoxide were carefully dissolved in 45 ml of ethanol while stirring under nitrogen and stirred for 1 hour. The compound of step A (4.38 g, 10 mmol) was added and the reaction stirred for 3.5 hours. Sodium borohydride (570 mg, 15 mmol) was added and the reaction stirred for an additional 18 hours. Ammonia (16.3 ml, 2N) was added to give a thick suspension and 104 ml of methylene chloride were added. Diatomaceous earth (13 g) was added and the mixture was stirred and filtered through diatomaceous earth. The filtrate was washed once with brine, dried, stripped and chromatographed by elution of 90: 5: 0.5 methylene chlorite / methanol / concentrated ammonia. Fractions were combined, solvent stripped and dissolved in methylene chloride / isopropyl ether. Bubbling hydrogen chloride gas and concentrating the solution and triturating with isopropyl ether gave 2.86 g (55%) of the title product as a white foam.
[855] FDMS-M ⁺ 480;
[856] Elemental Analysis for C ₂₉ H ₄₀ N ₂ O ₂ SHClH ₂ O:
[857] Theoretical: C, 64.86; H, 8.11; N, 5.21.
[858] Found: C, 64.56; H, 8. 37; N, 4.93.
[859]
[860] <Example 37>
[861] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethylphenoxy) ethyl) -5-methyloxazole hydrochloride Monohydrate
[862] A. Preparation of Ethyl 4-chloro-3-oxopentanoate
[863] 1.0 g of acetonitrile with 34 g (200 mmol) of potassium ethyl malonate (Organic Synthesis Coll.Vol. IV, p. 417), 23.75 g (250 mmol) of magnesium chloride and 44.5 ml (320 mmol) of triethylamine while stirring under nitrogen Suspended in the air. 9.7 ml (100 mmol) of 2-chloro-propionyl chloride were added and the mixture was stirred under nitrogen for 18 hours. 100 ml of 5N hydrochloric acid were added and the reaction stirred for 2 hours. The layers were separated and the organics stripped to give 21.09 g of crude product, eluting 20% ethyl acetate / hexanes and filtering through 300 ml silica to give 10.37 g (58%) of product.
[864]
[865] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4-carbethoxymethyl-5-methyloxazole
[866] 6.6 g (26.5 mmol) of the compound of Example 1A and 10.3 g (57.7 mmol) of the compound of Step A were appropriately stirred together at 140 ° C. under nitrogen for a total of 6.5 hours. The reaction was cooled and chromatographed on 300 ml silica eluting with 20% then 50% ethyl acetate / hexanes to give 4.48 g (45%) of product.
[867] FDMS-M + = 373.
[868]
[869] C. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-hydroxyethyl) -5-methyloxazole
[870] The starting ester, 4.43 g (11.88 mmol) of the compound of Step B was dissolved in 83 ml of tetrahydrofuran with stirring under nitrogen. 450 mg (11.88 mmol) of solid lithium aluminum hydride (LAH) were carefully added. There was a lot of bubbles. The mixture was stirred for 30 minutes and another 225 mg (5.94 mmol) of another lithium aluminum hydride was added and the reaction stirred overnight under nitrogen. Water (0.675 ml) was added carefully, 0.675 ml of 15% sodium hydroxide was added followed by 2.0 ml of water. The inorganics were filtered off and the filtrate was stripped, dissolved in ethyl acetate, washed once with 1N hydrochloric acid, twice with brine, and stripped to yield 3.61 g (92%) of product without further purification. Used.
[871] FDMS-M + = 331.
[872]
[873] D. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formylphenoxy) ethyl) -5-methyloxazole
[874] 3.61 g (10.9 mmol) of the compound of Step C, 1.53 g (12.5 mmol) of 4-hydroxybenzaldehyde and 3.29 g (12.5 mmol) of triphenylphosphine were dissolved in 30 ml of tetrahydrofuran with stirring under nitrogen. The solution was cooled to −5 ° C. and a solution of 1.97 ml (12.5 mmol) of diethyldiazodicarboxylate in 10 ml of tetrahydrofuran was added with stirring for 10 minutes. The reaction exothermed to + 3 ° C. The crude was removed and the reaction stirred under nitrogen for 3 days. The reaction was stripped and dissolved in methylene chloride and placed in the freezer. The diethoxycarbonylhydrazine was then filtered off and the filtrate was chromatographed on 400 ml silica eluting with 5% isopropyl alcohol / hexane. Appropriate fractions were combined and stripped to yield 3.52 g (74%) of product, which was used without further purification.
[875] FDMS-M + = 435.
[876]
[877] E. of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethylphenoxy) ethyl) -5-methyloxazole hydrochloride hydrate Produce
[878] 0.71 ml (8.32 mmol) of methylethylamine and 2.46 ml (8.32 mmol) of Ti (OPr) ₄ were dissolved in 17 ml of ethanol for 10 minutes under nitrogen. 1.75 g (4.16 mmol) of the compound of Step D were added and the mixture was stirred for 4 hours. 240 mg (6.23 mmol) of sodium borohydride were added and the reaction stirred for 3 days. 5.8 ml of 2N ammonia was added to give a thick suspension. Methylene chloride (40 ml) was added followed by 5.3 g of diatomaceous earth and the mixture was stirred and filtered through diatomaceous earth. The filtrate was washed twice with brine and then dried. The organics were stripped and chromatographed by elution of 90: 10: 1 methylene chloride / methanol / concentrated ammonia. Fractions were combined, stripped and dissolved in methylene chloride / isopropyl ether. Hydrogen chloride gas was bubbled. The product was evaporated to dryness to give 1.36 g (63%) of white foam.
[879] FDMS-M + 478;
[880] Elemental Analysis for _{C 30 H 42 N 2 O 3} · HCl · H 2 O:
[881] Theoretical: C, 67.58; H, 8.51; N, 5.25.
[882] Found: C, 67.21; H, 8.61; N, 5.06.
[883]
[884] <Example 38>
[885] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethylphenoxy) ethyl) thiazole hydrochloride hydrate
[886] A. Preparation of N-methyl- (3,5-di-t-butyl-4-hydroxy) benzamide
[887] 75 g (300 mmol) of (3,5-di-t-butyl-4-hydroxy) benzoic acid and 53.46 g (330 mmol) of carbonyldiimidazole were refluxed in 900 ml of tetrahydrofuran with stirring under nitrogen for 2 hours. The reaction was cooled and 300 ml of 40% aqueous methylamine was added and stirred under nitrogen at room temperature for 18 hours. The mixture was stripped into a wet solid and 500 ml of water were added. The mixture was stirred and filtered to give 88.5 g (100%) of product containing approximately 30 mol% imidazole. The product was used without further purification.
[888]
[889] B. Preparation of N-methyl- (3,5-di-t-butyl-4-hydroxy) thiobenzamide
[890] 88.5 g (about 300 mmol) of the compound of Step A and 60.6 g (150 mmol) of the Lawesene reagent were dissolved in 300 g of hexamethylphosphoramide at 100 ° C. and stirred under nitrogen at 100 ° C. for 1 hour. The mixture was cooled, water was added, and the mixture was extracted twice with diethyl ether. The combined organic layers were washed three times with water and the organic layers were stripped to yield 91.3 g of crude product and triturated with 250 ml of methylene chloride to give 43.7 g of product. 350 ml of hexane was added to the filtrate with stirring to give 26.7 g of the second product. The filtrate was boiled up to 400 ml to afford 7.2 g of the third product. The total yield was 77.6g (93%).
[891]
[892] C. Preparation of 3,5-di-t-butyl-4-hydroxythiobenzoic acid, (3-ethoxycarbonyl-2-oxo-1-propionyl) ester
[893] 42.0 g (150 mmol) of the compound of Step B, 27 ml (200 mmol) of ethyl 3-chloroacetoacetate and 24.9 g (150 mmol) of potassium iodide were stirred in 1.0 L of tetrahydrofuran under nitrogen and refluxed for 4.5 h. The reaction was cooled and 75 ml of water were added and the mixture was stirred for 18 hours. The organics were stripped and the crude product was dissolved in chloroform, washed once with water and once with brine, chromatographed by eluting with a 90: 10: 1 methylene chloride / methanol / concentrated ammonia gradient in methylene chloride for 10 minutes. . Some purified product was then chromatographed on 600 ml silica eluting with 10% ethyl acetate / hexanes to give 28 g (44%) of product.
[894] FDMS-M + = 394.
[895]
[896] D. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4-carbethoxymethylthiazole
[897] 25.1 g (63.7 mmol) of the compound of Step C and 19.6 g (255 mmol) of ammonium acetate were refluxed in 320 ml of glacial acetic acid with stirring under nitrogen for 3.25 hours. The reaction was cooled and ethyl acetate and water were added. The layers were separated and the aqueous layer was washed once with ethyl acetate. The combined organic layers were washed once with water and eight times with saturated sodium bicarbonate to give a final wash having a pH of 9. The organic layer was stripped and the crude product was chromatographed on 600 ml silica eluting with 10% ethyl acetate / hexanes to give 14.96 g (57%) of product.
[898] FDMS-M + = 375.
[899]
[900] E. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-hydroxyethyl) thiazole
[901] 5.0 g (13.33 mmol) of the compound of Step D were dissolved in 95 ml of tetrahydrofuran with stirring under nitrogen. 760 mg (20 mmol) of solid lithium aluminum hydride were carefully added. Many bubbles occurred. The mixture was stirred under nitrogen for 1 hour. 0.76 ml of water H ₂ O were carefully added, 0.76 ml of 15% sodium hydroxide was added followed by 2.3 ml of water. The inorganics were filtered off and the filtrate was stripped and dissolved in ethyl acetate and washed once with 1N hydrochloric acid and twice with brine and stripped to give 4.42 g (99%) of the product, which was used without further purification. It was.
[902] FDMS-M + = 333.
[903]
[904] F. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formylphenoxy) ethyl) thiazole
[905] 4.20 g (12.6 mmol) of the compound of Step E, 1.76 g (14.44 mmol) of 4-hydroxybenzaldehyde and 3.79 g (14.44 mmol) of triphenyl phosphine were dissolved in 37 ml of tetrahydrofuran with stirring under nitrogen. The solid was cooled to −10 ° C. and a solution of 2.27 ml (14.44 mmol) of diethylazodicarboxylate in 12.5 ml of tetrahydrofuran was added with stirring for 10 minutes. The reaction exothermed to -1 ° C. The crude was removed and the reaction stirred overnight under nitrogen. The reaction was stripped and dissolved in methylene chloride and placed in the freezer. The diethoxycarbonylhydrazine was then filtered off and chromatographed on 400 ml silica eluting with 15 then a 20% ethyl acetate / hexanes gradient. Appropriate fractions were combined and stripped to yield 3.98 g (72%) of product, which was used without further purification.
[906]
[907] G. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-methyl-N-ethylaminomethylphenoxy) ethyl) thiazole hydrochloride hydrate Manufacture
[908] 0.96 ml (11.26 mmol) of N-methyl-N-ethylamine and 3.33 ml (11.26 mmol) of Ti (OPr) ₄ were dissolved in 20 ml of ethanol with stirring under nitrogen. The mixture was stirred for 10 minutes. 2.46 g (5.63 mmol) of the compound of Step F were added and the mixture was stirred for 2.5 hours. 320 mg (8.44 mmol) of sodium borohydride were added and the reaction stirred for 3.5 days. 7.85 ml of 2N ammonia was added to give a thick suspension followed by 55 ml of methylene chloride. 7.2 g of diatomaceous earth were added and the mixture was stirred and filtered through diatomaceous earth. The filtrate was washed twice with brine and then dried and the organics were stripped and chromatographed by eluting 90: 10: 1 methylene chloride / methanol / concentrated ammonia. Fractions were combined, stripped and dissolved in methylene chloride / isopropyl ether. Bubbling hydrogen chloride gas and concentrating the product and triturating with isopropyl ether yielded 1.54 g (54%) of white foam.
[909] FDMS-M + 480;
[910] Elemental Analysis for C ₂₉ H ₄₀ N ₂ O ₂ SHCl1.75H ₂ O:
[911] Theoretical: C, 63.48; H, 8. 17; N, 5.11.
[912] Found: C, 63.55; H, 7.89; N, 4.86.
[913] NMR (CDCl ₃ ) δ 1.46 (t, 3H, J = 4 Hz), 1.49 (m, 18H), 2.62 (d, 2H, J = 4 Hz), 2.89 (m, 1H, J = 4 Hz), 3.15 (m, 1H), 3.50 (bs, 2H), 4.10 (m, 2H), 4.41 (t, 2H, J = 4 Hz), 5.74 (s, 1H), 6.96 (d, 2H, J = 7 Hz ), 7.12 (s, 1H), 7.50 (s, 2H, J = 7 Hz), 7.90 (s, 2H).
[914] <Example 39>
[915] E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) -2-propenyl) oxazole hydrochloride Hydrate
[916] A. Preparation of 4- (2-bromoethyl) -2- (3,5-di-t-butyl-4-hydroxyphenyl) oxazole
[917] Bromine (6.09 ml, 118 mmol) was added to the solution of triphenylphosphine (31.0 g, 118 mmol) in methylene chloride (394 ml) with stirring. A small amount of additional triphenylphosphine was added to make the solution clear. To this solution was added a mixture of Example 1C compound (25.0 g, 78.9 mmol) and imidazole (10.7 g, 158 mmol) dissolved in methylene chloride (315 ml) for 15 minutes. The reaction was stirred at rt for 1 h and filtered. The filtrate was evaporated to dryness, triturated with methylene chloride / toluene and filtered. This filtrate was chromatographed on silica gel using hexane-ethyl acetate with gradient to give the subtitle product (25.4 g, 85%).
[918]
[919] B. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-triphenylphosphonium ethyl) oxazole bromide
[920] Tri while stirring to a solution of 4- (2-bromoethyl) -2- (3,5-di-t-butyl-4-hydroxyphenyl) oxazole (25.4 g, 66.8 mmol) in xylene (135 ml) Phenylphosphine (17.5 g, 66.8 mmol) was added. The reaction was heated to reflux for 22 hours and xylene was decanted from the precipitated product. The product was triturated in diethyl ether, filtered and then with ethyl acetate and filtered to intermediate phosphonium salt 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- Triphenylphosphonium ethyl) oxazole bromide (30.7 g, 72%) was obtained.
[921]
[922] C. Preparation of E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole diethyl acetal
[923] Of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-triphenylphosphonium ethyl) oxazole bromide (28.1 g, 43.8 mmol) in tetrahydrofuran (220 ml) To the solution was added terephthalaldehyde mono-diethylacetal (8.68 ml, 43.8 mmol). The mixture was cooled to −10 ° C. and a 1M solution of sodium hexamethyldisilazane (87.5 ml, 87.5 mmol) in tetrahydrofuran was added dropwise for 8 minutes keeping the temperature below 4 ° C. The reaction was stirred for 3 h at 0 ° C., quenched with water and diluted with ethyl acetate and water. The pH was adjusted to 8.5 with 1N hydrochloric acid. The organic layer was extracted with brine, dried over sodium sulfate and evaporated to dryness, and chromatographed on silica gel using gradient hexane / acetone to give olefin intermediate E-2 (3,5-di-t-butyl-4 A trans isomer (2.6 g, 12%) of -hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole diethyl acetal was obtained.
[924]
[925] D. Preparation of Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole diethyl acetal
[926] The crude fraction from the chromatography was chromatographed again on silica gel using hexane-diethyl ether with gradient to give the subtitle product (1.6 g, 7%).
[927]
[928] E. Preparation of E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole
[929] E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole in diethyl ether (51 ml) To a solution of diethyl acetal (2.53 g, 5.14 mmol) was added 1N hydrochloric acid (51 ml) with stirring followed by concentrated hydrochloric acid (5.1 ml). The reaction was stirred for 18 hours and then basified with saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness, and chromatographed on silica gel using a gradient of hexane-ethyl acetate to give the desired product (1.19 g, 55%).
[930]
[931] F. E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethyl-phenyl) -2-propenyl) Preparation of Oxazole Hydrochloride
[932] Triethylamine (0.79 ml, 5.7 mmol), titanium tetraisopropoxide (1.68 ml, 5.7 mmol), and finally with stirring in a solution of ethylmethylamine hydrochloride (0.54 g, 5.7 mmol) in ethanol (5.8 ml) With E-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole in ethanol (7.1 ml) 1.19 g, 2.85 mmol) was added. The reaction was stirred for 4.5 hours and then sodium borohydride (0.16 g, 4.28 mmol) was added. After 20 h at rt, the reaction was poured into 20 ml 2N ammonium hydroxide and diluted with methylene chloride. The mixture was filtered through diatomaceous earth and the filtrate was extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using a gradient of methylene chloride-methanol to give the free base (0.79 g, 60%). The free base (0.79 g, 1.71 mmol) was dissolved in methylene chloride (17 ml), treated with hydrogen chloride gas and evaporated to afford the desired product (0.83 g, 98%).
[933]
[934] _{C 30 H 41 ClN 2 O 2} · Elemental Analysis for 1.5H ₂ O:
[935] Theoretical: C, 68.75; H, 8. 46; N, 5.34.
[936] Found: C, 69.06; H, 8. 30; N, 5.49.
[937] <Example 40>
[938] Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) -2-propenyl) oxazole hydrochloride Monohydrate
[939] A. Preparation of Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole
[940] To a solution of the compound of Example 39D (1.59 g, 3.23 mmol) in diethyl ether (32 ml) was added with stirring 1N hydrochloric acid (32 ml) followed by concentrated hydrochloric acid (3.2 ml). The reaction was stirred for 30 minutes and then basified with saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness, and chromatographed on silica gel using a gradient of hexane-ethyl acetate to give the desired subtitle product (1.15 g, 85%).
[941]
[942] B. Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethyl-phenyl) -2-propenyl) Preparation of Oxazole Hydrochloride
[943] Triethylamine (1.14 ml, 8.18 mmol), titanium tetraisopropoxide (2.42 ml, 8.18 mmol), and last with stirring in a solution of ethylmethylamine hydrochloride (0.78 g, 8.18 mmol) in ethanol (4.1 ml) Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyl) -2-propenyl) oxazole in ethanol (10 ml) 1.71 g, 4.09 mmol) was added. The reaction was stirred for 3.5 hours and then sodium borohydride (0.23 g, 6.14 mmol) was added. After 18 hours at room temperature, the reaction was poured into 30 ml 2N ammonium hydroxide and diluted with methylene chloride. The mixture was filtered through diatomaceous earth and the filtrate was extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel with gradientd methylene chloride-methanol to give the free base (1.63 g, 86%). The free base (1.3 g, 2.82 mmol) was dissolved in methylene chloride (28 ml), treated with hydrogen chloride gas and evaporated to afford the desired product (1.40 g, 100%).
[944]
[945] _{C 30 H 41 ClN 2 O 2} · elemental analysis of the H ₂ O:
[946] Theoretical: C, 69.95; H, 8.41; N, 5.44.
[947] Found: C, 70.08; H, 8. 10; N, 5.61.
[948] <Example 41>
[949] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) propyl) oxazole hydrochloride hydrate
[950] Z-2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyl) -2-prop in toluene (26 ml) To a solution of phenyl) oxazole (1.2 g, 2.6 mmol) 5% palladium on carbon (0.12 g) was added with stirring. The suspension was exposed to 1 atmosphere of hydrogen for 5 hours and filtered. The filtrate was evaporated to dryness and chromatographed on silica gel with methylene chloride-methanol having a gradient to give a saturated free base (0.99 g, 82%). The free base (1.05 g, 2.27 mmol) was dissolved in methylene chloride (23 ml), treated with hydrogen chloride gas, evaporated and triturated with diisopropyl ether to afford the desired product (1.00 g, 88%). .
[951]
[952] _{C 30 H 43 ClN 2 O 2} · Elemental Analysis for 1.5H ₂ O:
[953] Theoretical: C, 68.48; H, 8.81; N, 5.32.
[954] Found: C, 68.40; H, 8.63; N, 5.22.
[955] <Example 42>
[956] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylaminomethyl) phenoxymethyl) oxazole hydrochloride
[957] A. N-carbo (3,5-di-t-butyl-4-hydroxy) phenyl-DL-serine methyl ester
[958] To a suspension of benzoic acid in tetrahydrofuran (165 ml) was added 1,1'-carbonyldiimidazole in portions for 20 minutes. The resulting gold solution was stirred at 22 ° C. for 20 minutes and then added dropwise to the solution described above.
[959] To the suspension of DL-serine methyl ester in tetrahydrofuran (115 ml) was added diisopropyl ethyl amine and dimethyl formamide (70 ml). The resulting colorless solution was stirred for 1 hour at 22 ° C. and activated benzoic acid derivative (described above) was added. The reaction was stirred at 22 ° C. for 5 days and then concentrated to oil under vacuum. The oil was treated with ethyl acetate (250 ml) and washed three times with 1: 1 brine: 0.1N hydrochloric acid and once with salt. The organics were dried over sodium chloride and warmed up on a steam bath, filtered hot and the filtrate was concentrated in vacuo to an oil. The oil was then treated with 1: 1 hexanes: ethyl acetate and reduced in volume to approximately 250 ml on a steam bath followed by sonication. The mixture was cooled to −20 ° C. for approximately 2 hours to form crystals. The crystals were collected by filtration and washed with 70% hexanes: ethyl acetate to give 49.13 g of the title compound. The filtrate was concentrated in vacuo to oil. The oil was treated with 1: 1 hexanes: ethyl acetate then eluted with a gradient of 50 to 70% hexanes: ethyl acetate for 30 minutes. The desired fractions containing the title compound were combined and concentrated to oil under vacuum. The title compound was recrystallized from diethyl ether: hexane to give 11.32 g of the title compound. A total of 60.45 g (56%) of the title compound was isolated.
[960] Melting Point (℃): 108-109
[961] Mass spectrum (FDMS): m / z 351 (M).
[962]
[963] Elemental Analysis for C ₁₉ H ₂₉ NO ₅ :
[964] Theoretical: C, 64.94; H, 8.32; N, 3.99.
[965] Found: C, 65.20; H, 8.42; N, 4.22.
[966] B. 4-((RS) carbomethoxy) -2- (3,5-di-tert-butyl-4-hydroxyphenyl))-2-oxazoline
[967] N-carbo (3,5-di-t-butyl-4-hydroxy) phenyl-DL-serine methyl ester (0.17 mol, 58.81 g) and imidazole (0.18 mol) in acetonitrile (890 ml) at 22 ° C. , 12.53 g) was added triphenylphosphine (0.18 mol, 48.28 g) followed by carbon tetrabromide (0.18 mol, 61.05 g). After stirring for 2.5 hours, the reaction was concentrated in vacuo to a foam containing crystalline material. The mixture was treated with ethyl acetate: hexanes (100 ml) and then cooled to -20 ° C. Insolubles were collected by filtration and discarded. The filtrate was pre chromatographed by eluting with 25 to 45% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound and the eluted impurity were again chromatographed by eluting with a 15 to 35% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 55.75 g (99%) of oil, which slowly crystallized.
[968] Melting Point (℃): 102-104
[969] Mass spectrum (FDMS): m / z 333 (M).
[970]
[971] Elemental Analysis for C ₁₉ H ₂₇ NO ₄ :
[972] Theoretical: C, 68.44; H, 8. 16; N, 4.20.
[973] Found: C, 68.33; H, 8. 10; N, 4.34.
[974] C. 4- (Carbomethoxy) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) oxazole
[975] ((RS) -4-carbomethyloxy) -2- (3,5-di-tert-butyl-4-hydroxypentyl))-2-oxazoline (0.66 mol, 220.15 g in acetone (1.6 L) ) Was treated with activated manganese oxide (6.60 mol, 574.0 g). The suspension was stirred at 22 ° C. for 17.5 hours and then heated to 45 ° C. for 1 hour. Diatomaceous earth (250 ml) was added to the reaction and the suspension was then filtered through a pad of silica (2.5 cm x 14.5 cm) and diatomaceous earth (250 g). Insoluble matter was rinsed with acetone until no product was observed in the filtrate by thin layer chromatography. The filtrate was concentrated in vacuo to afford 303.5 g of a black solid. The material was treated with diethyl ether (500 ml) and placed on a steam bath until the solids dissolved and then hexane (250 ml) was added. The solution was boiled until crystals formed. The mixture was cooled to 22 ° C., the crystals were collected by filtration and washed with 2: 1 hexanes: diethyl ether to give 98.1 g of the title compound containing impurities. This material was recrystallized several times as described above to give 92.46 g of the title compound. Additional title compound was isolated by multiple recrystallization of the filtrate to give 36.94 g.
[976] The filtrate from crystallization was concentrated to a solid in vacuo and recrystallized as described above to give 43.46 g of the title compound. The filtrate was concentrated in vacuo to a solid. The solid was treated with methylene chloride and then divided into two classes. Each class was pre chromatographed by eluting with a 5 to 25% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound and the eluted impurities were combined and concentrated in vacuo to yield a black solid. This solid was recrystallized as described above to yield 20.74 g of a yellow / green solid. The solid was then triturated in boiling 1: 4 ethyl acetate: hexanes (200 ml), filtered hot and washed with 1: 4 ethyl acetate: hexanes to afford 17.99 g of the title compound. Additional title compound was recrystallized from the filtrate to yield 0.65 g. A total of 148.04 g (68%) of the title compound was isolated.
[977] Melting Point (℃): 163
[978] Mass spectrum (FDMS): m / z 331 (M).
[979]
[980] Elemental Analysis for C ₁₉ H ₂₅ NO ₄ :
[981] Theoretical: C, 68.86; H, 7. 60; N, 4.23.
[982] Found: C, 69.11; H, 7.72; N, 4.21.
[983] D. (4- (hydroxymethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl))-2-oxazole
[984] Dark blue solution of 4- (carbomethoxy) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) -2-oxazole (0.39 mol, 127.71 g) in tetrahydrofuran (2.6 L) Was treated with methanol (0.58 mol, 23.4 ml) in a three neck 12 L flask. After this time lithium borohydride (0.58 mol, 12.59 g) was added carefully for 60 minutes. During the addition, the reaction was cooled with an ice bath to maintain the temperature between 19 and 24 ° C. As soon as the addition of borohydride was complete, the orange color reaction was slowly refluxed (about 50 minutes). After refluxing for 4.5 hours, the tan-yellow reaction was cooled to 22 ° C. The reaction was then carefully treated with 5N hydrochloric acid (620 ml) for 30 minutes. Violent gas evolution was observed during the first 40 ml of hydrochloric acid. Ethyl acetate (1 L) was added and the reaction was divided into two classes. Each class was treated with water (500 ml) and the phases were separated. The aqueous phases were combined and extracted twice with ethyl acetate. The organic phases were combined and concentrated to oil under vacuum. Diethyl ether (500 ml) was added to the oil and the volume was reduced to approximately 500 ml on a steam bath and then cooled to −78 ° C. for 1 hour (using dry ice / acetone). After warming to 22 ° C., the resulting crystals were collected by filtration and washed with diethyl ether to give 56.55 g of the title compound. Further 52.76 g was obtained by recrystallization of the subsequent filtrate. A total of 109.31 g (94%) of the title compound were isolated.
[985] Melting point (° C.): 150.
[986] Mass spectrum (FDMS): m / z 303 (M).
[987]
[988] Elemental Analysis for C ₁₈ H ₂₅ NO ₃ :
[989] Theoretical: C, 71.26; H, 8.31; N, 4.62.
[990] Found: C, 71.52; H, 8. 26; N, 4.79.
[991] E. 4- (Bromomethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) oxazole
[992] Suspension of 4- (hydroxymethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) oxazole (44.2 mmol, 13.41 g) in acetonitrile (230 ml) triphenylphosphine (53.0 mmol, 13.91 g) followed by carbon tetrabromide (53.0 mmol, 17.59 g). The resulting solution was stirred at approximately 22 ° C. for 3 hours. Thereafter, additional carbon tetrabromide (22.0 mmol, 13.13 g) and triphenylphosphine (22.0 mmol, 5.79 g) were added to the reaction. After stirring for an additional 40 minutes, the reaction was quenched with water (5 ml), stirred for 10 minutes, concentrated in vacuo and stored for approximately 16 hours. The material was then placed in chloroform and prechromatographic by eluting with a 35 to 50% chloroform: hexanes gradient for 30 minutes. Fractions containing the title compound were combined, dried over sodium sulfate, filtered and concentrated in vacuo to afford 9.7 g of the title compound which was left at 22 ° C. to yield crystals.
[993] Melting Point (℃):
[994] Mass spectrum (FDMS): m / z 367 (M + l).
[995]
[996] Elemental Analysis for C ₁₈ H ₂₄ BrNO ₂ :
[997] Theoretical: C, 59.02; H, 6. 60; N, 3.82.
[998] Found: C, 58.83; H, 6.53; N, 3.85.
[999] F. 4- (4- (2-formyl) phenoxy methyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl)) oxazole
[1000] 4- (Bromomethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) oxazole (26.5 mmol, 9.70 g), 4-hydroxybenzaldehyde in methyl ethyl ketone (275 ml) (29.1 mmol, 3.56 g), a suspension of potassium carbonate (79.4 mmol, 10.97 g) and potassium iodide (26.5 mmol, 4.39 g) was refluxed for 2 hours. The reaction was then cooled to approximately 22 ° C., filtered and concentrated to oil under vacuum. The oil was treated with ethyl acetate (250 ml) and then washed twice with saturated aqueous sodium bicarbonate, once with aqueous sodium hydrogen sulfate and once with brine. The organic layer was dried over sodium sulphate, filtered and concentrated in vacuo to an oil. The material was placed in ethyl acetate and pre chromatographed by eluting with a 30% to 50% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound and the eluted impurities were again chromatographed by eluting with a 25 to 35% acetone: hexane gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 8.9 g (82%).
[1001] Melting Point: 160 (℃)
[1002] Mass spectrum (FDMS): m / z
[1003]
[1004] Elemental Analysis for C ₂₅ H ₂₉ NO ₄ :
[1005] Theoretical: C, 73.69; H, 7. 17; N, 3.44.
[1006] Found: C, 73.72; H, 7. 16; N, 3.45.
[1007] G. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methylethylamino methyl) phenoxymethyl) oxazole hydrochloride
[1008] The title compound was purified from 4- (4- (2-formyl) phenoxymethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl)) oxazole and N-methyl-n-ethylamine Was prepared substantially as described in Example 11 except for using. The crude material was pre chromatographed by eluting with a gradient of 0 to 10% (methanol: ammonium hydroxide): chloroform for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 6.0 g. The material was dissolved in diethyl ether (100 ml) and then saturated with hydrochloric acid gas. The resulting precipitate was collected by filtration and washed with diethyl ether. This material was dissolved in methylene chloride (50 ml) and washed with 0.1N ammonium hydroxide (50 ml). The organic layer was dried over sodium sulfate and filtered. The filtrate was pre chromatographed by eluting with a gradient of 0 to 10% (methanol: ammonium hydroxide): chloroform for 30 minutes. Fractions containing the title compound were combined and concentrated to foam under vacuum. The foam was treated with diethyl ether (100 ml) and saturated aqueous sodium bicarbonate (100 ml). The phases were separated and the aqueous phase was extracted with diethyl ether (1 x 50 ml). The organic phases were combined, dried over sodium sulphate, filtered and added slowly to a saturated solution of hydrogen chloride in diethyl ether. The resulting suspension was concentrated in vacuo to yield 4.74 g of the title compound as a foam.
[1009] Mass spectrum (FDMS): m / z 450 (M-HCl)
[1010]
[1011] Elemental Analysis for C ₂₈ H ₃₉ ClN ₂ O ₃ :
[1012] Theoretical: C, 69.05; H, 8.07; N, 5.75.
[1013] Found: C, 68.95; H, 7.98; N, 5.76.
[1014] <Example 43>
[1015] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4-((4-N-ethyl-N-propylaminoethylphenoxy) methyl) oxazole hydrochloride
[1016] A. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4-((4-N-ethyl-N-propionylaminoethylphenoxy) methyl) oxazole
[1017] To a solution of N-ethyl, N-propionyl tyramine (2.84 g, 12.83 mmol) in tetrahydrofuran (32.1 ml) was added 60% sodium hydride dispersion (0.56 g, 14.11 mmol) with stirring. After stirring for 10 minutes, the compound of Example 42 (E) (4.70 g, 12.83 mmol) was added. The reaction was stirred at room temperature for 5 hours, then poured into ethyl acetate, extracted with 10% sodium sulfate and then extracted with brine. The organic layer was dried over sodium sulfate, evaporated to dryness and chromatographed on silica gel using hexane-ethyl acetate with gradient. Further chromatography using toluene-acetone with a gradient yielded the intermediate phenyl ether (2.10 g, 32%).
[1018]
[1019] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4-((4-ethylpropylaminoethylphenoxy) methyl) oxazole hydrochloride
[1020] 2M borane-dimethylsulfide (5.9 ml, 11.81 mmol) in tetrahydrofuran (55 ml) with stirring in a solution of intermediate phenyl ether (1.87 g, 3.69 mmol) prepared as above in tetrahydrofuran (55 ml). Was added. The reaction was heated to reflux for 3 hours. After dissolving again in methanol, 0.99 M hydrochloric acid in methanol (5.0 ml) was added. The reaction was heated to 60 ° C. for 18 hours. After cooling to room temperature, the pH was adjusted to 8.5 with 1N sodium hydroxide and the solvent was distilled off. The residue was dissolved in ethyl acetate and saturated sodium bicarbonate. The organic layer was washed with brine, dried over sodium sulphate, evaporated to dryness and chromatographed on silica gel using a gradient of methylene chloride-methanol to give the free base (1.20 g, 66%). The free base (1.31 g, 2.66 mmol) was dissolved in methylene chloride (40 ml), treated with hydrochloric acid and evaporated to give the desired product (1.43 g, 100%).
[1021]
[1022] _{C 31 H 45 ClN 2 O 3} · Elemental Analysis for 0.6H ₂ O:
[1023] Theoretical: C, 68.96; H, 8.62; N, 5.19.
[1024] Found: C, 68.76; H, 7. 40; N, 5.25.
[1025] <Example 44>
[1026] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-N-methyl-N-ethylaminomethylphenyloxy) propyl) oxazole
[1027] A. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-hydroxypropyl) oxazole
[1028] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-formylethyl) oxazole in diethyl ether (270 ml) (Example 43C) (9.01 g, 27.3 mmol To the solution of was added sodium borohydride (1.03 g, 27.3 mmol) in water (90 ml). After stirring for 3 days, the reaction mixture was poured into diethyl ether, extracted with 1N hydrochloric acid and then extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness to afford intermediate primary alcohol (9.2 g, 100%).
[1029]
[1030] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-formylphenyloxy) propyl) oxazole
[1031] 4-hydroxybenzaldehyde (3.68 g, 30.20 mmol) and triphenylphosphine (7.91 g, with stirring) in a solution of the above-described intermediate primary alcohol (9.1 g, 27.45 mmol) in tetrahydrofuran (82 ml) 30.20 mmol) was added. After cooling to −20 ° C., a solution of diethylazodicarboxylate (4.75 ml, 30.20 mmol) in tetrahydrofuran (27 ml) was added dropwise over 30 minutes. The reaction was warmed to room temperature and stirred for 18 hours, during which time it was diluted with diethyl ester and extracted with water, 1N sodium hydroxide and brine. The organic layer was dried over sodium sulphate, evaporated to dryness and chromatographed on silica gel using hexane-acetone with a gradient to give the intermediate aldehyde (7.7 g, 64%).
[1032]
[1033] C. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3- (4-methylethylaminomethyl-phenyloxy) propyl) oxazole hydrochloride
[1034] To a solution of the above-prepared intermediate aldehyde (2.8 g, 6.43 mmol) in dichloroethane (22 ml) with N-ethyl-N-methyl amine (0.55 ml, 6.43 mmol) and sodium triacetoxyborohydride ( 3.81 g, 18.0 mmol) was added. After 20 hours, the reaction was quenched with saturated sodium bicarbonate and diluted with ethyl acetate. The organic layer was extracted with brine, dried over sodium carbonate and evaporated to dryness, and chromatographed on silica gel using a gradient of methylene chloride-methanol to give the free base (2.38 g, 77%). The free base was dissolved in methylene chloride (70 ml), treated with hydrochloric acid and evaporated to give the desired product (2.4 g, 94%).
[1035]
[1036] _{C 30 H 43 ClN 2 O 3} · Elemental Analysis for 0.5H ₂ O:
[1037] Theoretical: C, 68.75; H, 8. 46; N, 5.34.
[1038] Found: C, 68.93; H, 8.34; N, 5.17.
[1039] <Example 45>
[1040] 2- (3,5-dimethoxy-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethyl-phenyloxy) ethyl) oxazole
[1041] A. 4-benzyloxy-3,5-dimethoxybenzamide
[1042] To the solution of 4-benzyloxy-3,5-dimethoxy benzoic acid (23.4 g, 81.2 mmol) in tetrahydrofuran (325 ml) was added carbonyldiimidazole (14.46 g, 89.3 mmol) with stirring. After refluxing for 2 hours, the reaction was cooled to room temperature and ammonium hydroxide (81 ml) was added. The reaction was stirred at rt for 1.5 h, diluted with ethyl acetate and then acidified with 1N hydrochloric acid. The organic layer was extracted with saturated sodium bicarbonate and then brine. The organic layer was dried over sodium sulphate and evaporated to dryness to afford intermediate benzamide (22.8 g, 98%).
[1043]
[1044] B. 2- (4-benzyloxy-3,5-dimethoxyphenyl) -4- (ethylacetate) oxazole
[1045] A suspension of intermediate benzamide (22.8 g, 79.35 mmol) in 4-chloroacetoacetate (47.6 ml, 352 mmol) was heated to 130 ° C. for 2 hours with azeotropic removal of water with stirring. The reaction was then poured into ethyl acetate and the resulting suspension was filtered. The filtrate was extracted with water, saturated sodium bicarbonate, 1N hydrochloric acid and then brine. The organic layer was dried over sodium sulfate, evaporated to dryness and distilled to remove 4-chloroacetoacetate. The distillation vessel was triturated with methylene chloride and filtered and the filtrate was chromatographed on silica gel using hexane-ethyl acetate with gradient to give the intermediate ethyl ester (11.7 g, 37%).
[1046]
[1047] C. 2- (4-benzyloxy-3,5-dimethoxyphenyl) -4- (2-hydroxyethyl) oxazole
[1048] To a solution of intermediate ethyl ester (11.7 g, 29.44 mmol) in tetrahydrofuran (200 ml) was added dropwise 1 M lithium aluminum hydride (26.5 ml, 26.5 mmol) in tetrahydrofuran for 10 minutes. After an additional 30 minutes, the reaction was quenched by dropwise addition of water (1.0 ml), 15% sodium hydroxide, followed by water (3.0 ml) again. Insolubles were filtered off and washed with ethyl acetate. The filtrate was extracted with 1N hydrochloric acid followed by brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using gradient hexane-acetone to afford the intermediate primary alcohol (7.9 g, 76%).
[1049]
[1050] MS 355 (M ⁺ )
[1051] D. 2- (4-benzyloxy-3,5-dimethoxyphenyl) -4- (2- (4-formyl-phenyloxy) ethyl) oxazole
[1052] To a solution of intermediate primary alcohol (7.9 g, 22.22 mmol) in tetrahydrofuran (67 ml) was added 4-hydroxybenzaldehyde (2.98 g, 24.44 mmol) and triphenylphosphine (6.41 g, 24.44 mmol) with stirring. Added. After cooling to 20 ° C., a solution of diethylazodicarboxylate (3.85 ml, 24.44 mmol) in tetrahydrofuran (22 ml) was added dropwise over 26 minutes. The reaction was warmed to rt and stirred for 18 h, during which time it was diluted with diethyl ether and extracted with water, 1N sodium hydroxide, and brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using gradientd methylene chloride-ethyl acetate to give the intermediate aldehyde (7.9 g, 77%).
[1053]
[1054] E. 2- (4-benzyloxy-3,5-dimethoxyphenyl) -4- (2- (4-methylethylaminomethyl-phenyloxy) ethyl) oxazole
[1055] To a solution of intermediate aldehyde (5.3 g, 11.53 mmol) in dichloroethane (40 ml) was added ethylmethylamine (0.99 ml, 11.53 mmol) and sodium triacetoxyborohydride (6.84 g, 32.28 mmol) with stirring. . After 20 hours, the reaction was quenched with saturated sodium bicarbonate and diluted with ethyl acetate. The organic layer was extracted with brine, dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using a gradient of methylene chloride-methanol to give the intermediate benzyl amine (4.9 g, 84%).
[1056]
[1057] F. 2- (3,5-dimethoxy-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethyl-phenyloxy) ethyl) oxazole hydrochloride
[1058] Concentrated hydrochloric acid (175 ml) was added to the solution of the above-prepared intermediate benzyl amine (4.4 g, 8.75 mmol) in methanol (175 ml) with stirring. The reaction was heated to 70 ° C. for 1 h, cooled to rt, neutralized with sodium bicarbonate and extracted with ethyl acetate. The organic layer was extracted with brine, dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using methylene chloride-methanol having a gradient to give a free base (2.8 g, 70%). The free base was dissolved in methylene chloride (75 ml), treated with hydrochloric acid and evaporated to give the desired product (3.08 g, 100%).
[1059]
[1060] _{C 23 H 29 ClN 2 O 5} · Elemental Analysis for 1.5H ₂ O:
[1061] Theoretical: C, 57.98; H, 6.94; N, 5.62.
[1062] Found: C, 58.04; H, 6. 78; N, 5.89.
[1063] <Example 46>
[1064] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-methylthioethyl) methylaminomethyl-phenyloxy) ethyl) oxazole hydrochloride
[1065] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylaminomethylphenyloxy) ethyl) oxazole (8.06 g, 18.48 in dimethylformamide (46 ml) To the solution of mmol, 60% sodium hydride dispersion (1.77 g, 44.35 mmol) was added with stirring. After 20 min stirring, 2-chloroethyl methyl sulfide (1.84 ml, 18.48 mmol) was added. The reaction was heated to 80 ° C. for 7.5 hours at which time additional chloroethyl methyl sulfide (1.84 ml, 18.48 mmol) was added at 2.5 and 4.5 hours. The reaction was quenched with water and diluted with ether and saturated sodium bicarbonate. The aqueous layer was extracted with ethyl acetate and the combined organics were extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using hexane-acetone with a gradient to give the free base (4.6 g, 46%). The free base (1.00 g, 1.96 mmol) was dissolved in methylene chloride (20 ml), treated with hydrochloric acid and evaporated to afford the desired product (1.09 g, 100%).
[1066]
[1067] Elemental Analysis for C ₃₀ H ₄₃ ClN ₂ O ₃ S · 0.7H ₂ O:
[1068] Theoretical: C, 64.37; H, 7.99; N, 5.00.
[1069] Found: C, 64.25; H, 7.83; N, 4.74.
[1070] <Example 47>
[1071] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-methylthioethyl) methylaminomethyl-phenyloxy) ethyl) oxazole, S-oxide Hydrochloride
[1072] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-methylthioethyl) methylaminomethyl-phenyloxy) ethyl in methylene chloride (18 ml) To a solution of free base (1.8 g, 3.52 mmol) prepared for oxazole was added 55% m-chloroperbenzoic acid (1.11 g, 3.52 mmol) in methylene chloride (11 ml) with stirring at 0 ° C. for 10 minutes. It was. After stirring at 0 ° C. for 1.5 h, the reaction was diluted with methylene chloride and extracted with saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate, evaporated to dryness and chromatographed on silica gel with gradient chloroform-ethanol to give the free base (0.79 g, 43%). The free base (0.78 g, 1.46 mmol) was dissolved in methylene chloride (15 ml), treated with hydrochloric acid and evaporated to give the desired product (0.80 g, 96%).
[1073]
[1074] Elemental Analysis for _{C 30 H 43 ClN 2 O 4} S · 1.1H 2 O:
[1075] Theoretical: C, 61.80; H, 7.81; N, 4.80.
[1076] Found: C, 61.55; H, 7. 50; N, 4.55.
[1077] <Example 48>
[1078] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-ethylpropylaminoethylphenoxy) oxazole
[1079] A. N-ethyl, N-propionyl tyramine
[1080] A solution of propionic acid (6.5 ml, 87.12 mmol) in tetrahydrofuran (73 ml) for 30 minutes with stirring to a solution of carbonyldiimidazole (14.13 g, 87.12 mmol) in tetrahydrofuran (109 ml) at −5 ° C. Was added drop wise. After stirring for 20 minutes, N-ethyl tyramine (12.0 g, 72.6 mmol) in tetrahydrofuran (73 ml) was added for 20 minutes. The reaction was warmed to rt and stirred for 4 h. Methanol (7.3 ml) was added and stirring continued for 30 minutes. The reaction was diluted with ethyl acetate and extracted by extraction with 1N hydrochloric acid, saturated sodium bicarbonate, and brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel with gradientd methylene chloride-methanol to give N-ethyl, N-propionyl tyramine (6.95 g, 43%).
[1081]
[1082] B. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-N-ethyl-N-propionylamino ethylphenoxy) ethyl) oxazole
[1083] Stirred to a solution of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2-hydroxyethyl) oxazole (5.51 g, 17.38 mmol) in tetrahydrofuran (47 ml) N-ethyl, N-propionyl tyramine (3.5 g, 15.8 mmol) and triphenylphosphine (4.55 g, 17.38 mmol) were added. After cooling to 0 ° C., a solution of diethylazodicarboxylate (2.73 ml, 17.38 mmol) in tetrahydrofuran (16 ml) was added dropwise for 10 minutes. The reaction was warmed to rt and stirred for 22 h, evaporated, triturated with methylene chloride (50 ml) and filtered. The filtrate was chromatographed twice on silica gel using gradient methylene chloride-ethyl acetate and hexane-acetone to give the intermediate phenyl ether (2.95 g, 36%).
[1084]
[1085] C. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-ethylpropylaminoethylphenoxy) ethyl) oxazole
[1086] To a solution of lithium aluminum hydride (0.42 g, 10.98 mmol) in tetrahydrofuran (22 ml) at 0 ° C. was added dropwise sulfuric acid (0.30 ml, 5.49 mmol) while maintaining the temperature below 10 ° C. with stirring. The reaction was warmed to rt, stirred for 1 h and cooled back to 0 ° C. Intermediate phenyl ether (2.86 g, 5.49 mmol) in tetrahydrofuran (5.5 ml) was added dropwise keeping the temperature below 5 ° C. The reaction was stirred at 0 ° C. for 2.5 h and then quenched with water (11 μL). The reaction was diluted with methylene chloride and 5N hydrochloric acid. The aqueous layer was extracted twice with methylene chloride. The combined organics were extracted with brine, then saturated sodium bicarbonate and dried over sodium sulfate. Chromatography on silica gel using methylene chloride-methanol with a gradient gave the free base (1.12 g, 40%). The free base (1.12 g, 2.21 mmol) was dissolved in methylene chloride (30 ml), treated with hydrochloric acid gas and evaporated to give the desired product (1.22 g, 100%).
[1087]
[1088] Elemental analysis for C ₃₂ H ₄₇ ClN ₂ O ₃ · 2.8H ₂ O:
[1089] Theoretical: C, 64.75; H, 8.93; N, 4.72.
[1090] Found: C, 64.86; H, 8.55; N, 4.70.
[1091] <Example 49>
[1092] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-butylethylaminomethyl-phenyloxy) ethyl) oxazole
[1093] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-phenyloxy) ethyl) oxazole (5.0 g, 11.88 mmol) in methanol (59 ml) To the suspension was added N-ethyl-N-butyl amine (16.2 ml, 119 mmol). After 30 minutes, the pH was adjusted to 7 using acetic acid. After an additional 30 minutes, sodium cyanoborohydride (0.75 g, 11.88 mmol) was added and the pH was adjusted to 6 with acetic acid. The mixture was stirred for 5.5 h and the methanol was evaporated. The resulting residue was dissolved in ethyl acetate and saturated sodium bicarbonate. The organic layer was extracted with brine, dried over sodium sulfate and evaporated to dryness, and chromatographed on silica gel using a gradient of methylene chloride-methanol to give the free base (2.82 g, 47%). The free base was dissolved in methylene chloride (75 ml), treated with hydrochloric acid and evaporated to give the desired product (2.88 g, 95%).
[1094]
[1095] Elemental Analysis for _{C 32 H 47 ClN 2 O 3} · H 2 O:
[1096] Theoretical: C, 68.49; H, 8. 80; N, 4.99.
[1097] Found: C, 68.59; H, 8. 77; N, 4.99.
[1098] <Example 50>
[1099] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-ethyl, i-propylaminomethyl-phenyloxy) ethyl) oxazole
[1100] To a suspension of N-ethyl, N-isopropylamine (3.31 ml, 11.88 mmol) in ethanol (24 ml) is added titanium tetraisopropoxide (7.01 ml, 23.8 mmol) with stirring followed by ethanol (24 ml) 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-phenyloxy) ethyl) oxazole (5.0 g, 11.88 mmol) was added. The reaction was stirred for 5 hours and sodium borohydride (0.67 g, 17.8 mmol) was added. After 18 hours at room temperature, the reaction was poured into 100 ml 2N ammonium hydroxide and diluted with methylene chloride. The mixture was filtered through celite and the filtrate was extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel using a gradient of methylene chloride-methanol to give the free base (2.30 g, 39%). The free base was dissolved in methylene chloride (75 ml), treated with hydrochloric acid and evaporated to give the desired product (2.28 g, 92%).
[1101]
[1102] _{C 31 H 45 ClN 2 O 3} · Elemental Analysis for 0.5H ₂ O:
[1103] Theoretical: C, 69.19; H, 8.62; N, 5.21.
[1104] Found: C, 69.05; H, 8. 82; N, 5.24.
[1105] <Example 51>
[1106] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4- (2-methyloxyethyl) methylaminomethyl-phenyloxy) ethyl) oxazole
[1107] To a solution of 2-methoxyethylmethylamine (1.07 ml, 10 mmol) in ethanol (5 ml) was added titanium tetraisopropoxide (2.95 ml, 10 mmol) with stirring followed by 2- in ethanol (7.5 ml). (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-formyl-phenyloxy) ethyl) oxazole (2.11 g, 5 mmol) was added. The reaction was stirred for 4 hours and then sodium borohydride (0.28 g, 7.5 mmol) was added. After 21 h at rt, the reaction was poured into 35 ml 2N ammonium hydroxide and diluted with methylene chloride. The mixture was filtered through celite and the filtrate was extracted with brine. The organic layer was dried over sodium sulphate and evaporated to dryness and chromatographed on silica gel with gradientd methylene chloride-methanol to give the free base (2.21 g, 89%). The free base was dissolved in methylene chloride (45 ml), treated with hydrochloric acid and evaporated to afford the desired product (2.28 g, 96%).
[1108]
[1109] _{C 30 H 43 ClN 2 O 4} · elemental analysis of the H ₂ O:
[1110] Theoretical: C, 62.62; H, 8. 26; N, 5.10.
[1111] Found: C, 65.63; H, 8.01; N, 7.03.
[1112] <Example 52>
[1113] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylaminoethyl) phenoxymethyl) oxazole hydrochloride
[1114] A. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-formyl-N-ethylamino ethyl) phenoxymethyl) oxazole
[1115] Add 60% sodium hydride (20.8 mmol, 0.83 g) to a solution of N-formyl-N-ethyl-p-hydroxyphenethylamine (18.9 mmol, 3.65 g) in tetrahydrofuran (47 ml) at room temperature. It was. The resulting suspension was stirred for 10 minutes at room temperature and then the compound of Example 42 (E) (18.9 mmol, 6.92 g) was added directly. The reaction mixture was stirred at rt for 5 h and then poured into a 1: 1 mixture of ethylene acetate (500 ml) and 10% aqueous sodium hydrogen sulfate solution (500 ml). The phases were separated and the organic phase was washed with brine (500 ml). The organic layer was concentrated to oil under vacuum. The oil was eluted with a 15 to 25% acetone: hexanes gradient for 30 minutes and then eluted with a 25 to 35% acetone: hexanes gradient for 20 minutes. Fractions containing product were combined and concentrated in vacuo to yield 3.2 g of foam. This material was used for the next step without further purification.
[1116] B. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylamino ethyl) phenoxymethyl) oxazole hydrochloride
[1117] Concentrated sulfuric acid (6.7 mmol, 0.66 g) was added dropwise to a suspension of lithium aluminum hydride (13.4 mmol, 0.507 g) in tetrahydrofuran (20 ml) at −10 ° C. (ice / acetone cold bath). The reaction was stirred at room temperature for 50 minutes, cooled to 0 ° C. and treated with a solution of the above compound of Part A (6.7 mmol, 3.20 g) in tetrahydrofuran (5.0 ml) for 30 minutes. The suspension was stirred for approximately 4 hours at room temperature and then quenched with water (0.4 ml). The resulting thick suspension was treated with chloroform (100 ml), 5N hydrochloric acid (50 ml) and brine (20 ml). The phases were separated and the aqueous phase was extracted with chloroform (3 x 50 ml). The organic layers were combined and washed with saturated aqueous sodium bicarbonate (2 x 50 ml) followed by brine (1 x 200 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to yield 4.28 g of oil. The material is then eluted with a 0 to 5% (methanol: 1% ammonium hydroxide): chloroform gradient for 30 minutes and then eluted with a 5 to 10% (methanol: 1% ammonium hydroxide): chloroform gradient for 20 minutes. Preparative chromatography. Fractions containing the desired compound were combined and concentrated in vacuo to yield 1.76 g of oil. The oil was treated with chloroform and then hydrogen chloride gas was passed through the solution. The solution was concentrated in vacuo to yield 1.76 g of foam and dried overnight in a 60 ° C. vacuum oven.
[1118] Mass spectrum (FDMS): m / z
[1119]
[1120] Elemental Analysis for C ₂₉ H ₄₁ ClN ₂ O ₃ + 0.3 mol H ₂ O:
[1121] Theoretical: C, 68.77; H, 8.23; N, 5.53.
[1122] Found: C, 68.60; H, 8. 15; N, 5.43.
[1123] <Example 53>
[1124] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((RS)-(4N-ethyl-N-methylaminomethyl) phenoxymethyl) oxazoline
[1125] A. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((RS) -hydroxymethyl) oxazoline
[1126] A suspension of lithium aluminum hydride (48 mmol, 1.82 g) in tetrahydrofuran (121 ml) at −10 ° C. was added to a compound of Example 42 (B) (24.0 mmol, 8.01 g) in tetrahydrofuran (15 ml). It was added dropwise to the solution. This mixture was stirred for approximately 3.5 hours at room temperature and then quenched with water (3.41 ml). Filter aid was added to the reaction and the suspension was then filtered through a pad of silica. The filtrate was dried over sodium sulfate, filtered and concentrated in vacuo to yield 7.41 g of crude material. This material was pre chromatographed by eluting with a gradient of 80 to 100% ethyl acetate: hexanes for 30 minutes. Fractions containing the desired compound were combined and concentrated in vacuo to yield 3.47 g.
[1127] Mass spectrum (FDMS): m / z 305 (M).
[1128] Elemental Analysis for C ₁₈ H ₂₇ NO ₃ :
[1129] Theoretical: C, 70.79; H, 8.91; N, 4.59.
[1130] Found: C, 70.65; H, 9.05; N, 4.56.
[1131] B. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((RS)-(4-formyl) phenoxymethyl) oxazoline
[1132] The compound of Part A (10.0 mmol, 3.06 g), p-hydroxybenzaldehyde (11.0 mmol, 1.35 g) and triphenylphosphine (11.0 mmol, 2.63 g) in tetrahydrofuran (18 ml) cooled to 0 ° C. To the solution of diethylazodicarboxylate (11.0 mmol, 1.74 g) was added dropwise. The solution was stirred at rt for 4.5 h and then concentrated to oil under vacuum. The oil was treated with chloroform (4 ml) and the crystals were collected by filtration. Water (10 ml) was added to the filtrate and the pH was adjusted to 8.65 with 0.1 N sodium hydroxide and the phases were separated. The organic phase was washed with water (2 x 10 ml) and brine (1 x 10 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo. This material was pre chromatographed by eluting with a gradient of 40 to 60% ethyl acetate: hexanes for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 2.38 g of a white solid.
[1133] Mass spectrum (FDMS): m / z 409 (M).
[1134]
[1135] C. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((RS)-(4N-ethyl-N-methylaminomethyl) phenoxymethyl) oxazoline
[1136] Titanium isopropoxide (9.8 mmol, 2.78 g) was added to a solution of N-methylethylamine (4.9 mmol, 2.00 g) in ethanol (9 ml) at room temperature. The mixture was stirred at room temperature for 5 minutes and then the compound of Part B (4.9 mmol, 2.00 g) was added directly. The suspension was stirred at rt for 8.6 h and then sodium borohydride (7.3 mmol, 0.28 g) was added directly followed by ethanol (16 ml). The reaction mixture was stirred for approximately 96 hours at room temperature and then treated with saturated aqueous ammonium hydroxide solution. The resulting thick suspension was stirred for 10 minutes and the filter aid was added with water (25 ml) and then filtered through the filter aid. Insoluble material was washed with methylene chloride and brine. The phases of the filtrate were separated and the aqueous phase was extracted with methylene chloride (2 x 50 ml). The organic phases were combined, dried over sodium sulfate, filtered and concentrated in vacuo to afford 3.15 g of oil. Crystals formed in the oil and were triturated in 9: 1 hexanes: diethyl ether. Insolubles were collected by filtration. The material was prechromatographic. The product was eluted with a 0 to 10% methanol: chloroform gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 889 mg. This material was placed in chloroform (25 ml) and washed with aqueous saturated sodium bicarbonate (2 × 10 ml) and brine (1 × 10 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to afford 720 mg.
[1137] This material was recrystallized from diethyl ether to give 640 mg of the title compound. This material was dried in a vacuum oven at 45 ° C. overnight.
[1138] Mass spectrum (FDMS): m / z 453 (M + l).
[1139]
[1140] Elemental Analysis for C ₂₈ H ₄₁ ClN ₂ O ₃ :
[1141] Theoretical: C, 74.30; H, 8.91; N, 6.19.
[1142] Found: C, 74.45; H, 9. 10; N, 6.22.
[1143] <Example 54>
[1144] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -5-((4-N-methyl-N-ethylaminomethyl) phenoxymethyl) benzoxazole
[1145] A. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -5-methoxybenzoxazole
[1146] 2-hydroxy-5-methoxyaniline (36.9 mmol, 5.13 g), boric acid (36.9 mmol, 2.28 g) and 3,5-di-tert-butyl-4-hydroxybenzoic acid (36.9 in xylene (550 ml) Mmol, 9.23 g) was replenished using Dean Stark trap for approximately 2 days. The reaction mixture was concentrated to oil under vacuum. The oil was treated with ethyl acetate (200 ml) and washed with saturated aqueous sodium bicarbonate (3 × 200 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to yield 15.96 g of black oil. This material was pre chromatographed by eluting with 15 to 30% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to give 5.18 g of solid.
[1147] Mass spectrum (FDMS): m / z 353 (M).
[1148]
[1149] Elemental Analysis for C ₂₂ H ₂₇ NO ₃ :
[1150] Theoretic value: C, 74.76; H, 7. 70; N, 3.96.
[1151] Found: C, 74.62; H, 7.57; N, 4.01.
[1152] B. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -5-hydroxybenzoxazole
[1153] A solution of the compound of Part A (14.7 mmol, 5.18 g) in methylene chloride (26 ml) at −78 ° C. was treated with boron tribromide for 5 minutes. The reaction was stirred at −78 ° C. for 45 minutes, then at −10 ° C. for 1 hour and cooled to −78 ° C. again. After this time, the reaction was quenched with acetone (3 ml), warmed to 0 ° C. and saturated aqueous sodium bicarbonate (25 ml) was added. Additional saturated aqueous sodium bicarbonate (25 ml) was added followed by ethyl acetate (250 ml). The phases were separated and the aqueous phase was extracted with ethyl acetate (100 ml). The combined organic phases were dried over sodium sulphate, filtered and concentrated in vacuo to yield 2.2 g of a solid. Solid precipitate formed during drying with sodium sulfate. This material was carefully separated from sodium sulfate to give 3.23 g of additional title compound.
[1154] Mass spectrum (FDMS): m / z 340 (M + l).
[1155]
[1156] Elemental analysis for C ₂₁ H ₂₅ NO ₃ 0.3M H ₂ O:
[1157] Theoretical: C, 73.14; H, 7. 48; N, 4.06.
[1158] Found: C, 73.04; H, 7. 35; N, 4.00.
[1159] C. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -5- (4-formylphenoxy) benzoxazole.
[1160] The compound of Part B (14.6 mmol, 4.97 g), powdered potassium carbonate (29.3 mmol, 4.05 g), 4-bromobenzaldehyde (29.3 mmol, 5.42 g) and copper (I) iodide (0.7) in pyridine (25 ml) Mmol, 0.139 g) was sonicated for approximately 4 hours, then concentrated in vacuo and heated to 140 ° C. for approximately 17 hours. The reaction was then cooled to rt, ethyl acetate (100 ml) was added and the reaction washed with water (3 × 100 ml) and 10% aqueous sodium hydrogen sulfate (2 × 100 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to yield 7.64 g of oil. The material was pre chromatographed by eluting with a 10 to 25% acetone: hexane gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo. Fractions containing impurities along with the title compound were rechromatated by fusing a gradient of 2 to 5% ethyl acetate: hexane for the first 12 fractions (fraction volume approximately 250 ml) and eluting with 10% acetone: hexane . Fractions containing the title compound were combined with the fractions tested before and concentrated in vacuo to yield 2.18 g of solid. This material was used for the next step without further purification.
[1161] Mass spectrum (FDMS): m / z 443 (M).
[1162]
[1163] D. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -5-((4-N-methyl-n-ethylaminomethyl) phenoxymethyl) benzoxazole
[1164] To a suspension of the above compound of Part C (4.6 mmol, 2.06 g) in ethanol (27.6 ml) was added N-ethyl-N-methylamine (9.3 mmol, 0.549 g) followed by titanium (IV) isopropoxide. It was. After stirring for 4 hours at room temperature, sodium borohydride (7.0 mmol, 0.263 g) was added. This suspension was stirred at room temperature for approximately 15.5 hours and then quenched with 2N ammonium hydroxide (31 ml). The suspension was stirred for 15 minutes and the filter aid was added and filtered through a filter aid pad. Insolubles were washed with chloroform (100 ml) and brine (100 ml). The phases were separated and the aqueous phase was extracted with chloroform (3 x 50 ml). The combined organic phases were concentrated in vacuo to oil. The material was then pre chromatographed by eluting with a gradient of 0 to 10% (methanol; 1% ammonium hydroxide): chloroform for 30 minutes. Fractions containing the title compound were combined, dried over sodium sulfate and filtered. The filtrate was saturated with hydrogen chloride gas. The solution was then concentrated to foam under vacuum. The foam was dried in a vacuum oven at 60 ° C. overnight to yield 0.766 g of the title compound.
[1165] Mass spectrum (FDMS): m / z 486 (M-HCl).
[1166]
[1167] <Example 55>
[1168] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-ethyl-N-methylamino methyl) phenoxyethyl) -1,3,5-oxadiazole
[1169] A. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (methoxyethyl) -1,3,5-oxadiazole
[1170] Thionyl chloride is added to a suspension of 3,5-di-tert-butyl-4-hydroxybenzoic acid (13.6 mmol, 3.41 g) in xylene (3.3 ml) at room temperature. The suspension was heated to 45 ° C. for 140 minutes to remove excess thionyl chloride. At this time, the chloride acid derivative was added to the dropwise funnel. This material was added to a solution of methoxyethylamide oxime (15.0 mmol, 1.78 g) in pyridine (6.7 ml) for 5 minutes. After the addition was complete, the reaction was heated to 100 ° C. for 1 hour. The suspension was concentrated to an oil and then heated to 130 ° C. for 1.5 h. The reaction was cooled to room temperature, methylene chloride and water were added and the phases separated. The aqueous phase was extracted with methylene chloride. The combined organic phases were washed with saturated aqueous sodium bicarbonate (2 x 50 ml) and brine (1 x 50 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to yield 4.4 g of oil. The material was pre chromatographed by eluting with 15% acetone: hexane. Fractions containing the title compound were combined and concentrated in vacuo to yield 2.12 g. This material was used for the next step without further purification.
[1171]
[1172] B. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (hydroxyethyl) -1,3,5-oxadiazole
[1173] Boron tribromide (19.1 mmol, 4.79 g) was added to a solution of the above compound of Part A (6.4 mmol, 2.12 g) in methylene chloride (11.3 ml) cooled to 0 ° C. The reaction was stirred at 0 ° C. for 2.7 hours and then quenched with saturated aqueous sodium bicarbonate (10 ml). Water (10 ml) and methylene chloride (10 ml) were added, the phases were separated and the aqueous phase was extracted with methylene chloride (1 x 25 ml). The combined organic phases were dried over sodium sulphate, filtered and concentrated in vacuo to yield 2.27 g of oil. The material was pre chromatographed by eluting with 20 to 35% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 1.63 g of the title compound.
[1174] Mass spectrum (FDMS): m / z 318 (M).
[1175]
[1176] Elemental Analysis for C ₁₈ H ₂₆ N ₂ O ₃ :
[1177] Theoretical: C, 67.90; H, 8.23; N, 8.80.
[1178] Found: C, 68.03; H, 8. 27; N, 8.67.
[1179] C. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-formylphenoxy) ethyl) -1,3,5-oxadiazole
[1180] A solution of the above compound of Part B (4.8 mmol, 1.49 g), triphenylphosphine (5.1 mmol, 1.35 g) and p-hydroxybenzaldehyde (5.1 mmol, 0.629 g) in tetrahydrofuran (8.6 ml) at 0 ° C. To this was added diethylazodicarboxylate (5.1 mmol, 0.895 g). The reaction was stirred at room temperature for 4 days and then concentrated to oil under vacuum. The material was pre chromatographed by eluting with 20 to 35% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing p-hydroxybenzaldehyde together with the title compound were combined and concentrated to an oil in vacuo. The oil was treated with ethyl acetate (50 ml) and washed with 10% aqueous potassium carbonate (3 x 50 ml) followed by 10% aqueous sodium hydrogen sulfate (1 x 50 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to give 520 mg of foam. The material was used for the next step without further purification.
[1181]
[1182] D. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-ethyl-N-methylamino methyl) phenoxyethyl) -1,3,5-oxa Diazole
[1183] A solution of the above compound of Part B (1.1 mmol, 0.450 g) in 1,2-dichloroethane (5 ml) was treated with sodium triacetoxyborane (1.1 mmol, 0.063 g) followed by N-methyl-N-ethyl amine (1.1 mmol, 0.063 g). The reaction was stirred at rt for approximately 24 h and then quenched with aqueous sodium bicarbonate (25 ml). Ethyl acetate was added and after 15 min stirring the phases were separated. The organics were washed with aqueous sodium bicarbonate (3 x 25 ml). The organic phase was concentrated to oil under vacuum. The material was then pre chromatographed by eluting with a gradient of 0 to 10% (methanol: 1% ammonium hydroxide): chloroform for 30 minutes. Fractions containing the title compound were combined, dried over sodium sulfate and filtered. The filtrate was saturated with hydrogen chloride gas. The solution was then concentrated to foam under vacuum. The foam was dried in a vacuum oven at 60 ° C. overnight to afford the title compound.
[1184] Mass spectrum (FDMS): m / z
[1185]
[1186] Elemental Analysis for C ₂₈ H ₄₀ ClN ₃ O ₃ :
[1187] Theoretical: C, 66.98; H, 8.03; N, 8.37.
[1188] Found: C, 66.86; H, 7.91; N, 8.27.
[1189] <Example 56>
[1190] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylamino methyl) -1,2,3,4-tetrahydronaphthyl- 6-oxyethyl) oxazole hydrochloride
[1191] A. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-carbomethoxymethyl) phenoxy) oxazole
[1192] Example 1, Part C of the above compound (31.2 mmol, 10.14 g), 4-hydroxyphenyl acetate (35.1 mmol, 5.85 g) and triphenylphosphine (35.1 mmol, 9.23) in tetrahydrofuran (56 ml) at room temperature To the solution of g) was added diethylazodicarboxylate (35.1 mmol, 6.13 g). The reaction was stirred at rt overnight then concentrated in vacuo to oil. The oil was treated with methylene chloride, filtered and the filtrate was concentrated to oil under vacuum. The material was pre chromatographed by eluting with 20 to 35% acetone: hexane gradient over 30 minutes. Fractions containing the title compound were chromatographed again, eluting with 15 to 30% acyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 12.07 g of oil.
[1193] Mass spectrum (FDMS): m / z 465 (m).
[1194]
[1195] Elemental Analysis for C ₂₈ H ₃₅ NO ₅ :
[1196] Theoretical: C, 72.23; H, 7. 58; N, 3.01.
[1197] Found: C, 72.47; H, 7.65; N, 3.10.
[1198] B. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-ethanoate) phenoxy) oxazole
[1199] A suspension of the above compound of Part A (26 mmol, 12.07 g) and lithium hydroxide (78 mmol, 1.86 g) in tetrahydrofuran (87 ml) and water (28 ml) was heated to 65 ° C. for 4.5 h. The reaction was then cooled to rt and brine (25 ml) and ethyl acetate (25 ml) and hexane (25 ml) were added. The phases were separated and the organic phase was washed with 10% aqueous sodium hydrogen sulfate (1 x 50 ml) and brine (1 x 50 ml). The organic phase was concentrated in vacuo and then pre chromatographed by eluting with a 0 to 10% methanol: methylene chloride gradient for 30 minutes. Fractions containing the title compound were rechromatated by eluting with a 0% to 3% methanol: methylene chloride gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 1.60 g of foam.
[1200] Mass spectrum (FDMS): m / z 452 (M + l).
[1201]
[1202] Elemental Analysis for C ₂₇ H ₃₃ NO ₅ :
[1203] Theoretical: C, 71.82; H, 7. 37; N, 3.10.
[1204] Found: C, 71.82; H, 7. 46; N, 3.03.
[1205] C. 6- [2- [3,5-Di-tert-butyl-4-hydroxyphenyl) -4-oxazolyl] -ethoxy] -tetralone
[1206] Thionyl chloride (4.2 mmol, 0.50 g) was added to a solution of the above compound of Part B (3.5 mmol, 1.59 g) and 1 drop of dimethylformamide in methylene chloride (5 ml) at room temperature. The solution was heated to 45 ° C. for 2 hours and then cooled to room temperature and concentrated to a foam under vacuum. To a suspension of aluminum chloride (10.6 mmol, 1.41 g) in methylene chloride (24 ml) at −10 ° C. was added a solution of hydrochloric acid in methylene chloride (3 ml) for 30 minutes. Thereafter, ethylene gas was bubbled into the suspension for approximately 105 minutes. The reaction was then poured under stirring in ice / water (50 ml). The phases were separated and the organic phase was washed with 1N hydrochloric acid (2 x 50 ml) and brine (1 x 100 ml). The organic phase was dried over sodium sulphate, filtered and concentrated in vacuo to yield 1.46 g of foam. The material was pre chromatographed by eluting with 20 to 35% ethyl acetate: hexanes gradient for 30 minutes. Fractions containing the title compound were combined and concentrated in vacuo to yield 680 mg of oil.
[1207] Mass spectrum (ion sprayed MS): m / z 462 (M + l).
[1208]
[1209] Elemental Analysis for C ₂₉ H ₃₅ NO ₄ :
[1210] Theoretical: C, 75.46; H, 7. 64; N, 3.03.
[1211] Found: C, 75.41; H, 7.39; N, 3.02.
[1212] D. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylamino methyl) -1,2,3,4-tetrahydronaph Tyl-6-oxyethyl) oxazole hydrochloride
[1213] This compound was prepared substantially as described in Example 55, Part D.
[1214] Mass spectrum (ion spray MS): m / z 505 (M + l).
[1215]
[1216] <Example 57>
[1217] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-keto-3- (4-methylethylaminomethyl-phenyl) propyl) oxazole
[1218] A. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (2-iodoethyl) oxazole
[1219] A solution of triphenylphosphine (118.8 mmol, 31.12 g) in methylene chloride (460 ml) was treated with iodine (approximately 30.17 g) until cloudy yellow persisted. The reaction was stirred for 15 minutes, then 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (2-hydroxyethyl) oxazole (79.2 mmol) in methylene chloride (300 ml) , 25.10 g) and imidazole (158.3 g, 10.77 g) were added for 10 minutes. At 3.0 hours the reaction was concentrated in vacuo and then taken up in methylene chloride and flash silica gel filtered. The desired product was eluted with 1: 1 ethyl acetate: hexanes and 500 ml fractions were collected. The desired fractions were combined, washed with 1N sodium thiosulfate (1 x 250 ml) and brine (1 x 250 ml), dried over magnesium sulphate, filtered and concentrated in vacuo to give 32.53 g (96%) of the title compound. Obtained.
[1220] Mass spectrum (FDMS): m / z 427 (M).
[1221]
[1222] Elemental Analysis for C ₁₉ H ₂₆ INO ₂ :
[1223] Theoretical: C, 53.40; H, 6. 13; N, 3.28.
[1224] Found: C, 53.64; H, 6.06; N, 3.30.
[1225] B. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (2-cyanoethyl) oxazole
[1226] To a solution of sodium cyanide (84.5 mmol, 5.50 g) in dimethylsulfoxide (120 ml) at 92 ° C. through a powder addition funnel for 85 minutes 2- (3,5-di-tert-butyl-4-hydroxyphenyl) 4- (2-iodoethyl) oxazole (70.4 mmol, 30.08 g) was added. After approximately 1.5 hours, the reaction was cooled to room temperature and treated with 1: 1 ethyl acetate: hexane (250 ml) and 10% aqueous potassium carbonate (250 ml). Three individual phases occurred. The lowest phase was separated off and discarded. The remaining phases were separated. The aqueous phase was extracted with 1: 1 ethyl acetate: hexanes (2 x 200 ml). The combined organic phases were dried over sodium chloride, filtered, reduced in volume and prechromatographic. The material was eluted with 10 to 30% ethyl acetate: hexanes. Fractions containing the desired product were combined, dried over MgSO ₄ , filtered and concentrated in vacuo to afford 18.25 g (79%).
[1227] Mass spectrum (FDMS): m / z 326 (M).
[1228]
[1229] Elemental Analysis for C ₂₀ H ₂₆ N ₂ O ₂ :
[1230] Theoretical: C, 73.59; H, 8.03; N, 8.58.
[1231] Found: C, 73.37; H, 8.05; N, 8.53.
[1232] C. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (2-formylethyl) oxazole
[1233] Solution of 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (2-cyanoethyl) oxazole (52 mmol, 16.99 g) in toluene (167 ml) at -60 ° C Was treated with a 1 molar solution of diisobutylaluminum hydride (67.7 mmol, 67.7 ml) in toluene for 8 minutes. After 15 min stirring at -78 ° C, the dry ice / acetone bath was removed and the reaction stirred at room temperature for 1.75 h. After this time the reaction was treated with methanol (6.5 ml) followed by a saturated solution of ammonium chloride (650 ml). After 1.5 hours of stirring at room temperature, the reaction was treated with 50% (v / v) sulfuric acid until a biphasic solution was formed. Crystals formed in the biphasic solution were filtered off. The phases were separated and the aqueous phase was extracted with ethyl acetate (2 x 250 ml). The combined organics were washed with saturated aqueous solution of sodium bicarbonate (1 × 250 ml) followed by brine (1 × 500 ml). The organic phase was reduced to approximately 50 ml total volume and prechromatographic. The material was eluted with a 0 to 10% methanol: toluene gradient. Fractions containing the desired product were combined, dried over magnesium sulfate, filtered and concentrated in vacuo to give 15.13 g (88%).
[1234] Mass spectrum (FDMS): m / z 329 (M).
[1235]
[1236] Elemental Analysis for C ₂₀ H ₂₇ NO ₃ :
[1237] Theoretical: C, 72.92; H, 8. 26; N, 4.28.
[1238] Found: C, 71.40; H, 8. 27; N, 4.23.
[1239] D. 2- (3,5-Di-t-butyl-4-hydroxyphenyl) -4- (3-hydroxy-3- (4- (1,3-dioxolan-2-yl) phenyl) propyl Oxazole
[1240] 1.6M n-butyl lithium (59.1) in hexane for 25 minutes in a -70 ° C. solution of 2- (4-bromophenyl) -1,3-dioxolane (21.67 g, 94.6 mmol) in tetrahydrofuran (142 ml) ml, 94.6 mmol) was added dropwise. The resulting suspension is stirred at −70 ° C. for 2 hours, wherein 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4- (2-form in tetrahydrofuran (43 ml) Milethyl) oxazole (10.39 g, 31.53 mmol) was added dropwise for 30 minutes. After 1.75 hours, the cooling bath was removed. At -35 ° C the reaction was quenched with saturated ammonium chloride and diluted with ethyl acetate and 10% sodium hydrogen sulfate. The organic layer was extracted with brine, dried (sodium sulfate), evaporated to dryness and chromatographed on silica gel using gradient methylene chloride: ethyl acetate to afford protected aldehyde / alcohol (7.84 g, 51%). .
[1241]
[1242] E. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-hydroxy-3- (4-formyl) phenyl) propyl) oxazole
[1243] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-hydroxy-3- (4- (1,3-) in acetone (82 ml) and water (25 ml) Pyridinium p-toluene sulfonate (0.21 g, 0.82 mmol) was added to the solution of dioxolan-2-yl) phenyl) propyl) oxazole (7.84 g, 16.34 mmol) with stirring. The reaction was refluxed for 1.5 hours and the acetone was evaporated. The remaining aqueous suspension was extracted with ethyl acetate. The organic layer was extracted with brine, dried (sodium sulfate) and evaporated to dryness to give an aldehyde / alcohol intermediate (6.82 g, 96%).
[1244] Mass spectrum (FDMS): m / z 435 (M).
[1245]
[1246] Elemental Analysis for C ₂₇ H ₃₃ NO ₄ :
[1247] Theoretical: C, 74.46; H, 7. 64; N, 3.22.
[1248] Found: C, 74.22; H, 7. 64; N, 2.96.
[1249] F. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-hydroxy-3- (4-methylethylaminomethyl-phenyl) propyl) oxazole
[1250] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-hydroxy-3- (4-formyl) phenyl) in methanol (50 ml) cooled to -10 ° C N-methylethylamine (118.9 mmol, 7.03 g) is added to a solution of propyl) oxazole (11.9 mmol, 5.18 g) followed by acetic acid (118.9 mmol, 7.14 g) and the temperature is below 4 ° C. during the addition Maintained. Thereafter, sodium cyanovoborohydride (12.5 mmol, 0.78 g) was added and then stirred at room temperature for 2 days. The reaction is then concentrated in vacuo, treated with 1: 1 ethyl acetate: hexane (50 ml), the phases are separated and the organics are aq. Saturated sodium bicarbonate (25 ml), 10% aqueous sodium hydrogen sulfate, finally brine ( 25 ml). The organics were concentrated in vacuo, treated with chloroform and prechromatographic. The material was eluted with a 0 to 10% (methanol: 1% ammonium hydroxide): toluene gradient for 20 minutes. Fractions containing the desired product were concentrated in vacuo and treated with chloroform followed by hydrogen chloride gas. The solution was concentrated to foam under vacuum. The foam was placed in methylene chloride (20 ml) and filtered through talc and washed with methylene chloride (10 ml). The filtrate was treated with diisopropyl ether (10 ml). The solution was boiled until it became approximately 10 ml, producing a rubbery material from the solution. The solution was decanted and the rubbery material was concentrated in vacuo to yield the title compound (1.78 g, 29%) as a foam.
[1251] Mass spectrum (ion sprayed): m / z 479 (M-HCl + 1).
[1252] ¹ H NMR (CDCl ₃ ): δ 8.12 (s, 2H), 7.62 (s, 1H), 7.53 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.1 Hz, 2H), 5.93 ( s, 1H), 4.88 (m, 1H), 4.14 (m, 2H), 3.18 (m, 1H), 2.95 (m, 2H), 2.88 (m, 1H), 2.63 (d, J = 4.8 Hz, 2H ), 2.20 (m, 2 H), 1.41 (m, 21 H).
[1253] _{C 30 H 43 ClN 2 O 3} · Elemental Analysis for 1.5H ₂ O:
[1254] Theoretical: C, 66.46; H, 8.55; N, 5.17.
[1255] Found: C, 66.38; H, 8.57; N, 5.22.
[1256] G. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (3-keto-3- (4-methylethylaminomethyl-phenyl) propyl) oxazole
[1257] To a solution of oxalyl chloride (0.23 ml, 2.68 mmol) in methylene chloride (6.1 ml) at 60 ° C. was added dropwise a solution of dimethylsulfoxide (0.38 ml, 5.37 mmol) in methylene chloride (1.2 ml). After warming to −20 ° C., a solution of the above compound of Part F (1.17 g, 2.44 mmol) in methylene chloride (2.4 ml) was added during which the temperature was kept between −20 and −25 ° C. After 30 minutes at this temperature, triethylamine (1.7 ml, 12.2 mmol) was added dropwise. The reaction was warmed to room temperature and diluted with water. The aqueous layer was extracted with methylene chloride. The combined organic layers were extracted with brine, dried over sodium sulphate, evaporated to dryness and chromatographed on silica gel using gradient methylene chloride-methanol to give the free base (1.37 g, 85%). The free base (0.67 g, 1.41 mmol) was dissolved in methylene chloride (20 ml), treated with hydrochloric acid and evaporated to give the desired product (0.71 g, 99%).
[1258]
[1259] _{C 30 H 41 ClN 2 O 3} · Elemental Analysis for 1.3H ₂ O:
[1260] Theoretical: C, 67.16; H, 8. 19; N, 5.22.
[1261] Found: C, 66.90; H, 7.75; N, 5.24.
[1262] <Example 58>
[1263] 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylaminoethyl) phenoxymethyl) oxazole hydrochloride
[1264] A. N-carbo (3,5-di-t-butyl-4-hydroxy) phenyl-DL-serine methyl ester
[1265] D, l-serine methyl ester hydrochloride (5 g, 20 mmol) in a 250 ml flask was slurried in 50 ml of methylene chloride at room temperature. Triethylamine (11.15 ml, 80 mmol) was added all at once and the resulting solution was stirred at room temperature for 1 hour. In a 250 ml separation flask, 3,5-di-tert-butyl-4-hydroxybenzoic acid was combined with 2-chloro-4,6-dimethoxy-1,3,5-triazine in 100 ml of methylene chloride. The resulting solution was cooled to −10 ° C. and 4-methylmorpholine was added dropwise and stirred at −10 ° C. for 1 hour. This solution was added dropwise to the free base solution of d, l-serine methyl ester at -10 ° C. After the addition was completed, the cooling bath was removed and the resulting solution was stirred at room temperature for 2 hours and quenched with 1N hydrochloric acid (50 ml). The organics were separated and washed with 50 ml of saturated brine solution, dried over magnesium sulfate and filtered. The filtrate was concentrated in vacuo to a white foam, dissolved in 40 ml of ether and softened with 40 ml of hexane. The resulting white solid was filtered to give 5.23 g of the desired product in 74.5% yield.
[1266]
[1267] B. 4-((RS) carbomethoxy) -2- (3,5-di-tert-butyl-4-hydroxyphenyl))-2-oxazoline
[1268] The compound of Part A (1 g, 2.85 mmol) was dissolved in 10 ml of methylene chloride at room temperature and thionyl chloride (0.23 ml, 3.13 mmol) was added dropwise. The resulting mixture was stirred at rt for 2 h and then quenched with 10 ml of saturated sodium bicarbonate. The biphasic solution was then stirred at room temperature for 30 minutes and the organics were separated and dried over magnesium sulfate. The desiccant was filtered and concentrated in vacuo to yield 0.75 g of a white foam with a yield of 79%.
[1269]
[1270] C. 4- (Carbomethoxy) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) oxazole
[1271] The compound of part B (5 g, 15 mmol) was dissolved in 50 ml of dry dioxane and 2,3-dichloro-5,6-dicyano-benzoquinone (3.75 g, 16.5 mmol) was added. The resulting solution was heated to reflux for 1.5 hours and then cooled to room temperature. The solution was filtered through a pad of silica gel and bleached with activated carbon (20 g) for 16 hours. The dark solution was filtered through diatomaceous earth and the filtrate was concentrated in vacuo to yield 4.90 g of a tan solid with a yield of 98.7%.
[1272]
[1273] D. (4- (hydroxymethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl))-2-oxazole
[1274] To a solution of lithium aluminum hydride (0.043 g, 1.1 mmol) in 10 ml of dry tetrahydrofuran at 0 ° C. was added the compound of Part C (0.25 g, 0.76 mmol) in one portion. After 1 hour the reaction was quenched by the addition of 0.25 ml of water, 0.25 ml of 15% NaOH and 0.75 ml of water. The resulting mixture was stirred at rt for 1 h and then filtered through celite. The pH of the filtrate was adjusted to 7 by addition of 1N hydrochloric acid. The mixture was extracted with ethyl acetate (2 x 50 ml). The organic solution was slurried with magnesium sulfate (0.5 g) and activated carbon (2 g) for 4 hours. The mixture was filtered through celite and concentrated on a rotary evaporator to yield the subtitle compound (0.173 g) as a gray solid.
[1275] E. Preparation of N-propyl-N-ethyl-4-hydroxyphenyl acetamide
[1276] To a solution of 4-hydroxyphenyl acetic acid (88.43 g, 653 mmol) in 700 ml tetrahydrofuran at −50 ° C. was added a solution of 4-methylmorpholine (66.1 g, 653 mmol) in 30 ml tetrahydrofuran. Iso-butylchloroformate (89.3 g, 653 mmol) was added to the mixture and the resulting solution was stirred at −50 ° C. for 2 hours. A solution of ethylpropylamine (57 g, 654 mmol) in 30 ml of tetrahydrofuran was added for 15 minutes. After 3 hours, the reaction mixture was poured into a 1: 1 mixture of ethyl acetate and 1N hydrochloric acid. The ethyl acetate layer was washed with sodium bicarbonate and brine, then dried over sodium sulfate, filtered and concentrated to give a clear colorless oil (135 g). Purification of industrial materials was accomplished by crystallization from ethyl acetate.
[1277] Spectroscopic data were collected from a 1: 1 mixture of amide rotamers.
[1278]
[1279] F. N-propyl-N-ethyl-4-hydroxyphenylethyl amine
[1280] A three-necked flask equipped with a condenser, an additional funnel and a Dean-Stark trap was charged with a solution of the compound of Part E (48.6 g, 220 mmol) in 250 ml of tetrahydrofuran and heated to 50 ° C. Borane dimethylsulfide (10.0-10.2M, 86 ml) was added dropwise. After the addition was complete, the mixture was heated to reflux for 3 hours with approximately 60 ml of distillate removed by Dean Stark trap. The reaction mixture was then concentrated by distillation to approximately 25% of the original volume. Methanol (150 ml) was slowly added to the mixture. The resulting mixture was heated to reflux for 30 minutes and then concentrated to 50 ml total volume by distillation. The solution was cooled to room temperature and a 0.77 M hydrochloric acid solution in methanol (285 ml) was added. The resulting mixture was concentrated to a white solid on a rotary evaporator. The residue was slurried in ethyl acetate (1% methanol) and heated to reflux. The mixture was cooled and filtered to give the hydrochloride salt of the desired product as a white solid (42 g).
[1281]
[1282] A portion (26 g) of this material was free basified by partitioning the pH to 8 between ethyl acetate and sodium hydroxide solution. The organic phase was dried over sodium sulphate, filtered and concentrated to give the desired product (24 g) as a clear colorless oil.
[1283] G. 4- (Bromomethyl) -2- (3,5-di-tert-butyl-4-hydroxyphenyl) oxazole
[1284] Phosphorous tribromide (0.089 g, 0.33 mmol) was added dropwise to a solution of the above compound of Part D above 3 ml of dry dichloromethane at 0 ° C. The mixture was warmed to 23 ° C. for 1 hour and then the reaction was quenched by dropwise addition of 3 ml of pH 7 buffer and the temperature was raised to 32 ° C. The organic phase was diluted with dichloromethane and brine was added to clarify the layer. The organic solution was collected, dried over magnesium sulfate, filtered and concentrated by rotary distillation to afford the subtitle compound (0.084 g) as a white foam.
[1285]
[1286] H. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-formyl-N-ethylamino ethyl)) phenoxymethyl) oxazole
[1287] To a solution of the above compound of Part F (2.22 g, 10.2 mmol) in dry tetrahydrofuran was added 60% sodium hydride (0.513 g, 12.8 mmol) in an inorganic oil. The resulting mixture was stirred overnight and the above compound of Part G (3.75 g, 10.3 mmol) was added. The mixture was heated to reflux for 7 hours and then cooled to 23 ° C. The mixture was diluted with ethyl acetate and washed with saturated ammonium chloride. The organic solution was dried over magnesium sulfate, filtered and concentrated to a solid and used in the next step without further purification.
[1288] I. 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylamino ethyl) phenoxymethyl) oxazole hydrochloride
[1289] Borane dimethylsulfide (3.2 equiv) was added dropwise to a solution of the crude amide (above) in 100 ml of dry tetrahydrofuran at 23 ° C. The resulting mixture was heated to reflux for 5 hours and then cooled to room temperature. The volatiles were removed by rotary evaporation and the residue was dissolved in methanol and heated to reflux for 1 hour. The mixture was cooled to 23 ° C. and hydrochloric acid (10 equiv) in ether was added. The resulting mixture was stirred overnight, then heated to reflux for 4 hours. The mixture was cooled to 23 ° C. and volatiles were removed in vacuo. The residue was partitioned between ethyl acetate and saturated sodium bicarbonate. The organic phase was washed with 1N hydrochloric acid and brine. A small amount of methanol was added to help layer separation. The organics were dried over magnesium sulfate, filtered and concentrated by rotary evaporation to give a foam. The residue was purified by silica gel chromatography first eluting 95% acetonitrile, 3% water and 2% ammonium hydroxide. Second silica gel purification eluting 90% chloroform and 10% methanol gave a white foam.
[1290] The white foam was dissolved in methylene chloride and hydrogen chloride (g) was bubbled into the mixture for 5 minutes. The mixture was stirred overnight and the solvent was removed by rotary distillation to give the title product (2.27 g) as a white foam.
[1291] MS-FD = 492.2.
[1292] <Example 59>
[1293] 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethylphenoxy) ethyl) oxazole
[1294] A. Preparation of 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (tosyloxyether) oxazole
[1295] The compound of Example 59 D (50 g, 157.5 mmol) was dissolved in 500 ml of methylene chloride at room temperature. Pyridine (51 ml, 630 mmol) and dimethylaminopropylamine (1.92 g, 15.75 mmol) were added all at once. Tosic anhydride (64.3 g, 196.9 mmol) was then added portionwise. The mixture was stirred for 30 minutes at room temperature and quenched with 200 ml of 1N hydrochloric acid. The mixture was separated and the organics were dried over magnesium sulfate. The desiccant was filtered off and the filtrate was filtered through silica gel charge and washed with 1.5 liters of methylene chloride. Methylene chloride was removed under vacuum to give a solid and slurried in 1 L of petroleum ether. The solid was collected by filtration and dried in a 40 ° C. vacuum oven. Obtained a gray solid (68.93 g).
[1296] Yield = 92.7%
[1297] Elemental Analysis:
[1298] Theoretical: C, 66.22; H, 7.05; N, 2.97.
[1299] Found: C, 66.38; H, 7. 18; N, 3.14.
[1300] B. Preparation of N-Methyl-N-ethyl-4-hydroxyphenylmethylamide
[1301] To a solution of p-hydroxybenzaldehyde (20.01 g, 163.9 mmol) in 400 ml of 1,2-dichloroethane was added N-methylethylamine (11.62 g, 196.7 mmol). The reaction vessel was purged with nitrogen and sodium triacetoxyborohydride (48.00 g, 226.0 mmol) was added as a solid. The reaction was quenched by adding saturated sodium bicarbonate. The aqueous layer was washed with ethyl acetate and then the pH was adjusted to 10. The aqueous phase was extracted with ethyl acetate. Ethyl acetate was washed with 1N hydrochloric acid (pH 1) and the organic phase was discarded. The pH of the aqueous phase was adjusted to 10 and the product extracted with ethyl acetate. The organic solution was dried over sodium sulphate, filtered and concentrated to a white solid.
[1302]
[1303] C. 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethylphenoxy) ethyl) oxazole
[1304] The compound of part A (4.72 g, 10 mmol) was combined with the compound of part B (1.73 g, 10.5 mmol) and solid sodium hydroxide (0.6 g, 15 mmol) in 43 ml of dry tetrahydrofuran at room temperature. The resulting mixture was heated to reflux for 8 hours under nitrogen. The mixture was cooled to rt and the solvent was removed in vacuo to give a residue. The residue was partitioned between ethyl acetate and 1N hydrochloric acid. The organic layer was separated and washed twice with 1N sodium hydroxide and once with brine. The organics were dried over magnesium sulfate. The drying agent was filtered off and the filtrate was concentrated in vacuo to yield 4.59 g of oil. The oil was dissolved in methylene chloride and filtered through a pad of silica gel. The silica gel was washed once with methylene chloride and once with methanol. Methanol was concentrated in vacuo to give a residue, which was partitioned between methylene chloride and saturated sodium bicarbonate solution. The organic layer was separated and dried over magnesium sulfate. The drying agent was filtered off and the filtrate was concentrated to give 3.39 g of the title product as a pink oil.
[1305] MS = 465.4.
[1306] Elemental Analysis:
[1307] Theoretical: C, 74.96; H, 8.68; N, 6.03.
[1308] Found: C, 74.67; H, 8. 44; N, 5.88.
[1309] <Evaluation>
[1310] The brain consumes about 20% of the total oxygen it breathes, despite only about 2% of its total body weight. Nerve units rely on oxidative metabolism for survival, but as a result of this process reactive compounds such as hydrogen peroxide and oxygen radicals are produced (Cohen and Werner, 1994). Despite the brain's high vulnerability to the attack of oxygen radicals, oxygen free radical reactions and oxidative damage are, in most cases, inhibited by antioxidant defense mechanisms in their basic state. However, there is a pathology of the central nervous system in which excessive oxygen free radicals are produced that compromise the defense mechanism. These unrestricted reactive oxygen species (ROS) can cause DNA damage, peroxidation of membrane lipids, and death of neurons.
[1311] Oxidative damage by free radical production and lipid peroxidation as well as the product of the arachidonic acid cascade is thought to be a major factor in the acute stage pathology of ischemia. Increasing the amount of free fatty acids after ischemia and during initial reperfusion can provide a substrate for lipid peroxidation and formation of products of the arachidonic acid cascade (Clemens et al., Stroke, Vol. 22, No. 8, Aug. 1991). .
[1312] There have been numerous reviews of the role of oxygen radicals in cerebral ischemia (Braugher and Hall, 1989; Hall and Braugher 1989; Koutos, 1989, Floyd, 1990; Nelson et al., 1992; Panetta and Clemens, 1993).
[1313] Evidence has recently gathered that free radicals are involved in the development of Parkinson's disease (Graham, 1984; Ogawa et al., 1993, Ben-Shackar et al., 1992; Carillo et al., 1993). In addition, reports suggesting the involvement of free radicals in the development of Alzheimer's disease and Down syndrome (Zelman et al., 1989. Ceballos-Pecot et al., 1992; Andorn et al., 1990; Subbarao et al., 1990, McIntosh et al., 1991). ). In addition, reports on the involvement of free radicals in the pathogenesis of ALS have recently been presented (Rosen et al., 1993; McNamara and Fridovich, 1993).
[1314] The compounds of the present invention inhibit the formation of reactive oxygen species in mammals and thereby cause symptoms and diseases thought to be caused by increased production of free radicals such as systemic and cerebral ischemia, Parkinson's disease, Alzheimer's disease, It is useful for treating Down syndrome and ALS.
[1315] Compounds of formula I have been shown to prevent ischemia-induced neuronal damage, as demonstrated in the following test system.
[1316] <Rat cerebral ischemia model>
[1317] Cerebral ischemia was induced in rats by occlusion of four arteries that supply the brain with the following procedure. Male Wistar rats were anesthetized with Metofane and placed in the stereotactic device. A longitudinal incision was made on the back of the neck. The neck muscles were exposed with the back of the spinal column. Two vertebral arteries were exposed where they passed through the first cervical spine. Two arteries were permanently occluded by the action of an electrocautery. After condensation of the vertebral artery, the rat was removed from the stereotactic device and the surgical wound closed. Incisions were made in two places on the mask of the neck. Two carotid arteries were exposed and dissected without surrounding nerves and binding tissue. A non-traumatic clasp, made primarily of silicone rubber tubing, was placed around each carotid artery in such a way that blood vessels were not traumatized or blocked. Indwelling cervical cannula was implanted into each rat for drug delivery. The surgical wound was then closed. Non-traumatic clasps are designed in such a way that they can be tightly tightened to occlude the carotid artery by pulling small silicone threads that protrude from the wound. Circulation to the brain through the carotid arteries could be restored by releasing tension on the plastic seal. After surgery, rats were recovered for 24 hours.
[1318] Tightening the clasp around the carotid artery caused cerebral ischemia. During this time, rats with successful ischemia lost stereotactic reflexes and became unresponsive to stimuli. The time of ischemia was 20 minutes, immediately reperfused after 20 minutes of ischemia, and the compound was administered by intravenous infusion at 10 mg / kg ingots followed by a constant intravenous infusion of 5.0 mg / kg per hour for 20 hours. After 5 days of ischemia, rats were sacrificed to perfused the brain, fixed with formalin and tissue evaluated.
[1319] One part of the brain most common in ischemic-induced damage in both rats and humans is the CA ₁ vertebral cell layer of hippocampus. For animals that do not respond for 20 minutes of ischemia, the CA ₁ vertebral cell layer is completely destroyed. This cell layer was examined under a microscope at the tissue incision from the hippocampus. Brain damage was graded as follows.
[1320] 0 = intact, intact cell layer
[1321] 1 = minor damage, 1/3 kill of CA _1st floor
[1322] 2 = moderate damage, 2/3 death of CA ₁ layer
[1323] 3 = severe damage,> 90% cell death
[1324] Injury at four parts of the dorsal hippocampus from each brain was measured for accurate injury assessment. Mean damage scores were calculated for each treatment group. The scores of the treated groups were statistically compared to the scores of the control group treated only with the vehicle (phosphate buffered saline) used to suspend the compound. Flow level was measured using the Man Whitney-U-test.
[1325] Usefulness was found when the compounds of the invention were tested in the assays described above.
[1326] The following three tests are useful for predicting the compound's ability to inhibit the formation of free radicals believed to be associated with diseases such as ischemia, Parkinson's disease, Alzheimer's disease, Down's syndrome and ALS.
[1327] <Lipid peroxidation test>
[1328] Compounds of Formula I are described in Aruoma et al., (1990), Free Rad. Res. Comm., 10: 143, has been used to inhibit the formation of lipid peroxides in mammals. The compounds of the invention tested in the cited assays were found to be active.
[1329] <Peroxide O ₂ · Secretion Test>
[1330] In addition, compounds of formula (I) are described in Lorico et al. (1986), Biochem. Pharmacol., 35: 2443, was used for its ability to inhibit peroxide O ₂ · secretion. The compounds of the invention tested in the above-mentioned assays have been found to be useful.
[1331] <H ₂ O ₂ secretion test>
[1332] Finally, Root et al., (1975), J. Clin. Invet., 55: 945] was used to test compounds of formula I and found to be effective in inhibiting H ₂ O ₂ secretion.
[1333] <Pharmaceutical formulation>
[1334] As mentioned above, the compounds of formula (I) can slow the progression of neurodegeneration associated with Parkinson's disease, Alzheimer's disease, Down's syndrome, Amyotrophic lateral sclerosis and prevent ischemia-induced cell damage, thereby providing valuable treatment methods To provide. The method of the present invention is characterized by administering an effective amount of at least one compound of formula (I) to achieve the desired therapeutic effect in a mammal in need of treatment for Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis or ischemia. .
[1335] Usually, the compounds of the present invention are most preferably administered at a concentration that will generally provide an effective result without causing any harmful or toxic side effects, and is a convenient subunit administered in a single unit dose or, if desired, at a suitable time per day. It can be administered by dividing.
[1336] The compounds used in the methods of the invention are effective against a wide range of dosages for the treatment of Parkinson's disease, Alzheimer's disease, ALS and ischemic induced cell damage. Thus, as used herein, the term "therapeutically effective amount" means a dosage range of about 0.5 to about 150 mg / kg body weight per day. For the treatment of adults, a range of about 1.0 to about 50 mg / kg per day is preferred. Preferably, the compound is administered intravenously at about 0.1-100 mg / kg body weight and injected intravenously in a constant amount of about 0.1-50 mg / kg per hour for about 24 hours. However, the actual amount of compound administered will be determined by the physician taking into account relevant circumstances, including the choice of the compound administered, the route of administration chosen, the age, weight, response of the individual patient, and the severity of the patient's symptoms, and thus It will be understood that the dosage range is not intended to limit the scope of the invention in any way.
[1337] The composition is preferably formulated in an intravenous dosage form such that each dosage comprises from about 4.5 to about 9.5 g of active ingredient with one or more suitable pharmaceutical diluents or excipients.
[1338] Neurodegenerative diseases, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and Down syndrome are chronic symptoms. The term "chronic" means worsening of slow progression and long duration. Thus, chronic neurodegenerative conditions are treated when diagnosed and continue during the course of the disease.
[1339] Ischemia refers to a phenomenon in which part or entire blood flow of tissue is deprived of hypoxia. This can manifest as an acute or chronic condition. The term "acute" refers to a condition that temporarily worsens after a brief exacerbation. Thus, the treatment of ischemic induced cell damage contemplates both acute and chronic forms. In acute cases, the compound is administered at the onset of symptom and the administration is stopped when the symptom disappears. As described above, chronic symptoms continue to be treated during the course of the disease.
[1340] The compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular or intranasal routes. Administration by the intravenous route is preferred. Whatever route of administration is chosen, such administration is accomplished through pharmaceutical compositions prepared by techniques well known in the pharmaceutical sciences.
[1341] In preparing a pharmaceutical composition, the one or more active ingredients are generally mixed with the carrier or diluted with the carrier or wrapped in the carrier or diluted with the carrier or containing capsules, sachets, paper and other containers. It may be wrapped in a carrier which may be a container. When the carrier is used as a diluent, a solid, semisolid or liquid material can serve as the vehicle, excipient or medium for the active ingredient. Thus, the composition can be used in tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solid or in a liquid medium), for example active compounds. It may be in the form of ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders containing up to 10% by weight.
[1342] Some examples of suitable carriers, excipients and diluents include lactose, textose, sucrose, sorbitol, mannitol, starch, gum acacia, calcium phosphate, algiates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrroly Pig, cellulose, water, saline solution, syrup, methylcellulose, methyl- and propylhydroxybenzoate, talc, magnesium stearate and inorganic oils. The formulation may further comprise lubricants, wetting agents, emulsifying and suspending agents, preservatives, sweeteners or flavoring agents. The composition may be formulated to provide rapid release, sustained release or delayed release of the active ingredient after administration to a patient using procedures well known in the art.
[1343] The following formulation examples can use any compound of formula III as the active ingredient. The examples are for illustrative purposes only and are not intended to limit the scope of the invention in any way.
[1344] <Formulation 1>
[1345] Hard gelatin capsules were prepared using the following ingredients.
[1346] Volume (mg / capsule) 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-ethylaminomethyl-phenoxy) ethyl) thiazole 500 Dried starch 200 magnesium 10
[1347] The ingredients were mixed and filled in hard gelatin capsules in an amount of 710 mg.
[1348] <Formulation 2>
[1349] Tablet formulations were prepared using the following ingredients.
[1350] Volume (mg / tablet) 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-dimethylaminomethylphenylthio) ethyl) oxazole 100 Cellulose, microcrystalline 400 Silicon Dioxide, Haze 10 Stearic acid 5
[1351] The components were blended and pressed to form tablets of 515 mg each weight.
[1352] <Formulation 3>
[1353] Tablets containing 50 mg each of the active ingredient were prepared as follows.
[1354] Volume (mg / tablet) 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethylphenylthio) propyl) -5-ethyl-thiazole 50 mg Starch 50 mg Microcrystalline cellulose 40 mg Polyvinylpyrrolidone (10% solution in water) 4 mg Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg talc 1 mg all 150 mg
[1355] The active ingredient, starch and cellulose were obtained from U.S. 45. Pass through the mesh sieve and mix thoroughly. A solution of polyvinylpyrrolidone was mixed with the resulting powder followed by 45 U.S. Passed through the mesh sieve. The granules thus prepared were dried at 50 to 60 ° C. and subjected to No. 18 U.S. Passed through the mesh sieve. 60 U.S. in advance Sodium carboxymethyl starch, magnesium stearate and talc, which were passed through a mesh sieve, were then added to the granules, mixed, and compressed into tablets to produce tablets of 150 mg each.
[1356] <Formulation 4>
[1357] Capsules containing 25 mg each of the medicament were prepared as follows.
[1358] Volume (mg / capsule) 2- (3,5-diethyl-4-hydroxyphenyl) -4- (2- (3-dimethylaminomethylphenoxy) butyl) oxazole 25 mg Starch 60 mg Microcrystalline cellulose 60 mg Magnesium stearate 5 mg all 150 mg
[1359] The active ingredient, cellulose, starch and magnesium stearate were blended and U.S. 45. Passed through a mesh sieve and filled into hard gelatin capsules in an amount of 200 mg.
[1360] <Formulation 5>
[1361] Suppositories containing 250 mg of each active ingredient were prepared as follows.
[1362] Volume (mg / suppository) 2- (3,5-di-t-butyl-4-methyloxyphenyl) -4- (2- (4-n-propylaminomethylphenoxy) ethyl) oxazole 250 mg Saturated Fatty Acid Glyceride 2,000 mg total
[1363] The active ingredient is 60 U.S. Suspended in saturated fatty acid glycerides through a mesh sieve and melted using the minimum required heat in advance. The mixture was then poured into a 2 g nominal capacity suppository casting and cooled.
[1364] <Formulation 6>
[1365] Suspensions each containing 100 mg of drug per 5 ml dose were prepared as follows.
[1366] Volume (mg / 5 ml) 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-n-hexylaminomethylphenylthio) methyl) oxazole 100 mg Sodium Carboxymethylcellulose 50 mg syrup 1.25 ml Benzoic acid solution 0.10 ml Flavor dose. coloring agent dose. Purified water Amount to 5 ml total
[1367] Medication No. 45 Mesh U.S. Passed through the sieve and mixed with sodium carboxymethyl cellulose and syrup to form a smooth paste. The benzoic acid solution, flavor and colorant were diluted with some water and added under stirring. Sufficient water was then added to make the desired volume.
[1368] <Formulation 7>
[1369] Capsules each containing 5 mg of the drug were prepared as follows.
[1370] Volume (mg / tablet) 2- (3-isopropyl-5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-diethylaminomethylphenoxy) ethyl) oxazole 5 mg Starch 164 mg Microcrystalline cellulose 164 mg Magnesium stearate 22 mg all 355 mg
[1371] The active ingredient, cellulose, starch and magnesium stearate were blended and U.S. 45. Passed through a mesh sieve and filled into hard gelatin capsules in an amount of 355 mg.
[1372] <Formulation 8>
[1373] Intravenous formulations were prepared as follows.
[1374] Volume (g) 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-n-butylmethylaminomethylphenoxy) ethyl) oxazole 5 g Isotonic acid brine 1 g all 6 g
[1375] The solution of this component was administered intravenously at a rate of 1 ml per minute to patients in need of treatment.

权利要求:
Claims (21)
[1" claim-type="Currently amended] Reacting a compound of formula X with an activator and treating with a base to form a compound of formula IX,
Cyclizing the compound of formula IX to form a compound of formula VIII,
Reducing the compound of formula VIII to form a compound of formula VII,
Mesylating or tosylation a compound of formula VII to form a compound of formula VI wherein PG is mesylate or tosylate, and
Alkylating a compound of formula (VI) with a compound of formula (V) to form a compound of formula (IV): or a pharmaceutically acceptable salt, hydrate or optical isomer thereof.
<Formula IV>

In the above formula,
R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
R ³ is H or-(C ₁ -C ₆ ) alkyl,
R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
q is 0 or 1,
t is 1-6.
<Formula X>

<Formula IX>

<Formula VIII>

<Formula VII>

<Formula VI>

<Formula V>

[2" claim-type="Currently amended] The method of claim 1, wherein R ⁶ is —NR ⁷ R ⁸ and R ³ is H. ⁶ .
[3" claim-type="Currently amended] The method of claim 1 or 2, wherein q is zero.
[4" claim-type="Currently amended] The method of claim 1, wherein the reducing agent is boron tetrahydrofuran.
[5" claim-type="Currently amended] The process according to any one of claims 1 to 4, wherein the tosylating agent is tosic anhydride.
[6" claim-type="Currently amended] 6. The process according to claim 1, wherein the alkylation is carried out in the presence of a base.
[7" claim-type="Currently amended] The method of claim 1, wherein the base is pyridine.
[8" claim-type="Currently amended] A process for preparing a compound of formula (IV) or a pharmaceutically acceptable salt, hydrate or optical isomer thereof comprising alkylating a compound of formula (VI) with a compound of formula (V)
<Formula IV>

In the above formula,
R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
R ³ is H or-(C ₁ -C ₆ ) alkyl,
R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
q is 0 or 1,
t is 1-6.
<Formula VI>

In the above formula, R ¹ , R ² and q are as defined above.
<Formula V>

In the above formula, R ⁶ and t are as defined above.
[9" claim-type="Currently amended] The method of claim 8, wherein q is zero.
[10" claim-type="Currently amended] The method of claim 8 or 9, wherein R ⁶ is —NR ⁷ R ⁸ .
[11" claim-type="Currently amended] The process according to claim 8, wherein the alkylation is carried out in the presence of a base.
[12" claim-type="Currently amended] The method of claim 8, wherein the base is pyridine.
[13" claim-type="Currently amended] The compound according to any one of claims 1 to 12, wherein 2- (3,5-di-t-butyl-4-hydroxyphenyl) -4- (2- (4-methylethylaminomethylphenoxy) ethyl A process for preparing oxazole hydrochloride hydrate.
[14" claim-type="Currently amended] Reacting a compound of formula XXVII with an activator (Wherein, R ³ is H or - (C ₁ -C ₆₎ alkyl) to the coupling with a serine methyl ester to form a compound of formula XXVI,
Cyclizing a compound of formula XXVI to form a compound of formula XXV,
Oxidizing the compound of formula XXV to form a compound of formula XXIV,
Reducing the compound of formula XXIV to form a compound of formula XXIII,
Halogenating the compound of formula XXIII to form a compound of formula XXII,
Compound of formula (XXII) Wherein R ³⁰ is — (CO) R ⁶ or NR ⁴⁰ R ⁴¹ wherein one of R ⁴⁰ and R ⁴¹ is hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, ,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, And the other is — (CO) C ₁ -C ₆ alkyl) to form a compound of formula XXI, and
A method for preparing a compound of formula (XX) or a pharmaceutically acceptable salt, hydrate or optical isomer thereof, comprising reducing a compound of formula (XI) to form a compound of formula (XX).
<Formula XX>

In the above formula,
R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
R ³ is H or-(C ₁ -C ₆ ) alkyl,
R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
q is 0 or 1,
t is 1-6.
<Formula XXVII>

<Formula XXVI>

<Formula XXV>

<Formula XXIV>

<Formula XXIII>

<Formula XXII>

In the above formula, X is halo.
<Formula XXI>

[15" claim-type="Currently amended] The method of claim 14, wherein R ⁶ is —NR ⁷ R ⁸ and R ³ is H. 16.
[16" claim-type="Currently amended] The method of claim 14 or 15, wherein q is zero.
[17" claim-type="Currently amended] The method according to claim 14, wherein the activator is 2-chloro-4,5-dimethyloxy-1,3,5-triazine.
[18" claim-type="Currently amended] Compound of formula (XXII) Wherein R ³⁰ is — (CO) R ⁶ or NR ⁴⁰ R ⁴¹ wherein one of R ⁴⁰ and R ⁴¹ is hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, ,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, And the other is — (CO) C ₁ -C ₆ alkyl) to form a compound of formula XXI, and
A method for preparing a compound of formula (XX) or a pharmaceutically acceptable salt, hydrate or optical isomer thereof, comprising reducing a compound of formula (XI) to form a compound of formula (XX).
<Formula XX>

In the above formula,
R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
R ³ is H or-(C ₁ -C ₆ ) alkyl,
R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
q is 0 or 1,
t is 1-6.
<Formula XXI>

[19" claim-type="Currently amended] A process for preparing a compound of formula XX, or a pharmaceutically acceptable salt, hydrate or optical isomer thereof, comprising reducing a compound of formula XXI:
<Formula XX>

In the above formula,
R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
R ³ is H or-(C ₁ -C ₆ ) alkyl,
R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Piperazin-1-yl substituted with
q is 0 or 1,
t is 1-6.
<Formula XXI>

In the above formula,
R ³⁰ is — (CO) R ⁶ or NR ⁴⁰ R ⁴¹ wherein one of R ⁴⁰ and R ⁴¹ is hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, ,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, The other is-(CO) C ₁ -C ₆ alkyl.
[20" claim-type="Currently amended] 20. The compound of any one of claims 14-19, wherein 2- (3,5-di-tert-butyl-4-hydroxyphenyl) -4-((4-N-methyl-N-ethylaminoethyl) Process for preparing phenoxymethyl) oxazole hydrochloride.
[21" claim-type="Currently amended] A compound of formula XXI: or a pharmaceutically acceptable salt, hydrate or optical isomer thereof.
<Formula XXI>

In the above formula,
R ¹ and R ² are, independently from each other,-(C ₁ -C ₆ ) alkyl,-(C ₁ -C ₆ ) alkoxy or phenyl,
R ³ is H or-(C ₁ -C ₆ ) alkyl,
R ³⁰ is — (CO) R ⁶ where R ⁶ is —NR ⁷ R ⁸ wherein R ⁷ and R ⁸ are independently of each other hydrogen, — (C ₁ -C ₆ ) alkyl, — (CH ₂ ) _p OH, Wherein R ⁹ is (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, Morpholin-1-yl, imidazol-1-yl, 4,5-dihydro-1H-imidazol-2-yl, thiomorpholin-1-yl, piperazin-1-yl, or- (C ₁ -C ₄ ) alkyl or Is piperazin-1-yl) or -NR ⁴⁰ R ⁴¹ wherein one of R ⁴⁰ and R ⁴¹ is hydrogen,-(C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p OH, ,-(CH ₂ ) _p -piperidyl,-(CH ₂ ) _p S (C ₁ -C ₆ ) alkyl,-(CH ₂ ) _p O (C ₁ -C ₆ ) alkyl, The other is-(CO) C ₁ -C ₆ alkyl),
q is 0 or 1,
t is 1-6.

类似技术:

---

公开号 | 公开日 | 专利标题

---

US9056874B2|2015-06-16|Complement pathway modulators and uses thereof

---

JP5815765B2|2015-11-17|Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators

---

US20190092755A1|2019-03-28|Compounds for treatment of cancer

---

TWI415841B|2013-11-21|Antagonists of lysophosphatidic acid receptors

---

US8377939B2|2013-02-19|Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842

---

JP2865211B2|1999-03-08|5&#39;-Indolinyl-5β-amidomethyloxazolidin-2-ones, 3- | phenyl-5β-amidomethyloxazolidine-2-ones and 3- | phenyl-5β-amidomethyloxazolidine -2-ones

---

KR100699614B1|2007-03-23|Substituted 4-alkoxyoxazol derivatives as ppar agonists

---

DE69434991T2|2008-03-06|Substituted morpholine derivatives and their use as pharmaceuticals

---

AU2003211617B2|2006-02-02|Ester compound and medicinal use thereof

---

US6982348B2|2006-01-03|Aminoethanol derivatives

---

US7795444B2|2010-09-14|Human protein tyrosine phosphatase inhibitors and methods of use

---

TW419471B|2001-01-21|Morpholine derivatives useful as tachykinin receptor antagonists, preparation thereof and pharmaceutical composition containing same

---

US7968552B2|2011-06-28|Oxadiazolidinedione compound

---

US5804601A|1998-09-08|Aromatic hydroxamic acid compounds, their production and use

---

JP4129286B2|2008-08-06|Novel thiazolidin-4-one derivatives

---

US10131655B2|2018-11-20|Substituted heterocyclic acetamides as kappa opioid receptor | agonists

---

JP4276074B2|2009-06-10|Activator of peroxisome proliferator-responsive receptor δ

---

FI91869C|1994-08-25|Process for the preparation of benzoxazole derivatives as antidiabetic agents

---

US6706743B2|2004-03-16|β3 adrenergic receptor agonists and uses thereof

---

AU707901B2|1999-07-22|Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present

---

US6300344B1|2001-10-09|Heterocyclic compounds

---

US8987256B2|2015-03-24|Oxo-heterocyclic substituted carboxylic acid derivatives and the use thereof

---

US7220745B2|2007-05-22|Heterocyclic compounds useful to treat HCV

---

ES2315912T3|2009-04-01|Derived from eter replaced by hexafluorisopropanol.

---

EP1244642B1|2004-04-28|Substituted oxazoles and thiazoles derivatives as hppar alpha activators

同族专利:

---

公开号 | 公开日

---

NO20001751D0|2000-04-05|

---

CN1281442A|2001-01-24|

---

EP0908454A3|2001-07-25|

---

IL135433D0|2001-05-20|

---

EP0908454A2|1999-04-14|

---

CA2305538A1|1999-04-15|

---

AU9575698A|1999-04-27|

---

HU0004862A2|2001-10-28|

---

WO1999018091A1|1999-04-15|

---

NO20001751L|2000-05-03|

---

ID24564A|2000-07-27|

---

TR200001750T2|2001-01-22|

---

EA200000403A1|2000-10-30|

---

US6448396B2|2002-09-10|

---

US20010027194A1|2001-10-04|

---

BR9812857A|2000-08-08|

---

HU0004862A3|2001-12-28|

---

PL339673A1|2001-01-02|

---

TR200100352T2|2001-06-21|

---

JP2001519341A|2001-10-23|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

法律状态:
1997-10-06|Priority to US6101397P

---

1997-10-06|Priority to US60/061,013

---

1998-09-23|Application filed by 피터 지. 스트링거, 일라이 릴리 앤드 캄파니

---

1998-09-23|Priority to PCT/US1998/019854

---

2001-03-26|Publication of KR20010024402A

优先权:

---

申请号 | 申请日 | 专利标题

---

US6101397P| true| 1997-10-06|1997-10-06|

---

US60/061,013|1997-10-06|

---

PCT/US1998/019854|WO1999018091A1|1997-10-06|1998-09-23|Novel compounds useful as neuro-protective agents|